



Dissecting Tumor Heterogeneity in Lung Cancer 
by 
























Walter Hilttelman, Ph.D.  
______________________________ 





Dean, The University of Texas 





Dissecting Tumor Heterogeneity in Lung Cancer 
A 
DISSERTATION 
Presented to the Faculty of 
The University of Texas 
MD Anderson Cancer Center UTHealth 
Graduate School of Biomedical Sciences 
in Partial Fulfillment 
of the Requirements 
for the Degree of 
DOCTOR OF PHILOSOPHY 
by 






To my parents and brother, for their unwavering and unconditional love and support, 





This work would not have been complete without the support and guidance of many 
people. First of all my academic advisor, Dr. Don L. Gibbons, who gave me the opportunity to 
work in his research group. From the beginning, he encouraged me to think through the 
scientific problems, to reason and to overcome hurdles in a systematic way. His enthusiasm 
for science kept me motivated even when I was brought down by negative data or failed 
hypotheses. He patiently worked with me to improve in my areas of weakness, including 
presentations and scientific writing, which have truly made me a better scientist. Even with all 
the ups and downs that came along the way, I knew I could count on him for his advice and 
support. I also want to thank my advisory committee members Drs. Varsha Gandhi, Andrew 
Gladden, Walter Hittelman, Jichao Chen and Lauren Byers for taking the time and providing 
valuable feedback that helped me bring this work to fruition.  
I also want to thank all the Gibbons lab members, current and former. The atmosphere 
in the lab has always been one of teamwork, support and encouragement which made lab work 
a little more fun. I want to thank Dr. Christin Ungewiss and Dr. Jonathon Roybal, who were 
there when I first joined the lab and who have remained very close friends even after leaving 
the lab. They always looked out for me and gave me unique tips for research that made my life 
much easier. I want to thank Dr. Letty Rodriguez and Dr. Jessica Konen who were there to 
brainstorm ideas with, and sometimes just as a sounding board when things did not go as 
planned, Laura Gibson for being an amazing lab manager and Jared Fradette for all the help 
with mouse experiments.  
I also want to thank all my friends in graduate school and outside, who shared these 
experiences with me and kept me sane. Exploring different restaurants in Houston with them 
was definitely something I looked forward to after a long week in lab.   
v 
Abstract 
Dissecting Tumor Heterogeneity in Lung Cancer 
Aparna Padhye, M.B.B.S. 
Advisory Professor: Don L. Gibbons, M.D., Ph.D. 
Lung cancer is a heterogeneous disease composed of genetically and phenotypically 
distinct tumor cells as well as a heterogeneous microenvironment consisting of non-cancer 
cells and extracellular matrix.  Constant interactions among these components ultimately leads 
to a complex tumor tissue that is ever evolving and poses a therapeutic challenge for sustained 
benefit. Strategies for targeting lung cancers are largely guided by the genetic alterations 
identified in the tumor specimens. However, in order to gain a better understanding of lung 
cancer progression and develop effective treatment modalities, studying tumor in context of its 
microenvironment is crucial. The first aim of this project was to establish an experimental model 
to capture tumor heterogeneity. We developed an Ex Vivo Tumor system that preserved tumor 
composition and allowed the introduction of specific modifications in the tumor 
microenvironment to investigate their role in tumor progression. We utilized this system to 
demonstrate the role of extrinsic as well as intrinsic alterations that modify tumor cell behavior. 
Next, we explored the biological phenomenon epithelial-to-mesenchymal transition as a source 
of tumor cell heterogeneity and therapeutic resistance. Genetically identical KRAS mutant lung 
cancer cells displayed different phenotypic states that were associated with distinct survival 
pathways that allowed cancer cells to escape therapeutic targeting. With the use of extensive 
in vitro, ex vivo and in vivo models, we identified that a combinatorial approach of utilizing 
CDK4 and MEK inhibitors to effectively control tumor growth by targeting distinct tumor 
subpopulations within lung cancer and prevented emergent resistance to either single agent.   
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Chapter 1: Introduction 
1.1 Lung cancer  
Lung cancer continues to account for the highest cancer-related mortality in the US1. 
Two-thirds of the patients present in the clinic at an advanced stage with metastatic disease 
progression that results in a dismal 5-year survival rate (Figure 1). The morbidity is also 
exacerbated in patients with early-stage disease, who may have initial an response to 
treatments but demonstrate a recurrence rate of approximately 50 percent due to the 
development of resistance to therapeutic agents.  
 
 
Figure 1. Lung cancer statistics. 
(A) Leading cancer types for the estimated new cancer deaths, US, 2021. (B) Top: Stage distribution 
for lung cancer, US, 2010 to 2016. Bottom: Five‐year relative survival for lung cancer by stage at 
diagnosis, US, 2010 to 2016. Obtained with permission from John Wiley and Sons. 
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Conventionally, lung cancer is broadly classified into small cell (SCLC) and non-small 
cell lung cancer (NSCLC) based on histopathological characteristics (Figure 2). SCLC occurs 
in about 20% of the patients while the majority of the burden comes from NSCLC (80%), 
which is further classified as adenocarcinoma (ADC, ~50%), squamous cell carcinoma (SCC, 
~40%) and large cell carcinoma (LCC, by exclusion of ADC and SCC). SCLC and LCC are 
distinct set of neuroendocrine malignancies and have an independent route of clinical 
management2,3. ADCs arise in more distal airways whereas SCCs arise in more proximal 
airways with a stronger associated with smoking. There are distinct biomarkers determining 
the origin of lung tumors which dictates the treatment decisions. 
Figure 2. Histological subtypes in Lung Cancer. 
Clincil subclassificaton of lung cancer based on histopathological characteristics and location of the 
tumor origins. Image was created with BioRender.com 
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1.2 Lung cancer heterogeneity 
Lung cancer patients presenting in the clinic at an advanced stage have a very high 
mutational burden4. The most commonly identified mutations in lung cancer patients are 
KRAS, EGFR, EML4-ALK, c-MET, AKT/PI3K and their associated signaling pathways5. The 
diagnosis and treatment strategies for lung cancer are based on the genetic defects detected 
from a small biopsy specimen and are used to classify patients for appropriate treatment 
approach. It is important to note that this approach has significantly improved patient outcome 
relative to the conventional cytotoxic chemotherapies like cisplatin and carboplatin6. The 
identification of driver mutations in patients allowed the combination of chemotherapy with 
targeted agents which significantly improved the response rate and progression-free survival 
in lung cancer patients. However, these therapies are designed to target only a specific 
subset of mutations and eventually become ineffective7 resulting in the recurrence of the 
disease8. This is the one of the greatest challenge faced by lung cancer patients and 
oncologists.  
While precision medicine largely focuses on genetic and molecular profiling of tumor 
cells, identification of various biomarkers to predict disease progression does not necessarily 
translate into successful clinical outcomes. The complexity of tumors and the heterogeneity 
within is now a well-established concept. The term tumor heterogeneity broadly encompasses 
tumor cell heterogeneity (intratumoral heterogeneity ITH), tumor microenvironment 
heterogeneity (TME), and inter patient heterogeneity. Lung cancer is not just a composition 
of epithelial cancer cells with different mutations but an ecosystem consisting of 
phenotypically distinct tumor cells, surrounded by cellular and non-cellular components that 
are dynamically interacting and causing tumor evolution. One of the most outstanding 
examples of clinical application of this concept has been utilization of immunotherapy. The 
development and success of immune checkpoint inhibitors in many susceptible tumors has 
led to the approval of anti-PD1 drugs either as single agent or combination with chemotherapy 
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for first-line treatment for many lung cancer patients. However, only a small percentage of 
lung cancer patients respond upfront and eventually develop resistance9-11. To overcome the 
therapeutic plateau in lung cancer patients, an extensive understanding of the complexities 
of lung cancer heterogeneity is needed. In the following sections, we discuss the different 
sources of intratumor heterogeneity in lung cancer and the current clinical approaches in lung 
cancer. We also discuss the importance of studying lung cancer microenvironment as a 
source of heterogeneity and its implications for improving patient outcome.  
 Genetic Heterogeneity  
Molecular characterization of lung cancer is primarily based on mutations in EGFR, 
KRAS, p53, c-MET, EML4-ALK and their associated signaling pathways7 (Figure 3). 
However, lung cancer cells within a single tumor carry multiple mutations which contributes 
to genetic heterogeneity. For a long time, the single oncogene paradigm which identified the 
founder events, such as KRAS or EGFR mutations, determined the treatment strategy. 
However, ADC and SCCs are characterized by high mutational burden and co-occurrence of 
multiple genomic alterations may have important biological implications on tumor evolution. 
The significance of co-mutations mediating phenotypic diversity has recently challenged the 
single oncogene paradigm but the biological effects remain largely uncaptured12.  
 
Figure 3. Oncogenic drivers in lung adenocarcinoma.  
Mutations in different oncogenes contribute to genetic heterogeneity in lung cancer.   
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One of the models that attempts to explain ITH is the clonal evolution (CE) model which 
is primarily gene centric13. In the classical view of CE, a single initiating cell gains mutational 
hits which divides to form other tumor cells. As the tumor progresses, different groups of cells 
acquire different genetic aberrations. The different tumor subpopulations undergo Darwinian 
evolution through natural selection and the subpopulations with greatest cellular fitness, 
attributed to acquisition of genomic alterations, dominate over the others providing a growth 
advantage to the tumor. As more and more mutations accumulate in the cancer cells, the 
tumor adopts to a more aggressive form. Thus, the tumor is composed of heterogeneous 
populations of cancer cells with different genetic backgrounds with variable invasive and 
metastatic potential, and responses to therapy. In order to support the CE model and trace 
the of evolution of clones in cancer, advanced techniques like multiregional sequencing and 
genome wide exome sequencing have been applied to patient derived samples from different 
cancers, including lung cancer14-16. Multi-region whole exome sequencing of patient derived 
lung cancer samples suggested that lung cancer follows a branching evolution. A study led 
by deBruin et al. identified regionally separated driver mutations showing branched evolution 
with driver mutations arising before and after sub clonal diversification15. Another study by 
Zhang et al. suggested that single region sequencing may be sufficient to identify the gene 
mutations associated with lung cancers16. However, limitations with these studies were the 
small sample size [25 and 11 patients respectively]. As the sample size gets larger, the 
chances of detecting more molecular defects in the genome increase. Therefore, these 
studies do not represent the entire population of NSCLC patients or the entire tumor within a 
single patient. Although these studies have limitations, identification of oncogenes and tumor 
suppressors remained a focus of research and management of patients guiding personalized 
medicine4. It has beyond doubt improved patient outcomes when compared to generalized 
chemotherapy based treatments. The progress, however, has been limited to specific groups 
of patients like those carrying EGFR, ALK, KRAS mutations17. Availability of easier, cheaper 
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and faster genome sequencing for detection of mutations is one of the reason for focusing on 
genetic aspect of lung cancer for designing therapies.  
The concept of co-mutations should also be kept in mind while understanding lung cancer 
progression,  a noteworthy example is the co-occurrence of KRAS and TP53 mutations in 
lung cancer12. The functional impact of such co-mutational burden on downstream signaling 
within lung cancer cells needs to be evaluated during therapeutic stratification of patients. 
Despite the presence of a large number of genetic alterations in a lung tumor, it is important 
to define which aberrations are functionally cooperative and biologically relevant. Many of the 
defects identified maybe presented as therapeutic challenges but may not always be 
translationally relevant. In addition, studies should account for the possible interactions that 
these genetic defects may cause between the different tumor subpopulations and the 
components of the tumor microenvironment (TME)18. It is challenging to incorporate for TME 
components at the time of diagnosis, but understanding tumor as a whole will provide better 
insight to its progression. Targeting only mutations identified in cancer cells eventually leads 
to failure of therapy because the tumor continues to evolve spatially and temporally under 
selective pressures. 
Epigenetic Heterogeneity 
Although epithelial cells in lung cancer acquire multiple genetic hits which largely 
influence the functional characteristics, there is still marked phenotypic plasticity between 
genetically identical cancer cells. It has been suggested that cells can exist in different 
phenotypic states which are regulated by intrinsic and extrinsic factors. Intrinsic factors 
include the fluctuations in gene expressions and other cellular processes, pre-existing 
differentiation states, genetic interactions between different mutations and epigenetic 
modifications. If these fluctuations cross a specific threshold, cells can cross over to a 
different phenotypic state19. Extrinsic factors include the dynamic interactions with the TME 
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which actively modulate the tumor progression. These alterations can be transient or 
permanent and can change cellular, molecular and epigenetic characteristics of cancer cells. 
Epigenetic regulation of gene expression is well recognized for maintaining the normal 
cellular functions and homeostasis in the tissues. These are heritable changes in gene 
expression without any genetic changes in the DNA20. The epigenetic mechanisms include 
DNA methylation, histone modifications and non-coding RNAs like microRNAs. Alterations in 
these epigenetic mechanisms can lead to a dysregulation in the homeostasis of the normal 
cellular state which leads to variations in the phenotype of the cancer cell while maintaining 
the same genetic background. Accumulation of epigenetic alterations overtime has been 
associated with progression from pre-neoplastic to neoplastic stage21.  
Alterations in DNA methylation status have been identified in lung cancer. Promoter 
regions of the tumor suppressor genes are more frequently hypermethylated in lung cancer, 
and these genes are involved in some crucial cellular functions like proliferation, apoptosis, 
adhesion, motility, cell cycle and DNA repair. Genes most commonly found hypermethylated 
in lung cancer are: p16INK4a, RASSF1A, APC, RARβ, CDH1, CDH13, DAPK, FHIT and 
MGMT22 which correlates with poor patient outcome. Analysis of patient samples in clinical 
studies represents a snapshot of the methylation status in the tumor and in a specific region 
of the tumor. Genome wide hypomethylation also occurs in lung cancers which leads to an 
oncogenic activation. This generally occurs in later stages in tumor progression. However, 
gene specific hypomethylation is found in MAGEA, TKTL1, BORIS, DDR1, TMSB10, TP73, 
ZNF711, G6PD AMD 14-3-3σ22. Histone modifications occur in concert with DNA methylation 
and are responsible for regulation of chromatin conformation and gene expression. 
Modifications occur at the histone tails which include acetylation, deacetylation, methylation, 
phosphorylation and ubiquitylation. There are different enzymes catalyzing these reactions 
(readers, writers and erasers) and the most common are Histone acetyl transferases (HATs) 
and Histone deacetylases (HDACs). Generally, HDACs are overexpressed in lung cancers 
and thus cause transcriptional silencing of tumor suppressor genes. Lower cellular levels of 
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histone modifications are associated with poorer clinical outcomes23. MicroRNAs are small 
non coding RNAs (~22 nucleotides) that bind to the 3’ untranslated regions of messenger 
RNA (mRNA), causing degradation of the mRNA or inhibition of protein translation resulting 
in decreased gene expression. Numerous microRNAs are frequently dysregulated in lung 
cancer at different stages of the disease24 A single microRNA can have multiple target genes 
and a single gene can be targeted by many microRNAs. This can lead to heterogeneity in the 
tissue as the regulation depends on the temporal and spatial characteristics of the tumor.  
Epigenetic studies have mainly focused on identifying the dysregulations associated 
with lung cancer in the clinic primarily for biomarker development. However, similar to the 
large scale studies for identifying new mutations in lung cancer, only correlative studies for 
epigenetic alterations may not be the best approach. Firstly, these epigenetic alterations 
occur commonly in many cancers and it is difficult to establish exclusivity. Secondly, there is 
limited data on epigenetics from normal lung for comparison. Thirdly, no single alteration will 
capture all the tumors on account of heterogeneity in lung cancers and since epigenetic marks 
are dynamic in nature, they are context dependent. 
Epigenetic alterations are also believed to maintain a small subpopulation of cells 
known as cancer stem cells (CSCs)25. The cancer stem cell model posits that cancers are 
maintained by a small subpopulation of cells that have stem cell like properties similar to stem 
cells that populate the normal tissues. These CSCs have almost unlimited proliferative 
capacity and differentiate into cells of different lineages giving rise to a hierarchical 
organization in the tumor26,27. The descendant cells have limited proliferative capacity and 
form the bulk of the tumor. Since they are of different lineages, they contribute to the 
heterogeneity in the tumor. These cancer stem cells are believed to promote tumor 
progression and metastasis and have inherent resistance to therapies. CSCs have been 
reported to exist in lung cancer and associated markers include CD133, CD44, expression 
and/or activity of the cytoplasmic enzyme aldehyde dehydrogenase ALDH and presence of 
cells known as side populations. Embryonic stem cell pathways such as Hedgehog, Notch 
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and WNT have also been reported to be altered in lung cancer28. However, lack of sensitivity 
and specificity of these markers and substantial experimental evidence stems the controversy 
of significance of CSCs.  
 The impact of selection forces on different phenotypes within heterogeneous tumors 
is reflected in terms of drug resistance as well as metastatic potential of cancer cells. It is 
challenging to account for these non-genetic traits in clinical practice, especially because the 
phenotypes can be highly plastic. Stochastic nature of biochemical processes within cancer 
cells can also affect the phenotype, for example variable gene expression in response to 
external modifications. However, greater efforts are being made to incorporate tumor cell 
heterogeneity in clinical decision making and understanding lung cancer biology at a 
fundamental level.  
 Microenvironmental heterogeneity  
Tumors are complex ecosystems surrounded by a microenvironment consisting of 
immune cells, fibroblasts, endothelial cells, extracellular matrix, chemokines and cytokines. 
They are continuously evolving which results in a heterogeneous mix of phenotypically 
different cells. Spatial and temporal variability of the tumor microenvironment (TME) with 
respect to the tumor also plays a role in heterogeneity. At a given time, each part of a tumor 
is exposed to different components of the TME. Thus, there may be additional stable 
phenotypic states of cancer cells which may not have been present in the normal tissue 
contributing to intra tumor heterogeneity. The bidirectional interaction between the cancer 
cells and TME can either promote or inhibit tumorigenesis18. The abnormal stroma 
surrounding the cancer cells can induce stress responses and genomic instability29, epithelial 
to mesenchymal transition30, cause vascular mimicry31 and promote tumorigenesis through 
tissue reorganization32. Some correlative clinical studies, in vitro and animal studies have 
demonstrated the significance of studying stroma and its association with lung cancer 
prognosis. However, most of these studies have limitations like studying a single component 
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or a unidirectional effect. Here, we briefly iterate what is known about the tumor 
microenvironment in lung cancer. 
Extracellular matrix (ECM) was considered just a supportive framework for tumors for 
a long time. However, it plays a more dynamic role in modulating the process of tumor 
progression33. ECM is composed of large variety of proteins, glycoproteins, proteoglycans, 
and polysaccharides34. It maintains tissue architecture and function through dynamic 
bidirectional interactions35 and disruption in this interaction can cause tumor formation and 
progression. On the other hand, it has also been demonstrated that altering the matrix 
components in a manner that mimics non-malignant tissue can revert the malignant 
phenotype in cancer cells36. Normal lung tissue is characterized by limited ECM components 
as well as  low stiffness.  Laminin and collagen IV are the predominant ECM proteins in non-
malignant lung tissue alongwith lower amounts of other collagens, elastin and 
glycosaminoglycans37. However, progression from non-malignant to premalignant and 
malignant lesions is characterized by dysplastic reaction which is associated with 
accumulation of and alteration in the ECM proteins38. One such example is an increased 
deposition of collagen I in the extracellular matrix that is highly cross-linked leading to greater 
linearity and organization which aids in invasion and metastasis of cancer cells39.  In SCLC, 
ECM proteins have been shown to protect against apoptosis, enhance tumorigenesis, and 
confer chemoresistance through beta-1 integrin mediated tyrosine kinases activation40. 
Thomas et al. showed that there was a positive correlation between the expression of 
metalloproteinases and metastasis in NSCLC41. SPARC/osteonectin synthesized by tumor 
stroma showed a strong association with intratumor hypoxia and acidity indicating a link 
between cellular metabolism and induction of supportive stroma that favors cancer cell 
migrations and invasion, leading to poor prognosis42. Integrin mediated adhesive interactions 
with ECM have been implicated in cancer progression and invasion43. ECM protein 
interactions with intergrins on cell surface can also modulate the phenotypic characteristics 
of the tumor cells by activating outside-in signaling and modulating the levels of microRNA-
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200. In turn, microRNA-200 family members can modulate the inside-out signaling that alters
ECM components in lung cancer. These signaling pathways allow the dynamic switch of 
cellular phenotype between metastasis-prone and metastasis-incompetent39,44,45.  
Fibroblasts are one of the principal cellular component of the TME and have a 
significant role in deposition of ECM46. Activated fibroblasts are found in cancers and are 
known as cancer associated fibroblasts (CAFs). Responses of fibroblasts to activation include 
proliferation, fibrinogenesis, and release of cytokine and proteolytic enzymes. Activated 
fibroblasts in CAFs are characterized as alpha-smooth muscle actin-positive myofibroblasts 
and actin-negative fibroblasts, both of which are competent to support tumor growth and 
progression47. Role of CAFs have been studied in lung cancers only recently48,49,50,51,52.  
Although CAFs are mostly considered pro-tumorigenic, there is some evidence indicating 
their anti-tumor effects. CAFs were shown to impart resistance to EGFR tyrosine kinase 
inhibitors through HGF production49, but a recent study suggested that there is an increased 
autophagy in lung cancer cells in response to erlotinib treatment when co-cultured with CAFs 
through an increased production of IL-6 an IL-8 48. Other groups suggest the supportive role 
of CAFs by demonstrating enhanced motility of NSCLC cells51, increased expression of MMP-
2 on CAFs with a cross-talk between CAFs and ECM, correlation of poor prognosis with 
increased CAFs50 and increased plasticity of cancer cells in presence of CAFs52.  A recent 
study in lung cancer demonstrated CAFs can also exhibit phenotypic heterogeneity that is 
determined by tumor cell interactions53, further underscoring the bi-directional heterotypic 
interactions.  
The microenvironment in lung cancer is rich in resident and circulating immune cells. 
Clinical correlative studies have shown that infiltrating immune cells can determine the 
prognosis of lung cancer. Using human lung tumor xenografts, it has been shown that 
inflammatory cells, tumor infiltrating lymphocytes (TILs), within the stroma are functional and 
can suppress tumor growth through exogenous cytokines like IL-1254. Increased infiltration 
and invasion of macrophage and mast cells55, dendritic cells56 and lymphocytes57,58 within the 
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tumor have been shown to correlate with better clinical outcome suggesting that stromal 
immune component may have an anti-tumor effect in NSCLC. Additionally, using mouse 
models of lung cancer, a specific gene expression signature was identified in the tumor 
associated macrophages suggesting that tumor cells affect the immune cells as much as the 
other way around and could be potentially used as surrogate tissue for patient stratification 
and predicting clinical outcome59. Recent data suggests that there is a heterogeneity in 
immune cell infiltrates between primary and metastatic sites in lung cancer60. CD4+ and CD8+ 
T cells were compared within tumor cell islets and stromal compartment by 
immunohistochemistry which showed that there were fewer immune cells in the tumor cell 
clusters. Majority of the immune cells were found in the stromal compartment of the tumor 
tissue. This was also true for metastatic lesions of the corresponding primary tumor. In 
addition, the metastatic lesions generally had significantly lower CD8+ T cells compared to 
the primary tumors. The differential pattern of immune cell infiltration in primary and 
metastatic tumor suggests a weakened immune response at the distant metastatic sites. 
In response to the structural changes, many metabolic alterations also occur during 
lung cancer progression such as release of cytokines, chemokines, growth factors, differential 
alterations in vasculature and hypoxia. The cross talk between stromal and cancer cells 
potentially occurs through soluble factors like cytokines and chemokines secreted by them. 
Many such factors have been identified in lung cancer. One of the earliest chemokines 
identified in lung cancer was SDF-1/CXCL12-CXC4 axis, which appeared to regulate 
metastasis61. Many others have shown that multiple paracrine signaling occurs in lung cancer, 
in order to create a more suitable microenvironment for tumor progression. CXCR4 and CCR7 
have been implicated in metastasis, IL-7R provides signals to lymphocytes and is associated 
with shorter survival in lung cancer patients62. Hepatocyte derived growth factor (HGF) from 
fibroblasts induces chemotherapeutic resistance to EGFR receptor tyrosine kinase 
inhibitors49. Tumor sub-clones in SCLC communicate via fibroblast derived growth factor (Fgf-
2) in order to promote metastasis63. Secreted factors from stromal component affect
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tumorigenesis and alter tumor cell secretome64. This suggests that there is an active 
exchange between cancer cells and stromal components which modify one another 
contributing to ITH. 
Rapidly dividing tumor cells and the recruitment of heterotypic cells supporting tumor 
growth can cause a strain on the oxygen supply in the tumor microenvironment. Hypoxia-
driven gene and protein changes can further enhance tumorigenesis by regulating other 
aspects of the stroma like ECM remodeling, EMT, promoting angiogenesis and imparting 
resistance to therapy65. However, evidence from another study suggests that hypoxic TME 
could also be anti-tumorigenic66. In an attempt to map the heterogeneity in the hypoxic TME, 
Cui et al. injected nude mice with lung cancer cell subcutaneously and injected 18F-
fluoromisonidazole and hypoxia marker pimonidazole hydrochloride intravenously. Series of 
PET scans, autoradiography and microscopy helped in the visualization of heterogeneity in 
hypoxic microenvironment. The study also suggested that cancer cells had shorter life span 
in a hypoxic in vivo environment, which is in contradiction to what is observed in vitro. 
Nevertheless, this study suggested that the cancer cells are spatially and temporally exposed 
to differential levels of oxygen which could alter their phenotypic characteristics thus 
contributing to ITH. Figure 4 summarizes the different sources of tumor heterogeneity within 
lung cancer. 




Figure 4. Origins of heterogeneity within lung cancer. 
Cell-intrinsic and cell-extrinsic factors contribute to tumor heterogeneity in lung cancer. Cell-to-cell 
variability in genetic and phenotypic characterisitcs cause tumor cell heterogeneity. Stromal 
components including extracellular matrix (ECM), immune cells, cancer associated fibroblasts (CAFs) 
and vascular supply are extrinsic factors that affect tumour cell heterogeneity and function. Multiple 
sources of heterogeneity within a tumor may co-exist and interact with each other overtime to shape 
up the heterogeneous cancer. Figure created with BioRender.com 
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 Clinical significance of tumor heterogeneity  
With technological advances in personalized medicine, great strides have been 
achieved in the outcome of lung cancer patients. Personalized medicine targeting specific 
mutations is a main treatment strategy adopted in the clinic. However, lung cancer 
heterogeneity plays an important role in the development of drug resistance. Thus, 
understanding the biology of lung cancer progression in context of heterogeneity due to both 
genetic and non-genetic factors is essential to improve therapeutic strategies. This 
knowledge would help revisit the approach of lung cancer diagnosis and classification with a 
treatment strategy that would take into account the complexity of tumors.  
Resistance to small molecule inhibitors is frequently attributed to accumulation of 
additional mutations or activation of a bypass pathway. One of the most successful targeted 
therapies in lung cancer is the use of EGFR tyrosine kinase inhibitors which include gefitinib 
and erlotinib.  However, about 50% of the patients treated with EGFR inhibitors acquire 
T790M mutations67  68. These patients are responsive to osimertinib, and as a first-line therapy 
the drug is able to prevent emergence of resistance due to T790M mutation69. MET and 
ERBB2 amplification have been reported to cause primary resistance to third-generation 
EGFR inhibitors, including osimertinib70. This is a key example of presence of co-mutations 
driving genetic heterogeneity in tumors ultimately leading to therapeutic resistance. It is vital 
to determine whether such co-mutations present are secondary drivers or merely passenger 
mutations. Molecular subtype of lung cancer is driven by ALK fusion accounts for a small 
percentage of patients, of which ~60% respond to targeted inhibitors such as crizotinib, 
ceritinib, alectinib, and brigatinib. These tumors also demonstrate abundant genomic 
heterogeneity which may account for differences in treatment response with targeted ALK 
inhibitors71. Many clinical trials have explored novel drugs for different driver mutations by 
restricting to specific molecular subtypes72. Large scale screening studies are also being 
conducted to identify novel drivers of lung cancer progression, metastasis and therapeutic 
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resistance4. This approach certainly provides a detailed insight into the molecular 
mechanisms in lung cancer. Nevertheless, both cell-intrinsic and cell-extrinsic factors should 
be evaluate in the consideration for improvement of clinical outcome. 
Targeting phenotypically distinct subpopulations by identifying therapeutic 
vulnerabilities allows for a robust control of tumor growth and this concept has been 
extensively applied in KRAS mutation driven lung cancers. Due to undruggable nature of 
KRAS oncoproteins, downstream effector pathways are targeted, which include MAPK 
pathway members73. Despite the availability of specific drugs targeting these pathways, 
clinical efficacy has remained poor as  single agent or in combination with chemotherapy 74,75. 
The underlying explanation is due to the presence of profound tumor heterogeneity. Cancer 
subpopulations with pre-existing resistance or emergence of acquired resistance to drugs 
eventually leads to the failure of therapy in the clinic76.  
Components of TME, especially CAFs and immune cells, also impart resistance to 
therapy by modulating cancer cell characteristics77. Cancer cells escape detection by the host 
immune system and in order to elicit a response, cancer drugs are usually designed to 
eradicate the cancer cells. In recent years, the importance of engaging the host immune 
system in cancer treatment has been recognized. Lung cancer cells escape immune 
detection many mechanisms.  There can be decreased tumor antigen presentation, 
recruitment of tumor suppressor cells, and engagement of checkpoint pathway inhibiting 
antitumor immunity78. The checkpoint pathways include cytotoxic T-lymphocytes antigen-4 
(CTLA-4) and programmed death receptor-1 (PD-1). Efforts are directed to block these 
pathways in order to elicit an immune response against the tumor cells. Anti-CTLA-4 include 
ipilimumab which has shown efficacy in melanoma79 [Phan 2003], is currently in clinical trials 
for lung cancer80. Anti-PD-1 agent nivolumab improved the overall survival in lung cancer 
patients after platinum based chemotherapy when compared to docetaxel81. Adoptive cell 
therapy is also being investigated where immune cells are isolated from peripheral blood 
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followed by ex vivo expansion of tumor suppressor cells and autologous administration in the 
host82. Significance of immunotherapy lies in the fact that it is effective regardless of any 
heterogeneity between the tumor cells. In addition, combining chemotherapy (paclitaxel) with 
immunotherapy (ipilimumab), targeted therapy (EGFR inhibitors) with immunotherapy 
(ipilimumab) and different checkpoint inhibitors (anti CTLA-4 and anti PD-1) has proven 
extremely effective and in fact are standard of care in NSCLC83. Although CAFs and ECM 
seem attractive targets for therapy to prevent tumor progression, due to limited preclinical, 
effective targeting has not been achieved. Therapies targeting vascular endothelial growth 
factor (VEGF) like bevacizumab, in combination with chemotherapy have been shown to have 
some benefit over chemotherapy alone84. However, due to heterogeneity in vasculature 
around the tumor tissue, the response to these agents is limited and not very consistent. 
Instead, the idea of reverting blood supply to normal conditions is being explored which can 
improve drug delivery and reduce TME heterogeneity85.   
These examples underscore the importance of understanding and targeting tumor 
heterogeneity for sustained benefit. Many unanswered questions that are worth exploring 
include: whether genetically different subsets of lung cancer have their own unique 
microenvironment and regulation, how does the targeted therapy affect the microenvironment 
and how does it influence the progression of the disease, how is the microenvironment 
different between primary, metastatic and recurrent tumor. To effectively understand these 
roles in context of all compartments of the TME, better modelling of the human disease is 
important. It can be achieved by using existing in vitro (primary cell cultures, co-cultures, 3-D 
systems) techniques and animal models (genetically engineered mouse models (GEMMs), 
syngeneic, xenografts, patient derived xenografts) in combination with clinical studies to 
boost the translation of experimental findings to the clinic. Efforts in the clinic must also be 
directed towards improving non-invasive imaging and diagnostic techniques to represent the 
heterogeneity in stroma for targeting the stroma in addition to the cancer cells. There are 
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limitations in all the models, but effectively combining these can closely recapitulate the 
human disease for understanding the biology and improving patient outcome. 
1.3 Models to study heterogeneity 
Despite extensive research efforts and advancements in the understanding of lung 
cancer progression, tumor growth control is only short-term and achieving complete/long-
lasting cures from current therapies seems unattainable. Strategies to prevent metastatic 
disease and therapeutically target mutant KRAS-driven cancers have been limited by many 
factors, including the significant heterogeneity of tumors. Many unanswered questions that 
are worth exploring include: whether genetically different subsets of lung cancer have their 
own unique microenvironment and regulation, how does the targeted therapy affect the 
microenvironment and how does it influence the progression of the disease, how is the 
microenvironment different between primary, metastatic and recurrent tumor. The modest 
translation of the extensive experimental research into clinical outcome begs the question if 
current decision-making approaches are accounting for all aspects contributing to tumor 
progression. Due to the paucity of suitable experimental models that reproduce ITH observed 
in human tumors, there has been a disparity between efficacy observed in pre-clinical models 
and the actual translatability into patient response. An untapped therapeutic potential of the 
other components of lung tumors needs to be exploited. Nuanced observations and evolving 
understanding of the effect of tumor subpopulations adopting distinct cellular states, 
extracellular matrix modulating the response to therapy, cancer-associated fibroblasts aiding 
in metastatic process and vascular compartment affecting drug delivery are moving to the 
forefront and have drastic implications on the sensitivity to therapies. To effectively 
understand these roles in the context of all compartments of the TME, better modelling of the 
human disease is important. It can be achieved by using existing in vitro (primary cell cultures, 
co-cultures, 3D systems) techniques and animal models (genetically engineered mouse 
models (GEMMs), syngeneic, xenografts, patient derived xenografts) in combination with 
clinical studies to boost the translation of experimental findings to the clinic. Efforts in the 
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clinic must also be directed towards improving non-invasive imaging and diagnostic 
techniques to represent the heterogeneity in stroma for targeting the stroma in addition to the 
cancer cells. There are limitations in all the models, but effectively combining these can 
closely recapitulate the human disease for understanding the biology and improving patient 
outcome.  
 Three dimensional models 
Artificially-created environment in which cancer cells are permitted to grow and 
interact with their surroundings in all three dimensions serve to bridge the gap between the 
uses of whole animals at one end of the spectrum, with cellular monolayers at the other. 3D 
spheroids more closely resemble in vivo tissue in terms of cellular communications and the 
development of extracellular matrices86,87. When normal human bronchial epithelial cells are 
grown in 2D cultures, they proliferate until they form a confluent monolayer, but in 3D Matrigel 
cultures, they differentiate into a characteristic lumen-containing glandular structure, termed 
an acinus representing in vivo characteristics88. 3D cultures can therefore be used to study 
tumor morphology and understand the differences between cell lines from tumors of similar 
and dissimilar organs and tissues. However, a limitation of monocellular 3D cultures derived 
from cancer cells cultured in petri dishes is that long term exposure to 2D culture causes 
alterations in the response of cancer cells to any external stimuli. Primary tumors that are 
isolated and cultured without prior adaption to 2D growth could provide better insights into 
the interactions occurring in a 3D space that can have effects on gene expression and cell 
behavior. With the ability to mimic in vivo phenotype, early steps in tumorigenesis can be 
captured and studied with tumors that harvested and grown in appropriate 3D environment.  
Microenvironment components play a significant role in cancer progression and 3D 
cultures provide an advantage to introduce heterotypic cells and different matrices which 
captures microenvironment heterogeneity. Selection pressure from TME components on 
cancer cells can affect the cellular phenotype and gene expression which can be studied in 
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a high throughput manner and in real-time which is difficult in animal models. Additionally, 
introduction of controlled modifications in the microenvironment components can allow the 
study of response of cancer cells to specific alterations in those components. For example, 
ECM-tumor cell interactions and matrix-dependent signaling that occurs in early tumor 
progression are not completely understood. Understanding the signaling pathways activated 
in response to ECM and disrupting these interactions early-on in tumor evolution will prevent 
the emergence of metastatic subpopulations and aggressive disease.  
3D cancer models are gaining increased traction in the field of drug discovery and 
development as well. Although 2D cultures continue to be the de facto platform used for 
pharmaceutical studies, the cells often adopt physiologically irrelevant phenotype and 
signaling patterns due to the lack of appropriate external cues. While cell lines provide us with 
excellent homogenous study material that have significantly contributed to drug discovery, 
3D models allow for more accurate representation of both the phenotype of cells as well as 
provide more realistic drug response by preserving tumor heterogeneity and thereby are more 
suitable for predicting outcomes to therapeutic agents89.  
 Mouse models 
Genetically engineered mouse models (GEMMs) have enabled numerous studies that 
would not be possible solely with patients’ samples or cancer cell lines, especially testing of 
targeted therapies in immunocompetent models. KRAS driven lung cancer mouse models 
have given great insights into progression from early to late tumorigenesis as well as 
combining with different oncogenes or tumor suppressors to elucidate biological relevance of 
specific oncogenes and tumor suppressors in tumor development. Limitation of these models 
arises due to lack of genetic complexity as they are driven by limited number of mutations, 
unlike human cancers. Due to the exposure to environmental carcinogens as well as other 
physiological factors in patients, tumors express high mutational burden which has impact on 
tumor evolution. Although mouse models do not necessarily provide this information, they are 
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highly reproducible and allow for more extensive analysis of tumor tissues over a period of 
time which is very difficult in patients90.  Next generation GEMMs represent conditional mouse 
models that are genetically engineered to accurately mimic sporadic human cancer are now 
being utilized to more accurately mimic human cancers, including heterogeneity91,92.  
About 30% of lung adenocarcinoma patients present with KRAS mutations usually with 
accompanying co-mutations like p53 which confers metastatic ability to cancer cells. Over a 
decade ago, our group generated a mouse model driven by KrasG12D/p53R172H mutation which 
develops spontaneous lung cancer and closely recapitulates the features of patients with 
metastasis prone lung adenocarcinoma93. This model has served greatly in understanding 
key aspects of Kras mutant lung cancer biology, including metastasis and tumor 
heterogeneity. Using this model, a panel of lung adenocarcinoma cell lines was derived from 
primary and metastatic sties. Cell lines were named according to the mouse number and site 
of derivation. Extensive characterization of these cell lines, both in vitro and in vivo, broadly 
classified them into 2 groups, metastasis competent, mesenchymal cancer cells and 
metastasis incompetent epithelial cancer cells. The genetic abnormalities that were detected 
in these cells were reminiscent of those seen in human lung adenocarcinoma. Thus, this 
model serves as an excellent starting point to study tumor heterogeneity in lung cancer that 
is relevant to the human disease. In addition to the spontaneous KrasG12D/p53R172H cancer 
model, we also utilize autochthonous models that are generated by administration of 
adenovirus expressing Cre recombinase. KrasG12D mutation is coupled with either p53 
homozygous deletion, homozygous mutation or heterozygous deletion and mutation. These 
models have many advantages as mentioned above. They are genetically more complex, 
demonstrate heterogeneity and can be controlled temporally. The models are described in 
further detail in Chapter 5 (5.2.7)  
1.4 EMT in lung cancer and therapeutic resistance 
The epithelial-to-mesenchymal transition (EMT) contributes to the progression of 
cancer by promoting loss of cell–cell adhesion, leading to a shift in cytoskeletal dynamics. 
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Hallmarks of EMT include the loss of stable cell junctions, apico-basal polarity and E-cadherin 
expression and concomitant increase of mesenchymal characteristics such as increased 
migratory ability, matrix degradation, and upregulation of markers such as N-cadherin and 
ZEB194 (Figure 5). Tumors with a mesenchymal phenotype are associated with aggressive 
disease and poor prognosis95. In addition to metastatic disease, EMT has also been 
implicated for development of resistance to chemotherapy, radiation and targeted therapies96-
101. Transcription factor ZEB1 is central to promoting a mesenchymal phenotype in cancer 
cells. ZEB1 represses the transcription of key epithelial genes, including E-cadherin and miR-
200. ZEB1 expression in patient samples is also associated with poor patient prognosis99. 
More details can be found in Chapter 4. 
It is now widely accepted that tumor cells are not locked in one or the other EMT states, 
rather are fluctuating between these cellular phenotypes. Within a heterogeneous tumor, at 
any given time, there are distinct tumor subpopulations that display characteristics on the 
EMT spectrum. As such, when a single drug is administered, a pre-existing resistant 
subpopulation emerges as well as previously sensitive cancer cells acquire resistant to the 
targeted therapy. To achieve robust response, all the subsets of cancer cells need to be 
efficiently targeted to prevent outgrowth. In order to do that, we need to understand the 
survival dependencies of the epithelial and mesenchymal tumor subpopulations and 
mechanistic pathways that drive intrinsic and acquired resistance. 




Figure 5. Epithelial to Mesenchymal Transition (EMT). 
Schematic illustration of cancer cells undergoing shift in phenotypic states from epitheilal on one end 
of the spectrum to mesenchymal on the other end with partial or hybrid states in the middle. Epithelial 
cancer cells are characterized by tight junctions and apico-basal polarity. Mesenchymal cancer cells 
are characterized by increased matrix degradation and ability to invade and metastasize. 
Illustration used with permission from Jared Fradette.  
1.5 Dissertation objectives 
The objectives of the project were two-fold: developing cancer models to effectively 
recapitulate tumor heterogeneity in lung cancer and leverage multiple strategies to identify 
therapeutic vulnerabilities of distinct tumor cell subpopulations for enhanced control of lung 
cancer progression. Chapter 3 and 4 describe the establishment and characterization of an 
Ex Vivo Tumor model with incorporation of sensor cells that detect dynamic changes in EMT 
status of cancer cells. We demonstrate the significance of utilizing these models for identifying 
novel biological process in lung cancer and as a high throughput screening tool.  
Chapter 5 identifies CDK4 as a major survival dependency in Kras mutant 
mesenchymal lung cancer cells. Targeting CDK4 and MAPK pathways with clinically 
approved pharmacological inhibitors showed a robust tumor growth control as well as 
prevented emergence of resistance to either single agent. We also describe the mechanistic 
basis of the increased dependency on CDK4 which occurs through dysregulated ZEB1-p21-
CDK4 axis. Correlation of ZEB1 and p21 in murine and human lung cancer tissue provides 
evidence for incorporating these as biomarkers to determine sensitivity to CDK4 inhibitors.   
 ____________________________________________ Chapter 2: Materials and Methods 
24 
 
Chapter 2: Materials and Methods 
2.1 Murine lung cancer cell lines and syngeneic mouse model. 
All animal experiments were reviewed and approved by the Institutional Animal Care 
and Use Committee at The University of Texas M.D. Anderson Cancer Center performed in 
accordance to their guidelines. All mice used in the studies were immunocompetent and 
assessed for health daily by the Department of Veterinary Medicine and Surgery (DVMS). All 
mice were genotyped to determine the mutational status by tail snips 2 weeks after birth. 
Primary and metastatic murine lung cancer cell lines previously derived from spontaneous 
Kras/p53 GEMMs93 were cultured in RPMI 1640 with 10% FBS. 344SQ cell lines are 
metastatic in vivo upon subcutaneous implantation. Wild-type 129/SV mice from our colony 
(males and females) of at least 8 week of age were used for the syngeneic tumor experiments. 
Subcutaneous injections of 1 million cells in single-cell suspension were placed in the 
posterior flank in 100 µL of media. Animals were monitored regularly and euthanized when 
they exhibited signs of morbidity or when size of the subcutaneous tumor required sacrifice 
(5–6 weeks). For intratracheal implantation of tumor cells, mice were anesthetized via intra-
peritoneal injection of room temperature 20 mg/ml avertin and intubated as previously 
described102. 2.5x104 cells in single-cell suspension of 50 µL of media were delivered through 
trachea and were allowed to grow for three weeks before harvesting. The animals received 
intraperitoneal injections 5 days/week with DMSO or dasatinib (purchased from Selleckchem) 
at a dose of 10 or 20 mg/kg in 50μl. Mice were examined for metastasis and tissues for the 
subcutaneous tumor, lungs and any organs with visible metastasis were collected. The results 
are represented as mean ± standard deviation and student’s t-test was performed for 
statistical significance. 
For in vivo tumor growth assays with transplantation of mouse lung cancer cell lines, 
male and female wild-type 129/Sv mice ages 3 months and up were used. Cells were 
implanted subcutaneously into the right flanks of 129/Sv mice and allowed to form tumors for 
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2 to 3 weeks, at which point tumor volumes were approximately 150 to 200 mm3 measured 
using digital calipers. For conditional mouse models of lung adenocarcinoma (KrasLSL/+, 
KrasLSL/+p53flox/flox and KrasLSL/+miR-200c-/-) (previously describes in ref.103), adenovirus-
expressing Cre recombinase was administered into mouse lungs at 3 months of age by 
intratracheal intubation at a viral titer of 2.5x107 viruses per mouse. Mice were housed 
specifically in suites designated for biohazard handling as approved under the IACUC 
protocol. Two weeks post-infection, mice were returned to the regular housing suite.  At 3 
months post-induction, mouse lungs were visualized by micro-CT scans to confirm tumor 
formation and measure tumor areas. For drug treatment experiments, mice were randomized 
to either treatment or vehicle control groups AZD6244 (Selleckchem) and palbociclib 
(MedChemExpress) were administered daily by oral gavage at a dosage of 25 mg/kg mouse 
weight and 50 mg/kg mouse weight, respectively. Tumor sizes were measured weekly after 
treatment began. AZD6244 was dissolved at 5 mg/mL in solvent (4% DMSO, 30% PEG 300, 
5% Tween 80), and palbociclib was dissolved at 10 mg/mL in solvent (Lactic acid buffer (50 
mM, pH 4.0)). Control mice received solvent at a volume equal to the drug dosage at the 
indicated drug concentrations. Mouse weights were measured weekly to adjust total dosage 
and assess the effects of drug combinations on mouse health. After euthanasia by CO2 
exposure at 3 L/min, syngeneic primary tumors and/or mouse lungs were formalin-fixed, 
paraffin-embedded, and sectioned for histological analysis.  
In vivo combination synergy analysis was done using the method of Bliss 
Independence as previously described 104. A primary analysis day was specified for each 
study, usually at or near the last day of treatment. On that day, the expected additive response 
(EAR) tumor volume for the combination group was defined, per the Bliss method, 
as EAR=(V1*V2)/VC, where V1 and V2 are the mean tumor volumes in the single-agent 
groups, and VC is the mean volume in the control group. Next, the control group tumor volume 
change from baseline was defined as ΔV=VC−V0. Then an additive range around the EAR 
was defined, via upper and lower limits, as EARU = min(2*EAR, EAR + 0.15*dV) and 
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EARL=max(EAR/2,EAR-0.15*dV). If the observed mean combination volume on that day was 
larger than the mean volume of either single agent, the combination was called antagonistic. 
If it was smaller than that but larger than EARU, the combination was called less than additive. 
If it was between EARU and EARL, then the combination was called additive; otherwise, the 
combination was called synergistic. 
2.2 Ex Vivo Tumors: isolation, processing and 3D assays 
Primary subcutaneous and orthotopic lung tumors were isolated and collected in PBS-
10% FBS solution at 6 weeks after implantation. Tumor tissues were initially subjected to 
mechanical breakdown by mincing the tumors with scalpel followed by chemical digestion in 
10 ml of 0.2% Collagenase A (Sigma Aldrich 10103578001), 0.2% trypsin (Gibco 27250018), 
0.5% FBS in RPMI for one hour at 370C. Tissue suspension was further broken down in a 
gentleMACS™ dissociator using the lowest setting to yield multicellular tumor aggregates. 
The solution was centrifuged at 1500 rpm for 10 min to remove Collagenase/trypsin from the 
solution and incubated with DNAase (2U/µL) for 5 minutes at room temperature. Three rounds 
of differential centrifugation were performed to remove any single cell from the EVTs. EVTs 
were cryopreserved in 90% FBS-10% DMSO solution for future use.  
The processed EVTs were cultured for one day in poly(dimethylsiloxane) (PDMS) 
microwell inserts designed for standard tissue culture plates1056. The microwells within each 
insert are ~100 µm in diameter allowing exclusion of aggregates greater than 100 µm and 
yielding EVTs of uniform size. EVTs harvested from microwells were embedded in 100 µL of 
Matrigel (BD 356231), plated on 8-well chamber slides pre-coated with 25 µL of Matrigel and 
incubated at 370C for 30 minutes. The cultures were supplemented with media containing 
RPMI 1640, 10% FBS, 2% Matrigel and 1% Penicillin-Streptomycin. Invasive potential of 
EVTs was tested in response to Transforming Growth Factor β (TGFβ) (CST # 8915LC) in 
the media and rat tail Collagen I (BD 354249) in the matrix. TGFβ at 5ng/ml was added to the 
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media and replenished every 48 hrs. EVTs were scored as invasion-positive in response to 
TGFβ if one or more protrusive structures were present. EVTs were embedded in 
Matrigel/Collagen mixture, plated on 8-well chamber slides pre-coated with 25 µL of Collagen 
mix at the indicated concentration, incubated at 370C for 45 minutes to allow polymerization 
of Collagen and then supplemented with RPMI 1640 containing 10% FBS, 2% Matrigel and 
1% Penicillin-Streptomycin. The structure sizes and invasion were scored at the end of the 
experiment, with structures counted invasion-positive in Matrigel/Collagen mixture if one or 
more protrusions were present. Cell viability of EVTs was measured using Cell Titer-Glo 
(Promega) following manufacturer recommendations. Luminescence intensity was measured 
with a Synergy HT microplate reader (BioTek) and normalized to intensities of controls. 
Spheres were imaged using an inverted microscope. Adobe Photoshop software 
(RRID:SCR_014199) was used for RFP and GFP pixel analysis by histogram analysis of 
green and red pixels as a percentage of total colored pixels per field of view (FOV). Minimum 
number of independent FOVs counted was 4. Spheres were also imaged using an Olympus 
IX73 microscope.  
2.3 Flow cytometry on EVTs for TME components 
For isolation of single cells from EVTs, media was removed from the wells and washed 
with PBS. EVTs were collected in 50 mL falcon tubes with 10 mL of cold PBS-EDTA and 
shaken at 4oC for 30 minutes. The solution was centrifuged, supernatant removed and 
resuspended in Collagenase-trypsin mix. This was shaken at 37oC for 30 minutes followed 
by neutralization with complete media. Supernatant was removed after centrifugation and 
cells were resuspended in 100 µL of FACS buffer (PBS+ 5% FBS). Samples were stained 
with conjugated flow cytometry antibodies for TME components. Zombie Aqua (Biolegend 
423101) was used as a marker to detect live cells. CAFs were detected with CD90.1 antibody 
(PerCP Mouse Anti-Rat CD90/Mouse Catalog No. 557266), endothelial cells were detected 
with CD31 antibody (PE anti-mouse Catalog No. 102407) and immune cells were detected 
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with CD45 antibody (FITC anti-mouse Catalog No. 103108). To further identify immune cells, 
we used CD3 antibody (PE/Dazzle™ 594 anti-mouse Catalog No. 100246) for T-cells and F-
480 antibody (APC/Cy7 anti-mouse Catalog o. 123117) for macrophages. All antibodies were 
used at 1:100 dilution and samples were stained for 30 mins. Analysis was done using FlowJo 
software (version 10). All subpopulations were analyzed independently under total live cells 
unless otherwise noted.  
2.4 Migration and invasion assays 
Cells were seeded at 5x104 per well in serum-free media in a 24-well Transwell or 
Matrigel plate (BD Biosciences, pore size 8 μm). RPMI with 10 % FBS was placed in the 
lower chamber as chemoattractant and cells were allowed to migrate for 6 (H157 cells) or 16 
hrs (murine cells) at 37 °C, 5 % CO2. The migrated/invaded cells were stained with 0.1 % 
crystal violet, captured in five microscopic fields at 4x magnification per well and counted. 
The results are represented as mean ± SD and student’s t-test was performed for statistical 
significance. The graphs in each figure represent one experiment. Each assay was performed 
in triplicate. 
2.5 Cell culture 
Human and murine lung cancer cell lines were cultured in RPMI1640 (Gibco, Thermo 
Fisher Scientific) supplemented with 10% fetal bovine serum (FBS, Gibco). 293T cells were 
cultured in DMEM (Gibco) supplemented with 10% FBS. All human cell lines were obtained 
through ATCC. Murine lung cancer cells were created from KrasLA1/+/p53R172H genetically 
engineered mice as previously described93. Manipulated human and murine cells cell lines 
with ZEB1 and miR-200 expression were derived as previously described103. All cells were 
cultured at 37OC in a humidified incubator at 5% CO2. Cell lines with inducible ZEB1, miR-
200, sh-CDK4 and sh-p21 expression were treated with a final concentration of 2 μg/mL 
doxycycline (dox) from Sigma-Aldrich.  
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2.6 Transfections, and lentivirus generation and transduction 
Transfections of si-RNAs were performed using the Lipofectamine 2000 Transfection 
Reagent (Thermo Fisher Scientific). For lentiviral transductions, viruses were first generated 
by co-transfecting packaging vector psPAX2, envelope vector pMD2.G, and the pLenti-puro 
expression vector into 293T cells using Lipofectamine 2000. Transfection medium was 
removed and 293T cells were cultured in RPMI 1640 supplemented with FBS for 48 hours. 
Viruses were then syringe-filtered through a 0.45 μm nylon filter and polybrene (Santa Cruz) 
was added to a final concentration of 8 μg/mL. Medium containing lentiviruses was then 
added to cells, left to allow infection of the cells for 48 hours, and replaced with fresh medium 
for further experiments. 
Generation of 344SQ_Z-cad cell lines: Reporter constructs d2GFP-Zeb1 3’ UTR and 
E-cadherin promoter-RFP were obtained106. 344SQ cell lines were transduced with lentiviral 
fluorescent sensors. Viruses were generated as described above. The 344SQ cells were 
sorted for GFP positive cells followed by RFP positive cells to confirm both plasmids were 
expressed in all cells using FACS Aria III (BD). After confirmation of GFP/RFP expression, 
the cells were referred to as 344SQ_Z-cad.   
Constitutive Cdkn1a overexpression cell lines were generated by using Cdkn1a 
mouse Tagged ORF Clone (Origene (NM_007669)). Cdkn1a ORF was also subcloned into 
dox-inducible pTRIPZ-GFP vector to generate doxycycline inducible cell lines using EcoRI 
and AgeI restriction cut sites. Constitutive Cdkn1a shRNAs were purchased from Milipore 
sigma. The sequences used in the experiments are listed in table S11. Dox-inducible shRNAs 
were expressed in Tet-pLKO-puro vector with a scramble sequence as the non-targeting 
control. Tet-pLKO-puro was a gift from Dmitri Wiederschain (Addgene plasmid # 21915; 
http://n2t.net/addgene:21915; RRID: Addgene_21915)107. CDK4 and Cdkn1a shRNA oligo 
sequences that were used in the studies are listed in Table 9.  
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2.7 RNA Isolation and RT-PCR  
Cultured cells were washed with PBS, and total RNA was isolated using TRIzol 
Reagent (Thermo Fisher Scientific). EVTs were isolated from the gels using cold PBS-EDTA. 
For dissolving the Matrigel/Collagen layer, Collagenase treatment was performed after the 
initial wash. Each well was incubated with Collagenase Type I (1,000 U/ml, Calbiochem 
#234153) for 30 min at 37 °C. Total RNA was isolated using TRIzol Reagent. For qPCR 
analysis of mRNA expression, cDNA was generated from purified mRNA using qSCRIPT 
reverse transcriptase mix (Quanta Biosciences). QPCR assays were performed using SYBR 
Green PCR Master Mix (Thermo Fisher Scientific) along with primers in Table 6 and 
normalized to the L32 gene. All qPCR reactions were performed using the 7500 Fast Real-
Time PCR System (Applied Biosystems). 
2.8 Protein isolation and western blotting 
Cultured cells were washed with PBS, and proteins were extracted from cell lysates 
using 1xRIPA buffer (Cell Signaling) with protease inhibitors and phosphatase. Samples were 
loaded onto a 10% SDS polyacrylamide gel, separated by SDS-PAGE, and transferred to a 
nitrocellulose membrane. Membranes containing the transferred proteins were blocked with 
5% w/v fat free dry milk (Bio-Rad) dissolved in TBST. Membranes were probed with the 
primary antibodies listed in Table 2 diluted in 1% w/v bovine serum albumin (BSA) and 
dissolved in TBST overnight at 4OC. Next, horseradish peroxidase (HRP)-conjugated 
secondary antibodies diluted in blocking solution were added to the membranes and 
incubated at room temperature for 1 hour. HRP-induced chemiluminescence signal was 
produced using Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific). ECL signal 
from antibody-probed protein was detected using autoradiography film (BioExpress) and 
developer. Subcellular fractionation assay was performed using Cell Fractionation Kit #9038 
according to manufacturer instructions. 
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2.9 Reverse Phase Protein Array (RPPA) preparation and analysis 
Cultured cells described above were washed with PBS, and proteins were extracted 
by the addition of lysis buffer (1% Triton X-100, 50 mM HEPES [pH 7.4], 150 mM NaCl, 1.5 
mM MgCl2, 1 mM EGTA, 100 mM NaF, 10 mM NaPPi, 10% glycerol, 1 mM 
phenylmethylsulfonyl fluoride, 1 mM Na3VO4, and protease and phosphoprotease inhibitors 
from Roche), incubated on ice for 20 minutes, centrifuged at 14,000 rpm for 10 minutes, and 
collected for supernatant. Protein concentration was measured using the Pierce BCA Protein 
Assay Kit (Thermo Fisher Scientific), and protein samples were prepared to a final 
concentration of 1 μg/μl after mixing with 4x SDS sample buffer (40% glycerol, 8% SDS, 
0.25M Tris-HCl pH 6.8, 10% 2-mercaptoethanol) to produce a 1x SDS sample buffer solution. 
Protein samples were then boiled at 100OC for 5 minutes and stored at -80OC for RPPA 
processing described here (https://www.mdanderson.org/research/research-resources/core-
facilities/functional-proteomicsrppa-core/rppa-process.html).  
2.10 In vitro Drug Response and Cell Growth Assays 
Cells were seeded in 96-well plates at 1,000 cells per well, and each row was treated 
with the indicated concentrations of drugs (the first row was the solvent control without any 
drug). After 48 hours of drug treatments, MTT reagent (Sigma-Aldrich) was added to each 
well at a final concentration of 0.5 mg/mL and incubated at 37OC for 1 hour. Color intensity 
measured at 570 nm, with 630 nm reading subtracted for background. Percent surviving 
fraction of cells was normalized against cells treated with solvent control only. 
2.11 Synergy determination  
 The Chou-Talalay method was used to determine possible synergistic effects 
between inhibitors108. Compusyn software (ComboSyn Inc.) was used to determine synergy 
between drug combinations. A fixed ratio of 1:1 µM was utilized over the concentration series 
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of 0.03, 0.06, 0.125, 0.25, 0.5, 1, 2 µM. Drug-drug interactions were analyzed based on 
combination index whereby interactions can be additive (CI=1), antagonistic (CI>1), or 
synergistic (CI<1). Drug concentrations in the combination were compared to the amount of 
drug alone required to reach same effects. This is expressed as the dose reduction index, 
DRI.   
2.12 Apoptosis detection 
Annexin and PI staining: Cells were harvested by trypsinization followed by PBS wash 
and twice with cold BioLegend's Cell Staining Buffer. 5 µL of FITC Annexin V and 10 µL of 
Propidium Iodide Solution were added to 100 µL of cell suspension followed by gentle 
vortexing and incubation for 15 min at room temperature in the dark. 400 µL of Annexin V 
Binding Buffer was added to sample. Analysis was done by flow cytometry using FlowJo 
software (v10).  
NucView 405 Caspase-3 Substrate assay: For detecting apoptosis in live Z-cad 
fluorescent cells, a blue fluorescent caspase-3/7 substrate was used at 2 µM concentration. 
Images were acquired using 405 nm laser excitation using an Eclipse Ti inverted microscope 
with A1+ confocal scanner (Nikon). Flow cytometry was also performed on cells incubated 
with NucView reagent. Briefly, cells were detached from culture substrate using trypsin. Cells 
were resuspended in media and NucView substrate at final concentration of 2 µM was added 
to the cells. Cells were incubated at room temperature for 30 minutes, protected from light 
followed by analysis by flow cytometry. 
2.13 Cell cycle analysis 
Cells were harvested by trypsinization followed by PBS washes. Cold 70% ethanol 
added to cells dropwise while vortexing was used for fixation for 30 min at 4OC. Cells were 
washed with PBS, centrifuged to collect cell pellet. Cells were treated with RNAase and then 
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stained with propidium iodide for 30 min at room temperature. Cell cycle was analyzed by 
flow cytometry using FlowJo software (version 10).  
2.14 Immunofluorescence 
Cells were plated on poly-L-lysine coated cover slips. Cells were fixed with 100% 
methanol, permeabilized with 0.3% Triton-X, and blocked with 5% normal goat serum. 
Primary antibodies listed in Table 5 were incubated overnight. Alexa-Fluor conjugated 
secondary antibodies were used for protein visualization (anti-mouse 546, anti-rabbit 488) 
and coverslips were mounted with ProLong Gold with DAPI for nuclear stain. Images were 
taken on the Olympus IX73 using a 40x objective.  
2.15 Immunohistochemistry 
Paraffin-embedded tissue sections were rehydrated, and heat-mediated antigen 
retrieval was performed using citrate buffer, pH 6.0 (Dako Agilent Technologies). 
Endogenous peroxidases were blocked with 3% H2O2 in TBS, and slides were further blocked 
with 5% goat serum in TBST. Tissues were probed with primary antibodies listed in Table 4, 
diluted in goat serum overnight at 4oC. Slides were then washed three times with TBST and 
incubated with streptavidin-conjugated secondary antibodies targeting rabbit IgG diluted in 
goat serum for 1 hour at room temperature. Slides were washed again and incubated with 
biotinylated HRP in goat serum for 30 minutes at room temperature. After washing, signal 
was attained by developing with DAB reagent (Dako) for 5 minutes at room temperature. 
Slides were washed with ddH2O to stop the reaction and then stained with Harris Hematoxylin 
(Thermo Fisher Scientific) for 1 minute and rinsed with warm tap water for 5 minutes. Slides 
were dipped eight times in 0.25% HCl in 70% ethanol and rinsed with tap water again for 5 
minutes. Slides were dehydrated and mounted for further analysis by bright field microscopy.  
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2.16 Short hairpin RNA (shRNA) screens  
Murine lung cancer cell lines (393P and 344P) were infected at a multiplicity-of-
infection (MOI) of 0.3 with a pooled shRNA lentiviral library targeting genes associated with 
known kinase activity (10 shRNA/gene, for target list see Table 12 and Table 14). Parallel in 
vivo and in vitro screens were performed, and the shRNA-coupled barcodes were detected 
by high-throughput sequencing technology [for detailed procedures and primer sequences 
see109]. In vivo and in vitro screens were carried out in triplicate and duplicate, respectively. 
Raw counts for the screen endpoints and a reference population, isolated after transduction, 
were normalized using the variance stabilizing transformation with the DESeq2 in R. The 
normalized counts were divided by the reference cells that were isolated immediately 
following transduction to estimate a fold change in barcode abundance. Four independent 
shRNAs targeting essential genes (RPL30, PSMA1) or luciferase (LUC) were cloned with 5 
unique barcodes each and incorporated in the library as positive and negative controls (20 
reagents/control, see Table 11 and Table 13). One LUC hairpin showed apparent off-target 
effect, which has been observed over a wide-spectrum of in vitro and in vivo screens. One 
hairpin for PSMA1 did not show robust drop out, and this pattern was consistent across the 
5 barcodes, indicating that this result was not reflective of poor screen performance. The 
separation of positive and negative controls was evaluated by the robust strictly standardized 
mean (SSM, Table 11Table 10 and Table 13), excluding the hairpins mentioned above. Fold 
change distribution was converted to percentiles, and biological replicates were collapsed for 
RSA analysis. The RSA logP-values and ranks are provided in Table 12 and Table 14.  
2.17 Immunoprecipitation assay 
Cells were washed twice with PBS on ice, scraped and pelleted. Supernatant was 
removed and the pellet was lysed in 500 µl lysis buffer [150 mM NaCl, 50 mM Tris-HCl (pH 
7.5), 0.5% NP-40, 50 mM NaF, 1 mM Na orthovanate, 1 mM β-glycerophosphate, 10% 
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glycerol, PMSF and protease inhibitor] and incubated on ice for 30 min. Samples were 
sonicated for 1 min and centrifuged at 13,000 rpm for 10 min. The supernatant was collected 
and precleared for 1 hour at 4OC with non-specific IgG and protein A/G agarose beads. 
Dynabeads were incubated for 1h with 2μg of antibody at 4°C on a rotating platform. 500 µg 
of pre-cleared lysate was subjected to immunoprecipitation overnight at 4°C. Antibody-
antigen complexes were washed with lysis buffer and then eluted with 2x SDS sample Buffer 
at 100OC and analyzed by western blot. Reagents used for IP are listed in Table 3. 
2.18 Chromatin Immunoprecipitation (ChIP) 
Cells were cross-linked with 1% formaldehyde at room temperature for 10 min. 
Glycine was added to a final concentration of 0.125 M for 5 min at room temperature. Cells 
were then washed with PBS with protease inhibitor, scraped and centrifuged (12,000 rpm, 
4OC for 2 min). The supernatant was removed and the pellet was resuspended in 1 ml of lysis 
buffer [50mM Tris-HCl (pH 8.1), 10mM EDTA, 1% SDS, protease inhibitor] incubated on ice 
for 10 min. Samples were sonicated on ice for 30 cycles at 50% amplitude with 5 seconds 
pulse intervals and 10 seconds rest intervals. Supernatants were recovered by centrifugation 
at 12,000 rpm for 5 min. Lysates are diluted 1:10 in ChIP dilution buffer [16.7 mM Tris-HCl 
(pH 8.1), 16.7 mM NaCl, 1.2 mM EDTA,  0.01% SDS, 1.1% Triton X-100,  protease inhibitor]. 
Sheared DNA was precleared with 2 μg sheared salmon sperm DNA and 30 μL protein A/G 
beads (sc-2003) at 4OC for 1 hour with rotation. Beads were pelleted, the supernatant was 
collected and an aliquot (1/20th) of the chromatin preparation was set aside and designated 
as the Input Fraction. The rest of the sample was divided into parts for incubation with 2 μg 
rabbit IgG (sc-2027) and ZEB1 (santacruz) antibodies overnight at 4OC with rotation. The 
immune complexes were captured the next day by incubation with 30 μL of pre-cleared beads 
and 2 μg sheared salmon sperm DNA for 2 h at 4OC. Beads were pelleted by centrifugation 
for 1 min at 4OC at 100 g and washed sequentially for 10 min at 4oC with rotation with 1 ml of 
the following buffers: low salt wash buffer [20 mM Tris-HCl (pH 8.1), 150 mM NaCl, 2 mM 
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EDTA, 1% Triton X-100, 0.1% SDS]; high salt wash buffer [20 mM Tris-HCl (pH 8.1), 500 mM 
NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS]; LiCl wash buffer [10 mM Tris-HCl (pH 8.1), 
1 mM EDTA, 1% sodium deoxycholate, 1% NP-40, 0.25 mM LiCl]. Finally, the beads were 
washed twice with 1 ml TE buffer [1 mM EDTA, 10 mM Tris–HCl (pH 8.0)] for 5 min at 4OC. 
The immuno-complexes were then eluted in 120 µl elution buffer [1% SDS, 100 mM NaHCO3] 
for 15 min with rotation at room temperature. Reverse cross-linking was done by adding NaCl 
to the final concentration of 200 mM to ChIP and input samples and incubating at 65OC for 6 
hrs. This followed by treatment with RNAase and proteinase K (40 µg/ml) incubating for 1 
hour at 45OC. DNA was purified using QIAquick PCR Purification Kit (Qiagen), and 50 ng of 
eluted DNA was used for each qPCR reaction with primers listed in Table 7 to quantify relative 
ChIP signal. Other reagents used for ChIP assay are listed in Table 8. 
2.19 Luciferase Reporter Assay 
pGL2-p21 promoter-Luc was purchased from Addgene. Human cells (H441, H358 
and H1299) expressing ZEB1 and miR-200 were co-transfected with 500 ng of the reporter 
construct and 50 ng of the pRL-TK renilla luciferase vector (Promega) using Lipofectamine 
2000 (Thermo Fisher Scientific). Assays were carried out using Dual-Luciferase Reporter 
Assay System (Promega), where renilla signal was used as an internal control. Relative 
luciferin signal was normalized to signal from the empty pGL2 promoter vector control. 
2.20 Statistical analysis 
 Unpaired students two-tailed t- test were performed for all statistical analysis with two 
comparisons, and one-way ANOVA for comparisons with 3 or more groups. Tukey’s 
correction was used to correct for multiple comparisons. A p-value of <0.05 was considered 
statistically significant. Error bars represent standard deviation unless otherwise noted. All 
analyses were performed in GraphPad Prism (v.8.0.0; RRID: SCR_002798) unless otherwise 
noted.  
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Table 1. Pharmacological agents 
Reagent Manufacturer   
Dasatinib Selleckchem 
AZD0530 Selleckchem 
TGF-β Cell Signaling  
Itgb1 BD Pharmingen 
Y-15  Selleckchem 
BGB324 Selleckchem 
Milciclib Selleckchem 
Palbociclib (in vitro) Selleckchem 






Table 2. Western blot antibodies 
   
Antibody Company Catalog 
Cortactin MilliPore 05-180 
Cttn pY421 Invitrogen 47768 
FAK Invitrogen AHO0502 
FAK pY397 Invitrogen 44624G 
FAK pY576/577 Cell Signaling 3281 
FAK pY861 Invitrogen 44-626G 
Integrin β1 Cell Signaling 4706 
N-cadherin BD Pharmingen 610921 
p130Cas Upstate 06-500 
p130Cas pY410 Cell Signaling 4011 
p-Paxillin Y118 Abcam 4833 
Paxillin Abcam 2264 
Src Cell Signaling 2108s 
Src pY416 Cell Signaling 2101L 
Vimentin Cell Signaling 3932S 
Zeb1 GeneTex GTX105278 
E-cadherin BD Biosciences 610181 
N-cadherin BD Biosciences 610921 
pCDK4 Abclonal AP0593 
CDK4 Abcam ab137675 
p21 Santa cruz sc-6246 
pErk Cell signaling 9101 
Erk Cell signaling 4695 
pRB S780 Cell signaling 8180 
pRB S807/811 Cell signaling 8516 
RB abcam ab218526 
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pFOXM1 abcam ab180710 
FOXM1 abcam ab207298 
Actin ProteinTech 66009-1-Ig 
Cleaved caspase-3 Cell signaling 9661 
Lamin A/C Cell signaling 2032 
Tubulin Cell signaling 2148 
 
 
Table 3. IP reagents 
  
Reagent Company Catalog 
CDK4 antibody Santa cruz sc-56277 
p21 antibody invitrogen PA1-30399 
Clean blot IP reagent thermofisher 21230 
normal mouse IgG santa cruz 2025 
normal rabbit IgG cell signaling 2729 
dynabeads protein a thermofisher 10001D 
Dynabeads protein g thermofisher 10003D 
 
 
Table 4. IHC antibodies  
Antibody Company Catalog 
p-Src Y418  MP569373 
Zeb1 Bethyl IHC-00419 
pRB Cell signaling 8516 
pCDK4 Invitrogen PA5-64482 
p21 Novus NB100-1941 
pErk Cell signaling 9101 
Ki67 Abcam ab15580 
 
Table 5. IF antibodies 
Antibody Company Catalog 
pRB Cell signaling 8516 
CDK4 Abcam ab137675 
pCDK4 Invitrogen PA5-64482 
p21 Santa cruz sc-6246 
 
Table 6. RT-PCR primers 
Gene name Primer sequence 
ms-L32-F GGAGAAGGTTCAAGGGCCAG 
ms-L32-R TGCTCCCATAACCGATGTTG 

















hs L32-F CCTTGTGAAGCCCAAGATCG 






Table 7. ChIP Primers 





CDKN1A-cp-F TATTAGCTGGGCATGGTGGT  
CDKN1A-cp-R GCAGCCCTGGCTTTTTGTTT  
 
Table 8. ChIP reagents 
Reagent Company Catalog 
ZEB1 antibody santa cruz H-102X 
normal rabbit IgG cell signaling 2729 
dynabeads protein a thermofisher 10001D 
 
Table 9.  List of shRNA oligonucleotides  
Gene name Primer sequence 
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Chapter 3: A novel ex vivo tumor system identifies Src-mediated invasion and 
metastasis in mesenchymal tumor cells in non-small cell lung cancer 
Contents of this chapter are derived from the publication Padhye, A. et al. A novel ex vivo 
tumor system identifies Src-mediated invasion and metastasis in mesenchymal tumor cells in 
non-small cell lung cancer. Sci Rep 9, 4819 (2019) with approval from Nature Publishing 
Group. 
3.1 Introduction 
Lung tumors display pronounced heterogeneity, including genetically and 
epigenetically distinct tumor cells surrounded by heterotypic cell types and extracellular matrix 
that dynamically interact with each of the cell types3,110,111. Experimental cancer research is 
often restricted to two dimensional in vitro cell cultures of immortalized cancer cell lines which 
largely fail to capture the cellular or microenvironmental heterogeneity of a tumor. For a 
fundamental understanding of cancer progression and therapeutic vulnerabilities, lung cancer 
should be studied in a context as close to an in vivo setting as possible. However, animal 
models can be limited by the degree to which conditions can be tested, with added time and 
expense.  
In order to address these deficiencies in current lung cancer models, we established 
an Ex Vivo Tumor (EVT) platform to culture lung tumors in 3D matrices. This system has 
specific advantages over the more commonly used in vitro and in vivo systems. First, it retains 
tumor cell heterogeneity contributed by genetically identical but phenotypically distinct 
subpopulations arising due to in vivo selection pressure and environmental influences3. Since 
the tumors are cultured in a 3D space, the responses of tumor cells to external manipulations 
like drug treatments are more realistic and can be studied in real time77,89,112. It affords an 
ability to rapidly test therapeutic sensitivity of tumors in a high throughput manner. Finally, the 
influences of the tumor microenvironment components can be effectively studied because 
controlled modifications can be introduced and the system can be tuned to test these 
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interactions113. EVTs are intended to bridge the gap between in vitro and in vivo models for 
mechanistic and therapeutic study of lung cancer. 
Our group and others have previously modeled lung adenocarcinoma using 
genetically-engineered murine (GEM) systems with mutant KRAS and p5393. These GEM 
models develop lung adenocarcinoma that recapitulates the aggressive and metastatic 
features observed in patients. Metastasis in this model occurs in a manner that is dependent 
on an epithelial-mesenchymal transition (EMT) regulated by a double-negative feedback loop 
between the microRNA-200 family and the ZEB1 transcription repressor114. Using syngeneic 
models, we have previously demonstrated that upon loss of the microRNA-200 family, the 
mesenchymal tumor cells are dependent on the interaction of the cell adhesion molecule 
integrin β1 and the extracellular matrix component collagen type I. This interaction drives the 
formation of the focal adhesion complex through recruitment of the adaptor molecule CRKL, 
which is a direct miR-200 target115. Herein, we use the EVT system to investigate the Src 
signaling pathway downstream of CRKL and demonstrate that lung cancer cells are highly 
dependent on Src activation for invasion and metastasis. Src is an oncogene that is 
overexpressed in many cancer types and known to be involved in multiple cellular processes, 
such as proliferation, cell morphology, migration, invasion and adhesion116. The tyrosine 
kinase acts as a signal transducer from cell surface receptors (e.g. integrins) through 
phosphorylation of tyrosine residues on substrates as FAK, Cas and paxillin117.  
To establish the EVT model we used KP syngeneic murine lung adenocarcinoma 
tumors93, which were isolated, processed and cultured in 3D matrices. We characterized the 
behavior of EVTs in different matrices and demonstrate the proof-of-principal for this system 
to tease out signaling pathways driving metastasis in vivo. Our findings demonstrate that 
matrix-dependent invasion of mesenchymal cells is mediated through activated Src signaling, 
which was validated by experiments using the in vivo models wherein Src inhibition 
suppresses metastases. Our study also establishes EVTs as a valuable model representative 
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of in vivo tumor response. The system presented here can be extended to identify and 
understand other novel signaling pathways that regulate malignant progression or define 
therapeutic sensitivities in lung cancer. 
3.2 Results  
 EVTs are representative of the cellular composition in primary tumors.  
To study the underlying mechanisms driving lung cancer progression, we wanted to 
develop a model that bridges the gap between conventional 2D cell culture systems and in 
vivo models. We utilized murine KP lung adenocarcinoma cell line models (e.g. 344SQ) 
implanted in immunocompetent syngeneic mice, which form primary tumors that grow over 
4-6 weeks and metastasize to the lungs and distant organs93. Primary tumors were harvested 
and processed by mechanical and enzymatic digestion to yield multicellular aggregates, 
referred to as Ex Vivo Tumors (EVTs) (Figure 6). Prior to embedding in 3D matrices, EVTs 
were cultured in laser ablated poly(dimethylsiloxane) (PDMS) microwell inserts designed for 
standard tissue culture plates, which we have previously described for single-cell 
suspensions105. The microwells within each insert are ~100 µm in diameter, allowing 
exclusion of tumor aggregates greater than 100 µm and thereby enhancing the uniformity of 
the starting size for EVTs. EVTs harvested from microwells were then embedded in different 
matrices for further downstream investigations.
 
Figure 6. Schematic description of isolation and 3D culture of EVTs. 
Syngeneic murine subcutaneous tumors were harvested 4 weeks after implantation. After isolation and 
processing of tumors, EVTs are cultured in microwells for one day to yield structures of uniform size. 
(Padhye et al, Sci Rep 9, 4819, 2019). 
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Tumor cells dynamically interact with the components of the tumor microenvironment 
(TME) like extracellular matrix (ECM), cancer associated fibroblasts (CAFs), immune cells 
and endothelial cells77,111,118. While establishing this system, we wanted to characterize the 
cellular TME components present in EVTs that may afford an advantage over conventional 
3D cell culture systems. We compared the cellular composition of primary syngeneic tumors 
and EVTs derived from them by flow cytometry. Figure 7 demonstrates the gating scheme for 
different TME cells within primary tumor and EVTs. The CD45 cell surface marker was used 
to identify immune cells within the live cell population, which were further classified as CD3+ 
T-cells or F4/80+ macrophages. The two immune cell subpopulations were primarily studied 
as they have been shown to actively modulate tumor cell behavior. The percentage of T-cells 
within primary tumors and EVTs was consistent (10-15%) and macrophages followed similar 
patterns (10-15%). CAFs were identified by the CD90 (Thy1) cell surface marker53,119 and 
were about 5-7% of the cells in tumors and EVTs. CD31+ endothelial cells made up about 
20% of the total live cell population in EVTs and primary tumors.  
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Figure 7. EVTs are representative of the cellular composition of syngeneic murine tumors.  
(Left) Gating scheme to show different TME cells within primary tumors and EVTs (Right) Flow 
cytometry analysis to compare the cellular composition of EVTs to the primary syngeneic tumors. No 
significant difference observed in percentage of T-cells, macrophages, CAFs and endothelial cells 
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We further analyzed T cell subpopulations in terms of CD4+ and CD8+ cells Figure 8. 
EVTs have a higher percentage of CD8+ T cells and lower percentage of CD4+ T cells when 
compared to primary tumors. On further sub-classification into exhausted T cells 
(PD1+/Lag3+) and regulatory T cells (CD25+/FoxP3+), we did not observe any differences 
between tumors and EVTs. 
 
Figure 8. Flow cytometry analysis of T cell subpopulations. 
CD8+ and CD4+ T cells within EVTs and primary syngeneic tumor were analyzed. No significant 
difference observed in percentage of CD3+T-cells but EVTs had higher percentage of CD8+ and lower 
percentage of CD4+ T cells compared to primary tumors. Further classification into exhausted CD8 T 
cells and regulatory CD4 T cells did not show significant differences between EVTs and primary 
tumors.(Padhye et al, Sci Rep 9, 4819, 2019). 
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To determine if TME cells were still present in 3D cultured EVTs after a few days 
without any external stimulation, EVTs were grown in Matrigel for 5 days and the percentage 
of different cell types was compared over time (Figure 9). Although there was a decline in the 
percentage of TME cells in cultured EVTs without any external stimulation, we were 
successfully able to detect TME components in EVTs at the time of seeding into matrices and 
after 5 days of culture, allowing us to mimic an in vivo environment. The presence of TME 
cells within EVTs can be further exploited to investigate the heterotypic interactions within 
tumors by utilizing appropriate stimulatory factors.  
 
 
Figure 9. Flow cytometry analysis of cellular composition of EVTs after 5 days in Matrigel. 
(Padhye et al, Sci Rep 9, 4819, 2019). 
 
  
 ______ Chapter 3: A novel ex vivo tumor system identifies Src-mediated invasion and 
metastasis in mesenchymal tumor cells in non-small cell lung cancer 
48 
 
 Immunofluorescence on tumor microenvironment components. 
Next, we optimized immunofluorescence staining of EVTs before and after culture in 
matrices in order to determine spatial distribution of TME components as well as presence of 
phenotypically different tumor cells. EVTs harvested from microwells stained for CD8+ T cells 
within the micro-tumors (Figure 10A). Further studies to examine the impact of immune cells 
on cancer cells can be designed with appropriate stimulatory factors. Additionally, the EVT 
platform can serve as a platform to interrogate the effect of immunotherapeutic agents.  
We also detected collagen I around the EVTs that were harvested from microwells 
with an increase in collagen I staining after being cultured in Matrigel for 5 days (Figure 10B) 
indicating that EVTs produce collagen production overtime. This underscores that EVTs 
indeed are capable of recapitulating in vivo like behavior. We also noted that EVTs were more 
organized in Matrigel as compared to microwells (Figure 10B), due to the presence of laminin 
in the matrix which is responsible for promoting epithelial like phenotype. Since EVTs are 
derived from tumors, there is marked tumor cell heterogeneity as well. Using the markers that 
are normally used to determine the EMT status of cancer cells, we observed that within EVTs 
derived from same tumors, there were cells expressing different EMT markers such as E-
cadherin, β-catenin, α-smooth muscle actin and vimentin (Figure 10B). EVTs from primarily 
epithelial cancer cells (393P) also retained cellular heterogeneity with the presence of cells 
with different EMT status (Figure 10C). Laminin production was also noted in EVTs isolated 
from microwells (Figure 10C). Orthotopic lung EVTs also behaved in a similar manner as 
EVTs derived from primary subcutaneous tumors. EVTs were more organized and epithelial-
like in Matrigel as seen by E-cadherin and β-catenin staining, but still retained some 
mesenchymal like features demonstrated by α-smooth muscle actin and collagen staining. 
Laminin production in EVTs cultured in microwells was also detected (Figure 10D). Findings 
from immunofluorescence staining are important as they highlight that EVTs are capable of 
modeling tumor microenvironment as well as tumor cell heterogeneity.  
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Figure 10. Immunofluroscent staining on EVTs for indicated markers. 
(A) EVTs were harvested from microwells after one day and stained for CD8 cells. (B-D) EVTs cultured 
in microwells and Matrigel were isolated and stained for indicated markers for tumor cells and matrix 
components.  
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 Establishing EVT platform for different tumor types. 
We have previously demonstrated that tumor cell phenotype can be altered by 
modulating intrinsic factors such as ZEB1/miR-200 axis93. The different phenotypic states of 
cancer cells are capable of interacting with tumor microenvironment in unique manner, which 
eventually contributes to a heterogeneity within tumors and leads to cancer progression. In 
order to model more complexities within lung cancer, we utilized 344SQ tumors with 
doxycycline inducible GFP-ZEB1 overexpression. Mice bearing 344SQ_ZEB1 tumors were 
divided into 2 groups: with and without doxycycline feed. Tumors were harvested from each 
group and processed to yield EVTs. EVTs from both groups were cultured in Matrigel with or 
without doxycycline. Based on the ZEB1 induction in vivo and ex vivo each condition was 
designated as - -, + -, - + and + +. EVTs without any ZEB1 overexpression (- -) were 
completely non-invasive whereas the same EVTs when treated with doxycycline ex vivo (- +) 
became significantly more invasive. Conversely, when EVTs that were induced in vivo were 
cultured without doxycycline in Matrigel, the invasive phenotype was shut down (+ -). EVTs 
that were under constant doxycycline exposure (+ +) had a much more significant invasive 
phenotype as well as larger structures (Figure 11A-C). These findings demonstrate the plastic 
nature of cancer cells and the ability to undergo phenotypic shift depending on intrinsic and 
extrinsic factors and are not locked in one constant cellular state. It is accompanied by 
transcriptional reprograming and activation of different signal transduction pathways for 
survival and escape from therapeutic targeting. Since these are important biological 
questions that need to be explored, EVTs with modifiable tumor cell phenotypes can serve 
as high throughput platform to incorporate a variety of complexities such as ECM alterations, 
heterotypic cells and response to pharmacological agents.  
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Figure 11. EVTs derived from ZEB1 overexpressing tumors.  
(A) EVTs cultured in Matrigel for 5 days with or without doxycyclline (2µg/ml) treatment. Images taken 
at day 5. Scale bar:100 µm. (B) Sphere size of EVTs measured on day 5. (C) Percentage of invasive 
structures were quantified on day 5.   
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Autochthonous lung tumor models represent human lung cancer more accurately. Our 
group utilizes KrasG12D/+ and KrasG12D/+; p53flox/flox driven lung tumor models to investigate 
cancer progression. Mutant Kras and Kras/p53 GEMMs tumors were cultured as EVTs in 
microwells, Matrigel or Matrigel/collagen I matrices to study tumor evolution of early-stage 
tumors. Immunofluroscent staining of Kras mutant EVTs revealed the presence of 
phenotypically distinct tumor cell subtypes with production of both laminin and collagen I 
(Figure 12A). Kras mutant lung cancers fail to generate cell lines when cultured in petri dishes. 
However, when cultured as EVTs in different matrices, tumors can be propagated overtime 
(Figure 12B). When cultured in Matrigel/collagen I, Kras and Kras/p53 mutant EVTs 
demonstrate an invasive phenotype that not observed in Matrigel alone (Figure 12C), 
recapitulating the phenotype observed in metastatic lung cancer with high collagen levels. 
Establishing the baseline morphological characteristics sets up EVTs for understanding tumor 
cell interactions with TME components, especially with ECM components. EVTs can allow us 
to drive the phenotype of the tumor cells towards a specific lineage and help us monitor the 
selection process over time. The effect of ECM and other TME components on the tumor 
heterogeneity within lung cancer as well as the emergence of more aggressive cellular 
phenotypes during cancer progression can be studied.  
When normal human bronchial epithelial cells are grown in 2D cultures they proliferate 
until they form a confluent monolayer, but in 3D Matrigel cultures, they differentiate into a 
characteristic lumen-containing glandular structure, termed an acinus representing in vivo 
characteristics. Similarly, autochthons lung tumor EVTs can be used to study tumor 
morphology and interactions occurring in a 3D space that can have effects on gene 
expression and cell behavior. Due to the ability to mimic in vivo microenvironment, early 
changes in tumor progression and evolution can be studied with EVTs. Selection pressure 
on cancer cells can affect the phenotype and gene expression which can be studied in a high 
throughput manner and in real-time which is more difficult in animal models. Additionally, 
controlled TME modification can help study the response of cancer cells to specific alterations 
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in those components. We have established a wide variety of EVT platforms which provides 
unique tools to assay different biological questions.  
 
Figure 12. EVTs derived from primary autochthnous lung tumors.  
(A) Immunofluroscent staining of Kras mutant EVTs from microwells for indicated markers. (B) Kras 
mutant EVTs cultured in Matrigel and Matrigel/collagen I for 4 days. (C) Images of Kras and Kras/p53 
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 EVTs are responsive to the external stimulus TGFβ and undergo EMT.  
Tumors are surrounded by extracellular matrix, which provides physical support as 
well as biochemical signals to tumor cells, and is frequently altered over the course of tumor 
progression. We initially utilized Matrigel, which is a solubilized basement membrane 
preparation rich in primarily laminin and collagen IV, to model the ECM-EVT interactions 
found in tumors. 344SQ_EVTs were cultured in Matrigel for 7 days and treated with TGFβ 
starting on the third day after seeding. TGFβ is frequently present at high levels in tumors and 
is known to induce an EMT by suppression of miR-200 expression93, thereby promoting 
invasion and metastasis. EVTs grown in Matrigel alone increase from ~75 µm to ~100 µm in 
size over 7 days, but upon treatment with TGFβ, they hyper-proliferate and are ~200 µm by 
day 7 (Figure 13A,B). TGFβ treated EVTs developed invasive protrusions suggesting a shift 
to a mesenchymal phenotype (Figure 13A, C). To confirm that EMT is occurring at a molecular 
level, we collected RNA and protein from EVTs at day 7. Quantitative RT-PCR analysis for 
canonical EMT markers E-cadherin, N-cadherin, vimentin and Zeb1 revealed that EVTs 
undergo EMT upon TGFβ treatment (Figure 13D, E). Consistent with our previous work using 
murine lung cancer cells alone93, with EVTs we observed an increase in Zeb1 in response to 
TGFβ, with subsequent transcriptional repression of the miR-200 family members miR-200 
a, b, c (Figure 13E). Additionally, we observed an increased expression of mesenchymal 
markers at the protein level by western blot analysis (Figure 13F). 
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Figure 13. EVTs are responsive to external stimulus TGFβ and undergo EMT.  
(A) 344SQ_EVTs are cultured in Matrigel for 7 days and treated with TGFβ (5 ng/ml) on day 3 (scale 
bar is 200 µM). In response to TGFβ, EVTs (B) hyper proliferate and (C) are more invasive. For each 
condition, 1000 structures were measured in size and scored for invasiveness. (D) Quantitative RT–
PCR of indicated markers, shown as fold change upon TGFβ treatment. (E) Taqman RT–PCR assay 
of individual miR-200 members for EVTs in Matrigel and following TGFβ treatment. ***p < 0.0001. (F) 
Western blot analysis for EMT markers in Matrigel with or without TGFβ treatment.  
(Padhye et al, Sci Rep 9, 4819, 2019). 
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To demonstrate the broader utility of the system, we intratracheally implanted RFP 
expressing 344SQ tumor cells into the lungs and harvested orthotopic lung tumors after three 
weeks of growth. H&E staining of lungs reveal presence of tumors formed from implantation 
of tumor cells. Lung-EVTs were cultured in Matrigel over 7 days and demonstrated similar 
morphological and molecular characteristics as EVTs derived from subcutaneous tumors 
(Figure 14A). In response to TGFβ, they developed an invasive morphology corresponding 
to the changes in EMT markers at the molecular level (Figure 14B). 
 
Figure 14. EVTs derived fron orthotopic lung tumors.  
(A) EVTs derived from orthotopic lung tumors are cultured in Matrigel for 7 days and sphere size is 
quantified during that time. H&E staining of the lungs to show tumors. (B) Lung EVTs are treated with 
TGFβ (5ng/ml) and demonstrate an increase in size and invasiveness Scale bar µM. Quantitative RT–
PCR of indicated markers, shown as fold change upon TGFβ treatment.   
(Padhye et al, Sci Rep 9, 4819, 2019).  
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 Extracellular matrix manipulations induce phenotypic alterations in EVTs.  
One of the factors contributing to intratumor heterogeneity is the plasticity of tumor 
cells to transition between different phenotypic states. Tumor cell intrinsic genetic or 
epigenetic alterations are usually considered drivers of cancer progression. However, 
modification of the extracellular matrix can independently modulate the phenotype of tumor 
cells with or without affecting the epigenetic state of the tumor cells. To test the effects of 
matrix composition on tumor behavior, we cultured 344SQ_EVTs in Matrigel or mixed in 
increasing concentrations of collagen I. The presence of higher amounts of collagen I has 
been shown to promote an invasive and more aggressive tumor phenotype. We observed 
that with each higher collagen I concentration the percentage of invasive EVTs significantly 
increased up to ~80% (Figure 15 A, B). These data demonstrate that ECM components are 
capable of driving the phenotypic behavior of the tumor cells. To determine if interaction with 
collagen I is altering the tumor cells by inducing an EMT, we collected RNA and protein from 
the structures. Quantitative RT-PCR (Figure 15 C) and western blot analysis (Figure 15 D) 
did not reveal an EMT occurring in EVTs, demonstrating that ECM is driving the invasive 
phenotype of the tumor cells without inducing epigenetic changes that result in a 
mesenchymal state.  
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Figure 15. Extracellular matrix manipulations induce phenotypic alterations in EVTs.  
(A) EVTs cultured in MG or MG/CG I with different concentrations of Collagen I for 5 days. (B) 
Quantification of invasive structures in response to alterations of the matrix. For each condition, 250 
structures were scored for invasiveness. (C) Western blot analysis of EMT markers.  (D) Quantitative 
RT–PCR of indicated EMT markers show no change in response to Collagen I in the matrix.  
(Padhye et al, Sci Rep 9, 4819, 2019). 
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To test the utility of this platform across different tumor cell types, we harvested EVTs 
from non-metastatic, epithelial 393P tumors. 393P_EVTs cultured in Matrigel grew as 
aggregates which were significantly invasive in response to TGFβ treatment or inclusion of 
collagen I in the matrix (Figure 16 A). An invasive phenotype was also observed with EVTs 
from orthotopic lung tumors cultured in Matrigel/Collagen I (Figure 16 B). Our previous work 
has revealed that Zeb1 expression drives a mesenchymal phenotype in non-metastatic, 
epithelial cell line 393P115. EVTs derived from genetically manipulated 393P cells with 
constitutive Zeb1 expression were cultured in Matrigel or Matrigel/Collagen I and displayed 
significant invasion in MG/CG I as compared to the 393P-Vector_EVTs (Figure 16 C). Overall, 
testing of multiple different tumor cell models demonstrates the utility of the EVT platform to 
study the dynamic interactions of cell intrinsic factors with the extracellular conditions.  
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Figure 16. 393P-ZEB1 EVTs retain responses to external stimuli. 
(A) Non-metastatic, epithelial 393P_EVTs cultured in Matrigel as control and treated with TGFβ or 
cultured in varying Collagen I mixtures. Quantification shows percentage of structures invasive in 
response to alterations. Western blot analysis on EMT markers. (B) Lung-EVTs are cultured in Matrigel 
or Matrigel/Collagen I with different concentrations of Collagen I for 5 days. (C) 393P_vector and 
393P_Zeb1 EVTs are cultured in Matrigel and Matrigel/Collagen I (3 mg/ml) for 5 days (scale bar: 
200 µM). Invasiveness of EVTs in response to intrinsic (Zeb1) or extrinsic (Collagen I) manipulation. 
Western blot analysis to show an EMT induction. 
(Padhye et al, Sci Rep 9, 4819, 2019). 
 
To further study the mechanism by which collagen I promotes an invasive phenotype, 
we cultured 344SQ_EVTs in Matrigel/Collagen I at 3 mg/ml concentration and treated with an 
integrin β1 blocking antibody. The antibody decreased the invasive ability of EVTs by two-
thirds (Figure 17A, B). Western blot analysis also demonstrated that FAK/Src signaling is 
activated in the presence of collagen I and is suppressed by addition of integrin β1 blocking 
antibody (Figure 17C). We tested the effect of integrin β1 blocking antibody on 393P_EVTs 
in Matrigel alone (Figure 17D). In the absence or presence of the blocking antibody, we did 
not observe any invasion of EVTs in Matrigel, further demonstrating that integrin β1 receptors 
on tumor cells require interaction with collagen I in the matrix to produce invasion.  
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Figure 17. Collagen I-integrin β1 interaction is necessary for invasive phenotype in EVTs. 
(A) 344SQ_EVTs cultured in Matrigel and Matrigel/Collagen I (3 mg/ml) and treated with an ITGβ1-
blocking antibody or IgM control for 5 days. (B) For each condition, 500 structures were scored for 
invasiveness. (C) Western blot analysis of FAK/Src signaling in EVTs treated with ITGβ1-blocking 
antibody. (D) 393P_EVTs cultured in Matrigel and Matrigel/Collagen I (3 mg/ml) and treated with an 
ITGβ1-blocking antibody or IgM control for 5 days.  
(Padhye et al, Sci Rep 9, 4819, 2019). 
 
To further test that invasion in EVTs is occurring through an integrin β1-collagen I 
interaction, we cultured EVTs of 344SQ with integrin β1 knockdown (344SQ_ITGB1 KD) in 
Matrigel and Matrigel/collagen I (Figure 18A). There was a significant decrease in the 
percentage of invasive EVTs in Matrigel/Collagen I upon integrin β1 knockdown as compared 
to EVTs from scramble control cells (Figure 18B). Western blot analysis showed a decrease 
in p-FAK and p-Src in integrin β1 knockdown EVTs (Figure 18C).  These results demonstrate 
the utility of EVTs for interrogating the role of TME components like ECM in cancer 
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progression and highlight the collagen I-integrin β1 interactions as critical to downstream 
signaling and tumor cell invasion. 
 
Figure 18. Integrin β1 knockdown overcomes invasive phenotype in EVTs. 
(A) 344SQ_scr and 344SQ_shITGβ1 EVTs cultured in Matrigel and Matrigel/Collagen I (3 mg/ml). (B) 
Percentage of invasive structures calculated at day 5. (C) Western blot to show integrin β1 knockdown 
and FAK/Src signaling. 
(Padhye et al, Sci Rep 9, 4819, 2019). 
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 Src pathway is required for initiation and maintenance of invasion in EVTs. 
We previously demonstrated that the EMT status of tumor cells modulates collagen I-
dependent activation by regulating integrin β1-mediated FAK activation115. We sought to 
further investigate the signaling downstream of integrin β1 that accounts for the invasive 
phenotype. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that mediates 
extracellular signals to the intracellular machinery to regulate cell migration and invasion. 
Cancer cells harness this pathway for increased and efficient invasion leading to metastatic 
disease (Figure 19A). The interaction of collagen I and integrin receptors recruit FAK to the 
sites which are known as focal adhesions and initiate a multistep process starting with auto-
phosphorylation of FAK at tyrosine 397 (Y397). This activates a cascade of signaling which 
also lead to activation of Src pathway. We utilized a pharmacological inhibitor Y-15 specific 
inhibitor of FAK that inhibits its autophosphorylation activity. When 344SQ cells cultured in 
2D were treated with Y-15 with dose escalation, there was a suppression of phospho-FAK 
(Figure 19B). Cells grown in 3D culture with Matrigel/collagen I matrix, the invasive structures 
formed were disintegrated when treated with FAK inhibitor (Figure 19C). EVTs, however, 
failed to show similar response to FAK inhibitor. There was a slight decrease in the length of 
the invasive protrusions without any disintegration (Figure 19C). Interestingly, when mice 
bearing subcutaneous tumors were treated with the same inhibitor, there was no significant 
impact on tumor weight or lung metastases (Figure 19D). Many preclinical models have 
demonstrated the benefits of FAK inhibitors in controlling tumor growth which do not always 
translate into an effective response in the clinic120. Our results are of importance because we 
demonstrate that EVTs are predictive of response of tumors, even when other 2D and 3D 
assays may demonstrate otherwise. Therefore, EVTs are a useful to perform an initial large 
scale screen of therapeutic agents in a cost effective manner, without using expensive animal 
models.  
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Figure 19. Response of EVTs to FAK inhibitor Y-15.  
(A) Role of FAKs in invasion (B) 344SQ cells treated with FAK inhibitor Y-15 for 72 hrs. (C) 344SQ 
cells and EVTs cultured in MG/CG I (3 mg/ml) for 5 days and treated 5 µM of Y-15. Images from day 
5. (D) 344SQ cells implanted subcutaneously in syngeneic wild type mice that were treated with Y-15 
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Stratification of murine KP cell lines derived from spontaneous Kras/p53 tumors by 
their epithelial or mesenchymal status revealed a significant activation of the downstream 
Src/cortactin pathway in the mesenchymal cells compared to the epithelial cells (Figure 20A, 
B). Furthermore, in the genetically manipulated 393P cells, we observed a direct correlation 
between the activation of this pathway and the Zeb1 levels (Figure 20C). To further study the 
importance of the Src pathway in regulating invasion, we assayed the effect of the Src 
tyrosine kinase inhibitor, dasatinib. Dasatinib treatment for 7 hours blocked FAK and Src 
activation (Figure 20C). Dasatinib treatment in 3D assays inhibited the collagen I-dependent 
invasion of the mesenchymal 393P_ZEB1 cells but had no effect on the control cells (Figure 
20D-E). To further elucidate the utility of EVTs for investigating signaling pathways 
responsible for lung cancer invasion and metastasis, we cultured EVTs derived from 344SQ 
tumors in Matrigel. This is one of the KP models that is mesenchymal and metastatic, owing 
to its ability to undergo epigenetic changes and readily respond to the external 
microenvironment, including ECM changes. 344SQ_ EVTs grown in Matrigel/Collagen I were 
tested for their dependency on Src signaling for invasion. Three groups were setup, with one 
serving as control without dasatinib, another received dasatinib at the time of seeding and 
the third group was allowed to invade in collagen I for 3 days before dasatinib was added to 
the culture. Dasatinib was able to significantly suppress invasion in both early and late 
conditions, emphasizing that Src is necessary for initiation and maintenance of invasion 
(Figure 20F, G). 
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Figure 20. Src pathway is required for initiation and maintenance of invasion.  
(A) Western Blot analysis shows increased Src pathway activation in the mesenchymal cells lines. (B) 
Western blot analysis to show the EMT markers in the murine KP cell line panel. (C) Western Blot 
analysis shows increased Src pathway activation in cell lines stably expressing Zeb1 which is inhibited 
upon treatment with dasatinib (50 nM). (D) 393P_Zeb1 and control cells grown in 3D cultures. Invasion 
of 393P_Zeb1 cells in a mixture of Matrigel/Collagen I (1.75 mg/ml) is inhibited upon dasatinib 
treatment (50 nM). Images were taken at day 7 after a 3 day treatment. (E) Quantification invasiveness 
of cells in 3D cultures from (D). Represented is the average of 3 wells, each measuring 30 structures 
in size and scoring 50 structures for invasiveness. (F) Dasatinib treatment of EVTs cultured in 
Matrigel/Collagen I (3 mg/ml) before (at day 0) and after initiation of invasion (day 4). Images were 
taken at day 3 and day 6. (I) Quantification of invasive structures before and after dasatinib treatment. 
For each condition, 500 structures were scored for invasiveness.  
(Padhye et al, Sci Rep 9, 4819, 2019). 
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 Dasatinib overcomes TGFβ mediated invasion and decrease in vivo 
metastases. 
TGFβ is a well-known EMT inducer to which we have previously shown the 
metastasis-prone KP cells are quite sensitive. We next tested if Src inhibition would block the 
TGFβ-induced EMT. We utilized dasatinib and a second Src inhibitor, AZD0530 
(saracatinib).We previously showed that inhibition of integrin β1 or the adaptor molecule 
CRKL significantly decreased the ability of the cells in 3D cultures to become invasive upon 
TGFβ treatment115. A similar result was seen in the combined treatment of TGFβ with the Src 
inhibitors, leading to a significant reduction in sphere size and invasion, which was more 
pronounced with AZD0530 treatment. 344SQ_EVTs cultured in Matrigel were treated with 
Src inhibitors alone or in combination with TGFβ. EVTs hyper-proliferated and developed 
invasive protrusions in response to TGFβ. This phenotype was suppressed in EVTs pre-
treated with dasatinib (Figure 21A-C) or AZD0530 (Figure 21D-F). TGFβ caused an increase 
of canonical mesenchymal markers like Zeb1 and Vimentin and suppressed E-cadherin 
levels. There was also an upregulation of p-FAK and p-Src in response to TGFβ. However, 
Src inhibition was able to overcome TGFβ mediated FAK/Src pathway activation and the 
subsequent invasive phenotype, despite the TGFβ-induced EMT in EVTs observed by 
western blot (Figure 21C, F). These results illustrate that the Src pathway is activated through 
integrin β1 in an ECM-dependent manner and cell invasion can be inhibited by targeting the 
cell-ECM interactions or signal transduction pathways in vitro and ex vivo. We were able to 
demonstrate the strength of EVTs to facilitate the interrogation of tumor phenotype at multiple 
levels, in a high throughput manner that would not be otherwise easily attainable in vivo. The 
344SQ cells are paradigmatic of the highly metastatic KP cells in our syngeneic murine 
model. To assess whether the EVT results were predictive of the in vivo activity of dasatinib 
to block the Src signaling pathway and suppress metastases, we injected syngeneic mice 
with 344SQ cells and dosed them with 10 or 20 mg/kg Dasatinib 5 days/week. Treatment at 
either concentration significantly reduced the number of lung metastases (Figure 21G, H).  
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Figure 21. Dasatinib overcomes TGFβ mediated invasion and decrease in vivo metastases.  
(A) EVTs culture in Matrigel for 8 days. Images were taken at day 8. Dasatinib (50 nM) was added at 
the time of seeding and TGFβ (5 ng/ml) at day 4. (B) Size of EVTs and invasiveness of EVTs on TGFβ 
and dasatinib treatments. (C) Western blot analysis of EVTs treated with Dasatinib and TGFβ at 
indicate concentrations. (D) 344SQ_EVTs culture in Matrigel for 8 days. Images were taken at day 8. 
AZD0530 (3 μM) was added at the time of seeding and TGFβ (5 ng/ml) at day 4. (E) Size of EVTs and 
invasiveness of EVTs on TGFβ and AZD0530 treatments. (F) Western blot analysis of EVTs treated 
with AZD0530 and TGFβ at indicate concentrations. (G) Primary tumor weight and (H) number of lung 
metastases in syngeneic mice treated with Dasatinib, n = 9 (10 mg/kg: solid shapes, 20 mg/kg: empty 
shapes) or vehicle, n = 10. 
(Padhye et al, Sci Rep 9, 4819, 2019). 
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3.3 Discussion   
The role of intra- and inter-tumor heterogeneity in driving tumor metastasis and 
therapy resistance has been greatly emphasized in recent years77,91,121. Tumors are not just 
a mass of cancer cells, but instead are composed of a heterogeneous tumor 
microenvironment, including changes in the ECM and heterotypic cell types, that dynamically 
interacts with tumor cells. The diverse selection pressures from the microenvironment 
profoundly affect the behavior and phenotype of cancer cells and must be taken into account 
while studying mechanisms that drive cancer progression. The goals of this study were to 
establish a unique system to better model in vivo conditions, identify mechanisms driving 
invasion of mesenchymal lung cancer cells and demonstrate the ability to identify therapeutic 
sensitivities of tumor cell subsets dependent upon the microenvironmental interactions.  
The Ex Vivo Tumors (EVTs) utilized in this study are micro-tumors derived from 
immunocompetent murine syngeneic tumors and cultured in 3D matrices. We determined 
that EVTs faithfully represent the cellular composition of tumors and retain the heterotypic 
heterogeneity within tumors. A decline of heterotypic cell types was observed in culture over 
time in the absence of additional stimulatory factors. However, such factors can be included 
in subsequent studies in order to study specific interactions of tumor cells with heterotypic 
cell types.  These features demonstrate that the EVT platform can be used to study micro-
tumors and investigate influences of non-tumor cells in a high throughput manner which 
cannot be achieved with conventional 2D or 3D cell cultures. 
EVTs were functionally characterized by investigating their responses to external 
manipulations like growth factors and matrix alterations. Using a laminin rich matrix we 
recapitulated a basement membrane-like microenvironment and EVTs were non-invasive 
even though primary tumors are highly metastatic93. This underlines the importance of 
architecture and contextual cues in growth of tumor cells which are lost in monolayer cell 
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cultures. TGFβ induced a central EMT and invasive phenotype in tumor cells. ECM 
modification promoted an invasive phenotype in EVTs without altering the EMT state of the 
tumor cells. This finding is in contrast to previously observed collagen I-mediated EMT in 
tumor cells through autocrine TGFβ signaling122. However, it is known that ECM components 
actively interact with tumor cells for malignant progression through a variety of signaling cues 
modulating cellular behavior, ranging from tumor cell survival to invasion and metastasis123,124 
and TGFβ-mediated signaling may be independent of collagen I influence. It also indicates 
that EVTs are more amenable to dynamic phenotypic alterations, which may be attributable 
to the presence of distinct tumor cell subpopulations. This emphasizes the importance of 
investigating TME-tumor cell interactions in the context of tumor cell heterogeneity. 
Monolayer cell cultures of tumor cells are unable to capture this heterogeneity and hence 
have limited biological relevance. 
Based on the effect of ECM composition on tumor cell phenotype observed in our 
system, we investigated the signaling downstream of collagen I-integrin β1 interactions as 
responsible for driving invasion and metastasis. An increased activation of Src signaling 
pathway molecules in mesenchymal cells suggested a dependency on p-Src for their invasive 
phenotype. Src inhibition has been shown to decrease migration in vitro, tumor growth and 
invasion in vivo in NSCLC using murine xenograft models125,126. Dasatinib has also shown to 
improve antitumor activity if anti-PD-1 by inhibiting T-regs cell population within tumors127. 
Furthermore, inhibition of Src using the ATP binding competitive inhibitor dasatinib decreased 
the development of liver metastases in a murine model of pancreatic carcinoma and caused 
a decrease in cell adhesion, migration and invasion in colon cancer cell lines. In thyroid 
cancer cell lines, dasatinib was shown to have a cytostatic activity both in vitro and in vivo 
causing cell cycle arrest and an increase in senescence128. Tumor cells in our 3D matrix 
experiments demonstrated that Src-mediated invasion was substrate dependent. Type I 
collagen in the matrix enhanced p-Src expression in tumor cells, which was abrogated upon 
treatment with Src inhibitors. Pharmacological inhibition of Src was sufficient to prevent 
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initiation and maintenance of invasive structures in 3D cultures with collagen I, further 
demonstrating the importance of Src signaling in lung cancer cells. TGFβ is a well-known 
inducer of EMT and subsequent invasive phenotype. TGFβ has also been shown to mediate 
cell adhesion to ECM and increased collagen I synthesis in a Src-dependent manner129. We 
wanted to test the hypothesis if Src inhibition is sufficient to overcome TGFβ-mediated 
invasion. A combination treatment with TGFβ and pharmacological Src inhibitors prevented 
invasion, despite EMT, emphasizing the high dependency of tumor cells on Src signaling. 
These findings were in concert with another study which demonstrated Src inhibition could 
overcome TGFβ induced myofibroblast differentiation130. Furthermore, in vivo studies showed 
a significant decrease in metastases with Src inhibition. We identified collagen I-integrin β1 
activated Src signaling as a major driver of invasion and metastasis in lung cancer. Combined 
with our previous findings, ITGβ1 and Src are interesting targets for a combinatorial treatment 
approach in lung cancer. Invasion mediated through the Src signaling pathway demonstrates 
the utility and applicability of EVTs as a potent tool for mechanistic interrogation of invasion 
and metastasis in lung cancer. The tumor model presented here incorporates tumor cell and 
tumor microenvironment heterogeneity arising in vivo in response to different selection 
pressures. It also retains the ability of tumor cells to respond to the intrinsic (Zeb1 expression 
in cells) and extrinsic manipulations (matrix and soluble factors). This suggests that 
phenotypic differences between tumor cells arise due to their differing ability to interact with 
the stromal components around them as much as due to genetic differences.  
Our next step is to expand the EVT system by introducing cellular complexities and 
accounting for the effect of tumor cell and tumor microenvironment heterogeneity. Early work 
led by Bissell and colleagues in the field was landmark to establish the significance of three-
dimensional models in normal breast epithelial differentiation and tumor cell 
morphogenesis131-134. The role of cell-cell and cell-matrix interaction has been widely 
emphasized for recapitulating tissue architecture, tissue morphogenesis, and epithelial 
organization and these aspects become significantly more important when investigating 
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biological phenomenon in cancer cells. Following the pioneering work in normal and 
malignant breast tissue, the field rapidly expanded to simulate 3D growth of different organs 
such as skin135,136, bone137,138, brain139,140, pancreas141,142 , colorectal143 and prostrate144,145. 
The most commonly used three dimensional systems to recapitulate tumor growth are usually 
monocultures of cancer cells112 146 or co-cultures to study heterotypic interactions between 
tumor cells and other cell types like CAFs or immune cells113,147 where multicellular spheroids 
are cultured in artificially created environments. A common objective for many of these 
studies is to serve as an intermediate between the use of whole animals at one end of the 
spectrum and cellular monolayers at the other, but are limited to studying a single TME 
component or a unidirectional effect. However, these models have been limited to interactions 
between one component of the TME with the tumor cells148. EVTs have a distinct advantage 
of recruiting TME cellular components and retaining the integrity of a tumor which confers the 
ability to investigate specific roles of TME components in the tumor progression118,149. In 
addition to heterotypic heterogeneity, we are able to account for tumor cell heterogeneity in 
the system. We have a large panel of murine NSCLC cell lines isolated from Kras/p53 GEM 
model from the primary and metastatic tumor sites, which demonstrate phenotypic 
differences. When re-implanted subcutaneously or orthotopically in syngeneic animals, the 
cell lines demonstrate varying metastatic potential and differential interactions with the TME 
components in vitro39,44,150,151. Therefore, EVTs derived from different cell types can allow us 
to tease out the tumor cell heterogeneity modulated by cell intrinsic and extrinsic 
manipulations, creating a robust tool for investigating lung cancer progression. 
Multiple groups have also demonstrated that in addition to recapitulating tissue 
morphology, the intracellular signaling characteristics are more accurately represented in 3D 
cultures152-155. Birgersdotter et al156, Li et al157 and Luca et al158 demonstrate considerable 
differences in gene expression and mRNA splicing patterns when cells are cultured under 2D 
versus 3D conditions. Other studies have utilized 3D tumor spheroid-based functional assays 
for target validation and drug evaluation and have demonstrated that sensitivity and response 
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of cancer cells to different compounds can vary between 2D and 3D cell cultures159. 
Organization of tumor cells in polarized structures in an integrin β4-dependent manner 
imparted resistance to apoptosis in mammary epithelium suggesting signaling pathways 
determining sensitivity to drugs can vary based on the tissue architecture160. 
It is now widely accepted that the response of tumor cells to drug treatments is not 
dependent on oncogenic drivers alone. The TME plays a very significant role in modulating 
the outcome of therapeutic interventions77,161-165. Multiple groups have attempted to capture 
the complexity of the microenvironment and test therapeutic sensitivity to drug treatments. 
For example, tumor cells have been cultured in different matrices to identify ECM 
combinations driving lung cancer163,166. Ex vivo systems to test the efficacy of immune 
checkpoint blockade are also currently being employed for facilitating efforts in precision 
immune-oncology167,168. Work done by such groups has given great insights into individual 
heterotypic interactions, however, these studies have been conducted using cell lines in an 
artificially created environment. Our tumor model incorporates cells from a tumor’s 
microenvironment allowing us to maintain the complexity of the tumors in a physiologically 
relevant context. Building on the groundwork in the present study, this approach can be 
utilized in a high throughput manner to investigate tumor cell and microenvironment 
heterogeneity in lung cancer metastasis and resistance to drug treatments.   
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Aparna Padhye, Joshua K. Ochieng, Laura Gibson, Lixia Diao, Natalie W. Fowlkes, Jared J. Fradette, 
David H. Peng, Robert J. Cardnell, Jeffrey J. Kovacs, Jing Wang, Lauren A. Byers and Don L. Gibbons. 
Cancer Res March 1 2021 (81) (5) 1398-1412; DOI: 10.1158/0008-5472.CAN-20-1895 with approval 
from American Association for Cancer Research. 
4.1 Introduction 
The epithelial-to-mesenchymal transition (EMT) is an epigenetic event that is required 
by cells to maintain normal biological processes such as organogenesis, tissue healing and 
embryonic development and is evolutionarily conserved169 170. It is a dynamic process which 
allows cells to acquire distinct phenotypic states in a bi-directional manner, across a 
spectrum. At one of the spectrum is an epithelial state characterized by tight cell junctions 
and apico-basal polarity and at the other end of the spectrum is a stem-like mesenchymal 
state with increased ability to self-renew and migrate171. Cancer cells are capable of activating 
this process to acquire more aggressive phenotype, including an increased metastatic 
potential and acquisition of therapeutic resistance. The ability of cancer cells to slide on the 
spectrum of different epigenetic states allows cancer cells to handle diverse environmental 
stressors which contributes to phenotypic heterogeneity. Accompanying alterations at the 
molecular level have been extensively studied, including transcriptional reprograming in 
cancer cells and have been correlated with tumorigenicity and metastatic propensity across 
several tumor types172-176, highlighting the importance of this complex process in driving tumor 
progression. In non–small cell lung cancer (NSCLC), the ZEB1/miR-200 double negative 
feedback loop is a tightly regulated axis that can lead to EMT via upregulation of ZEB1 and 
concurrent downregulation of epithelial features, including the miR-200 family, E-cadherin, 
and other epithelial differentiation genes93,177-179. Moreover, tumor microenvironment 
components such as extracellular matrix (ECM)39 and cancer associated fibroblasts (CAFs)53 
drive a mesenchymal phenotype in cancer cells. Upon EMT, cancer cells are more motile and 
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invasive, and this process can initiate the metastatic cascade. Besides an increase in 
invasiveness and metastatic propensity, mesenchymal tumor cells also gain characteristics 
that promote aggressiveness, including stem cell–like features and drug resistance. 
Enrichment of EMT markers at the RNA, protein and phenotypic levels has been described 
after exposure to a broad spectrum of therapeutic modalities, including hormonal therapies, 
chemotherapies, radiotherapy and many targeted therapies180. Thus, to improve prevention 
and treatment strategies, it is critical to better understand the survival dependencies of cells 
along the epithelial-to-mesenchymal spectrum.  
Methodologies that are generally utilized to study cancer cells undergoing EMT 
include cell lines in vitro and pathological specimens from tumors. These assays are either 
bulk assays like western blot analysis, or endpoint assay such as immunohistochemistry. 
These techniques preclude the assessment of the real-time, dynamic shifts in the phenotype 
of cancer cells within a heterogeneous population. In order to address these deficiencies, we 
utilized a dual fluorescent reporter system that functions as a sensor for dynamic monitoring 
of EMT states106. In a highly metastatic KP-mutant murine cell line, we expressed the Z-cad 
reporter and analyzed the impact of alterations in the matrix and drug treatments on epithelial 
and mesenchymal subpopulations over time in two- and three-dimensional (2D and 3D) 
culture model systems. We demonstrate that Z-cad cells are capable of demonstrating distinct 
EMT states in response to external manipulations in real time by fluorescent imaging. When 
combined with the EVTs platform, Z-cad EVTs served as heterogeneous micro-tumors which 
were very useful for screening for therapeutic agents targeting distinct cancer cell 
subpopulations.  




 Z-cad sensor cells detect the EMT status of tumors cells in real-time. 
In order to understand the role phenotypically distinct tumor cells in cancer 
progression, we utilized fluorescence protein tagged epithelial 393P and mesenchymal 
344SQ cells. Multi-cellular aggregates (MCAs) were generated by culturing cells either alone 
or in together 1:1 ratio in microwells as described in Chapter 3. MCAs were cultured in 
Matrigel for 8 days (Figure 22A). Over a course of 5 days, there was a significant increase in 
the size of the MCAs. Dual MCAs demonstrated the presence of both cell types but appeared 
smaller in size. Despite modeling tumor cell heterogeneity, the challenge was to determine 
whether there was dynamic shift in phenotypic status of tumor cells along the EMT spectrum 
within mosaics. Therefore, we utilized the dual fluorescence reporter system stably 
transfected in 344SQ cancer cells to detect EMT status of cancer cells in real-time. Briefly, 
this two-plasmid sensor system, termed the Z-cad sensor, uses one construct with a 
destabilized GFP linked to the 3′ UTR of Zeb1 and a separate plasmid with RFP expressed 
downstream of the E-cadherin promoter (Figure 22B). When cells are in a mesenchymal 
state, the endogenous ZEB1 protein levels are high, leading to suppression of its targets 
including miR-200 and E-cadherin, and thus RFP expression. In an epithelial state, high miR-
200 levels downregulate ZEB1 levels post transcriptionally via its 3′UTR, decreasing the GFP 
signal. The suppression of ZEB1 leads to the derepression of the E-cadherin promotor and 
increased RFP expression. We co-expressed the Z-cad sensor plasmids in the mesenchymal 
344SQ murine cell line (344SQ_Z-cad). We utilized the 344SQ because they display greater 
plasticity and readily undergo MET under different conditions44,93; thus, they were an ideal 
cell line to test the dynamic readout of the Z-cad reporter.  




Figure 22. Tools to study EMT mediated tumor cell heterogeneity.  
(A) Mosaics derived from epithelial 393P_GFP and mesenchymal 344SQ_RFP cells were cultured in 
Matrigel to study tumor cell heterogeneity. (B) Schematic diagram illustrating the Z-cad dual sensor 
constructs. The d2GFP-Zeb1 3′UTR construct constitutively expresses destabilized GFP under the 
control of a ubiquitin promoter. The Zeb1 3′ UTR, which contains eight miR-200–binding sites, is 
expressed downstream of d2GFP. The E-cad-RFP construct contains the E-cadherin promoter, with 3 
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We confirmed the functionality of the sensor in detecting each phenotypic state. In 2D 
culture, the 344SQ_Z-cad cell line is approximately 58% GFP+ at baseline by fluorescent 
imaging, whereas only approximately 4% of the population is RFP+ (Figure 23A)181. To 
determine that the sensor responds in a dynamic manner to EMT-promoting conditions, the 
344SQ_Z-cad cells were stimulated with TGFβ1 to further induce a mesenchymal state. As 
expected, the addition of TGFβ1 significantly increased the percentage of GFP+ cells within 
24 hours, with a significant decrease in the RFP+ epithelial cells occurring within 2 days and 
continuing throughout the experiment (Figure 23A). We also performed scratch assay to 
determine which cell subtype had a greater migratory capacity. After 2 days, GFP+ cells were 
detected at the leading edge which was expected as mesenchymal cancer cells have greater 
migratory, invasive and metastatic potential (Figure 23 B).  The phenotypically plastic 344SQ 
cells can shift their EMT status based on external stimuli. When cultured in a 3D laminin-rich 
Matrigel matrix, the cells form polarized epithelial spheres93. Thus, we tested whether these 
epithelial structures were also RFP+ by plating the 344SQ_Z-cad cells in a Matrigel matrix. 
Fluorescent imaging and flow cytometry confirmed that while 50% GFP+ after initial plating, 
each day in Matrigel caused a reduction in the GFP+ subpopulation with a steady increase in 
the RFP+ population (Figure 23 C, D). After 9 days in culture, the 3D structures were roughly 
40% RFP+ and <10% of cells maintained GFP expression. Again, addition of TGFβ1 at day 
5 of 3D culture stimulated EMT and produced GFP+ expression within 24 hours (Figure 23 
C, D) overcoming the influence of the Matrigel matrix. Additional characterization of the 
344SQ_Z-cad cells were published by our group (Konen et al181). 




Figure 23. Z-cad sensor cells detect the EMT status of tumors cells in real-time.  
(A) The 344SQ_Z-cad cells were grown over 4 days with and without TGFβ (5 ng/mL), and fluorescent 
microscopy was performed. Representative images are shown. (B) Scratch assay performed on Z-cad 
cells and observed for 48 hours to determine migratory subpopulations. (C) Fluorescent confocal 
images were acquired of 344SQ_Z-cad cells plated on a Matrigel matrix. On day 5, TGFβ (5 ng/mL) 
was added. Confocal images acquired over 9 days, and representative images are shown on each 
day. (D) Flow cytometry of the percentage of GFP+ and RFP+ cells was performed on the 344SQ_Z-
cad 3D spheres grown over 9 days as described in E.  
(Konen et al, Cancer Res March 1 2021 (81) (5) 1398). 
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As demonstrated in Chapter 3, our EVT setup is capable of modeling tumor 
microenvironment and therefore capture the heterogeneity within murine tumors. Since we 
had two strong experimental models for tumor heterogeneity, we decided to combine them to 
increase the complexity of EVTs. We implanted 344SQ_Z-cad cells in syngeneic wild type 
mice and allowed the tumors to develop for 4 weeks. At the time of necropsy, we collected 
tumors and processed them to yield EVTs (as mentioned before) as well as collected a 
representative sample for analysis of subpopulations within the tumors. We detected 
presence of both GFP+ and RFP+ cells in the tumors (Figure 24 A-D). We also generated 
MCAs from 344SQ_Z-cad cells taken from 2D culture and grown in microwells for a day. 
These were used as a comparison for the Z-cad_EVTs which clearly demonstrated more 
tumor cell heterogeneity than the pure MCAs (Figure 24 C, D). 
 
Figure 24. Z-cad cells cultured as MCAs and EVTs. 
(A) Representative dot plot of the percentage of GFP+ and RFP+ cells from a single 344SQ_Z-cad 
tumor. (B) Quantification of subpopulations in 344SQ-Zcad tumors. (C) 344SQ-Z-cad MCAs and EVTs 
after one day in culture in microwells. (D) Size of spheres derived from (C).   
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 Z-cad EVTs alter phenotype in response to matrix manipulation.  
After characterizing Z-cad cells and EVTs in terms of subpopulations, we wanted to 
confirm that Z-cad_EVTs retained their biological behaviors to external manipulations. For 
each assay, the Zcad_EVTs were cultured in microwells (MW) for one day before transferring 
to respective matrices. First we cultured the EVTs in laminin rich Matrigel. At the beginning 
of the assay, we observed a mixture of both RFP+ and GFP+ cells. However, continuous 
signals from Matrigel lead to an enrichment of RFP+ epithelial cells over 5 days as we have 
previously noted in our studies (Figure 25 A, B). Treatment with TGFβ drove the phenotype 
in the opposite direction, making the EVTs increasingly GFP+ as well as highly invasive 
(Figure 25 A, B, D). We confirmed that there was induction of EMT at the molecular level by 
collecting the EVTs from Matrigel and analyzing by qPCR for EMT markers ZEB1 and E-
cadherin (Figure 25 C).  
 




Figure 25. Z-cad EVTs alter phenotype in response to external stimulants.  
(A) Fluorescent confocal images of 344SQ_Z-cad EVTs cultured in Matrigel matrix for 5 days. EVTs 
were treated with TGFβ (5 ng/mL) one day after seeding. (B) Flow cytometry of the percentage of 
GFP+ and RFP+ cells was performed on EVTs in (A). (C) Real-time PCR (qPCR) analysis for relative 
expression of ZEB1 and E-cadherin of EVTs treated with TGFβ. (D) EVTs are highly invasive in 
response to TGFβ with enrichment of GFP+ cells.  
When Z-cad_EVTs were cultured in Matrigel/Collagen I for 5 days, a depletion of 
RFP+, an enrichment of GFP+ cells as well as very invasive phenotype was observed (Figure 
26A,B,D). Cells in the center of the sphere retained epithelial phenotype and were largely 
non-invasive. Treatment with dasatinib prevented the emergence of invasive phenotype 
(Figure 26A,D), however, did not necessarily promote an epithelial phenotype. This was in 
contrast with our previous observations where treatment with dasatinib induced an MET in 
wild type EVTs after about 8 days of treatment. With a long term treatment, we would expect 
to see similar results and this effect of Src-inhibitor on mesenchymal subpopulations needs 
further exploration. There was a moderate suppression of E-cadherin in Matrigel/Collagen, 
whereas ZEB1 levels remain unchanged (Figure 26C). The lack of significant changes in EMT 
markers can be due to one of 2 reasons: the signal is muted or missed because qPCR is a 
bulk assay or that ECM is driving the invasive phenotype of the tumor cells without inducing 
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epigenetic changes that result in a mesenchymal state. The complex interplay between 
epigenetic state and influence of the ECM on tumor cell phenotype warrant further 
investigations. 
 
Figure 26. Z-cad EVTs alter phenotype in response to matrix manipulation. 
(A) Fluorescent confocal images were acquired of 344SQ_Z-cad EVTs cultured in Matrigel/Collagen I 
(3 mg/ml) matrix for 5 days. EVTs were treated with dasatinib (50 nM) one day after seeding. (B) Flow 
cytometry of the percentage of GFP+ and RFP+ cells was performed on EVTs in (E). (C) Real-time 
PCR (qPCR) analysis for relative expression of ZEB1 and E-cadherin of EVTs in Matrigel and 
Matrigel/Collagen I. (D) EVTs are highly invasive Matrigel/Collagen I. Invasion is overcome with 
treatment of dasatinib.   
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 Screening of pharmacological agents to target EMT using Z-cad sensor cells. 
We next utilized the Z-cad sensors for testing the selective sensitivity of cancer cell 
subpopulations to different therapeutic agents. Mocetinostat, an HDAC-1 inhibitor, is a known 
to induce MET by upregulation of miR200182. We used it mocetinostat as a positive control to 
demonstrate the shift in EMT states. When 344SQ_Z-cad cells in 2D and Z-cad_EVTs in 
Matrigel were treated with mocetinostat, there was significant enrichment of RFP+ epithelial 
cells with a depletion of GFP+ cells (Figure 27A, B). On the other hand, as previously noted, 
MEK inhibitors are very effective in targeting Kras-mutant epithelial cells whereas 
mesenchymal cells remain largely resistant. These findings were confirmed when Z-cad cells 
and EVTs were treated with the MEK inhibitor AZD6244 (selumetinib), as significant decrease 
in viable RFP+ cells showed that MEKi preferentially targeted epithelial cells (Figure 27A, B). 
In fact, published work from our lab has shown that treatment with mocetinostat can sensitize 
murine tumors to selumetinib by inducing MET in mesenchymal subpopulations and therefore 
aid in overcoming therapeutic resistance103.  
We wanted to further expand our findings to identify effective combination strategies 
for targeting both epithelial and mesenchymal tumor cells. We integrated the information from 
published shRNA screens and RPPA datasets to narrow down potential targets, which can 
be found published by our group (Konen et al181). Two top hits, CDK4 and AXL, were 
significantly and differentially depleted in mesenchymal cancer cells. 344SQ_Z-cad cells and 
EVTs were treated with selective inhibitors for each, palbociclib and bemcentinib (BGB324), 
respectively. Flow cytometry analysis from 344SQ_Z-cad cells treated with single agents 
found that palbociclib and bemcentinib treatment significantly decreased the GFP+ viable 
population (Figure 27A, B). The information from preliminary drug screen provided sufficient 
evidence to further follow-up 2 combinations: MEKi + CDK4i and MEKi + AXLi, for targeting 
tumor heterogeneity mediated by EMT. MEKi + CDK4i combination was extensively 
evaluated and details can be found in Chapter 4. Part of the findings from MEKi + AXLi 
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combination are shown in Figure 27C-E. We embedded the 344SQ_Z-cad cell lines within a 
3D matrix and treated with single agent or combination of selumetinib and bemcentinib. To 
quantify, we calculated the percentage of the colored pixels that are either GFP or RFP per 
field of view (Figure 27C, D). Selumetinib treatment caused an enrichment in GFP+ structures 
whereas bemcentinib had little effect, likely due to the lower percentage of GFP+ cells at 
baseline. Therefore, we also utilized a collagen type I and Matrigel (Coll/MG) matrix, which 
promotes a mesenchymal phenotype as shown in Figure 27E. In a Coll/MG matrix, 344SQ_Z-
cad structures were 68% GFP+ at baseline (Figure 27C, D). Treatment with selumetinib had 
little impact in this matrix; however, bemcentinib significantly enriched the epithelial RFP+ 
population. In both matrices, the combination of selumetinib and bemcentinib returned the 
RFP and GFP percentages to about 50:50, suggesting that both tumor cell subpopulations 
are being targeted equally. We also analyzed the viability of these 3D structures in single-
agent and combination treatments. In MG, selumetinib significantly decreased cell viability, 
whereas bemcentinib had no significant effect. Combining selumetinib and bemcentinib 
significantly decreased viability compared with single-agent MEK inhibition. In Coll/MG, both 
single agents decreased viability to about 50%, whereas the combination had a greater 
impact than either single agent (Figure 27E). Further in vitro and in vivo validation of this 
combination can be found in the study by Konen et al181. Together, the data provides rational 
drug combination that co-targets MEK and AXL signaling pathways. This combination works 
effectively to target cells in an epithelial or mesenchymal phenotypic state, leading to 
significant repression of tumor growth and prevention of resistant outgrowth by targeting 
EMT-related tumor heterogeneity. 
  




Figure 27. Z-cad cells can detect differential drug sensitivities of cancer subpopulations.  
(A) 344SQ_Z-cad cells and EVTs were treated with DMSO, mocetinostat (1 µM), AZD6344 (5 µM), 
palbociclib (5 µM) and BGB324 (5 µM) in 2D culture (top) and Matrigel matrix (bottom). (B) Flow 
cytometry quantification of the shift in GFP and RFP subpopulations in response to each treatment in 
2D culture. (C) 344SQ_Z-cad cells were plated on a Matrigel (MG) or a Collagen I/Matrigel (Coll/MG) 
matrix. Two days after seeding, DMSO, AZD6244 (MEKi) (5 μM), BGB324 (AXLi) (2 μM), or the 
combination (combo) were added. Fluorescence microscopy was then performed, and representative 
images are shown on day 7 (MG) or day 5 (Coll/MG). Scale bar = 100 μM. (C) Images obtained from 
(B) were quantified for the percentage of RFP or GFP pixels (D) 344SQ_Z-cad cells were plated in 
Matrigel (MG) or Collagen/Matrigel (Coll/MG) matrix. After 24 hours, structures were treated with 
DMSO, MEKi (5 μM), AXLi (2 μM), or the combination. After 4 days of treatment, Cell Titer-Glo reagent 
was added and luminescence measured. (Konen et al, Cancer Res March 1 2021 (81) (5) 1398) 




EMT is a well-studied but complex and dynamic epigenetic reprogramming event that 
promotes tumor progression, metastasis, and drug resistance, facilitating cancer cell adaption 
to conditions within the TME to ensure survival and thereby producing considerable cellular 
heterogeneity. With a selective drug screen combined with models capturing tumor 
heterogeneity, we identified distinct therapeutic sensitivities in heterogeneous tumor 
subpopulations to prevent EMT-mediated escape. As the miR-200/Zeb1 axis is critical for 
EMT, this was an ideal model to evaluate EMT shifts in the face of ECM changes and targeted 
agent treatments. By expressing the Z-cad sensor in the murine 344SQ cells, we determined 
that collagen I promoted a mesenchymal phenotype, MEKi selumetinib and AXLi bemcentinib 
specifically target RFP+ epithelial and GFP+ mesenchymal populations, respectively, and 
when combined, significantly inhibit tumor cell growth in 2D and 3D in vitro systems.  
In addition to the identification of the therapeutic sensitivities, there a many more uses 
of Z-cad dual fluorescent sensors that need to be further explored. One such example is 
exploration of epithelial to mesenchymal plasticity (EMP) which is a broader, and more 
recently used, term encompassing the dynamic and directional transitory states, EMT and 
MET180. According to this description, only a small population within tumors exhibit the 
plasticity and transition between the 2 polar states. The spatial and temporal presence of 
these subpopulations determines their role in metastasis and therapeutic resistance. Another 
concept that is gaining more traction is the phenotype of cancer cells exhibiting partial/hybrid 
EMT where cells retain characteristics associated with the conventional epithelial and 
mesenchymal states. These cell are also know to be present in a metastable state and 
evidence from the past few years has shown that, among hybrid subpopulations, those that 
retain more epithelial features with less mesenchymal conversion have the greatest 
malignant and metastatic potential183,184. Based on mathematical modeling, it is predicted that 
a hybrid state occurs with medium levels of both miR200 and ZEB1185. The Z-cad cells appear 
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to have certain of these subpopulations as characterized by expressing both RFP and GFP 
or expressing neither. These double positive and double negative subpopulations could 
represent these hybrid states undergoing transition. It is possible that this subpopulation is 
maintained in a heterogeneous cell population as an equilibrium. Also, since these cells have 
both epithelial and mesenchymal characteristics, they are potentially more aggressive 
(collective migration, but also might not be targetable by either epithelial or mesenchymal 
targeting drugs) and can even be enriched in tumors following therapeutic targeting186. Open 
ended questions include what cell intrinsic and extrinsic factors promote the appearance and 
stability of these hybrid phenotypes and if those molecular mechanisms could be 
therapeutically targeted for translation relevance. Further exploration and characterizing of 
these cell types would allow us to explain the biological phenomenon of EMP.  
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Chapter 5: Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and 
therapeutic resistance in KRAS mutant lung cancer CDK4 
5.1 Introduction 
Activating KRAS mutation is one of the most frequent oncogenic events in lung cancer, 
occurring in about 30% of lung adenocarcinoma patients187-189. Despite the identification of 
the oncogene over 20 years ago and efforts to effectively treat this subset of patients, 5-year 
survival rates remain dismal1. Unlike EGFR mutant lung cancer, K-Ras oncoproteins are 
largely undruggable, with the very recent exception of the KRASG12C allele190,191. 
Pharmacological inhibitors of the MAPK pathway (e.g., MEK), such as selumetinib and 
trametinib are available, but preclinical and clinical trials have demonstrated poor responses 
to MEK inhibitors192. Combination of MEK inhibitors with conventional chemotherapy did not 
demonstrate any added benefit to progression free survival74.  Resistance to MEK inhibitors 
may be intrinsic (de novo) due to tumor cell heterogeneity or acquired due to tumor evolution 
as an adaptive response to pharmacological agents. In either case, the presence of 
phenotypically distinct tumor cell subpopulations with reprogrammed cellular machinery 
makes it difficult to effectively eliminate the broader tumor cell population. To address this, 
we need to understand the differences in the tumor cell subpopulations within a 
heterogeneous tumor.  
Genetically identical tumor cells possess the ability to undergo transcriptional 
reprogramming to activate alternate survival pathways and evade therapeutic targeting. 
Research from our group and others has extensively demonstrated that epithelial-to-
mesenchymal transition (EMT) is a central phenomenon occurring in K-Ras mutant lung 
cancer, which contributes to intracellular tumor heterogeneity, increased metastatic potential, 
therapeutic resistance to pharmacological agents and poor patient outcomes93,103,193. Murine 
lung cancer models driven by Kras and p53 mutations recapitulate EMT-mediated tumor cell 
heterogeneity with the ZEB1/miR-200 double negative feedback loop playing a central role in 
dynamically altering the cellular phenotype93. Our previous research highlighted the reliance 
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of K-ras mutant epithelial lung cancer cells on activated MAPK signaling pathway and 
increased susceptibility to MEK inhibitors. On the other hand, tumors demonstrating a 
mesenchymal phenotype remained largely unresponsive to MEK inhibitors. Moreover, after 
an initial response to MEK inhibition, epithelial tumors acquired therapeutic resistance by 
undergoing EMT103,194. The study identified an unmet need to develop therapeutic 
approaches to target distinct tumor subpopulations within heterogeneous K-ras mutant lung 
tumor to achieve a robust therapeutic response. Utilizing multiple loss-of-function shRNA 
screens, we analyzed the transcriptome of the phenotypically different tumor subpopulations 
and identified CDK4-RB as a major survival pathway in mesenchymal tumor cells. We 
validated our finding using multiple in vitro, ex vivo and in vivo models well suited for studying 
EMT-mediated tumor cell heterogeneity.  
CDK4 acts as a master integrator of mitogenic/oncogenic signaling cascades by initiating 
the inactivation of the central tumor suppressor RB and cell cycle commitment at the 
restriction point allowing cells to transition to S phase195. The CDK4 axis is altered in many 
cancers, with clinically approved pharmacologic inhibitors showing promising antitumor 
activity196. Some studies have shown that CDK4 and cyclin D1 expression is correlated with 
the presence of KRAS mutation in lung tumors197 and a synthetic lethal interaction occurs 
between K-ras and CDK4 in lung cancer tumor progression198,199. We found that the 
differential activation of the CDK4 pathway in epithelial and mesenchymal cells was 
determined by ZEB1-mediated p21 regulation. As an intrinsic regulator of CDK4, p21 levels 
in cells determine the downstream CDK4 pathway activity. p21 is transcriptionally regulated 
by ZEB1 by direct binding to the promoter region. Our study demonstrates in preclinical 
models that intrinsic and acquired MEK inhibitor resistance is associated with a rewired 
kinome in tumors by which the mesenchymal phenotype activates the CDK4 pathway as a 
common occurrence across models. This CDK4 signaling dependence resulted in a potential 
therapeutic approach to combine MEK and CDK4 inhibitors to target different tumor 
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subpopulations for a more robust tumor response and combat resistant outgrowth of 
epigenetic subsets in a heterogeneous tumor. 
5.2 Results 
 Mesenchymal lung cancer cells exhibit increased dependency on CDK4 
In order to effectively target the mesenchymal tumor subpopulations within 
heterogeneous tumors, we sought to identify the survival dependencies of these tumor cells. 
A loss of function screen with a barcoded, pooled small hairpin RNA (shRNA) library targeting 
about 500 genes with known kinase activity (Kinome) was conducted. Each gene was 
targeted with 10 unique shRNA sequences to limit false hits due to off-target effects. This 
library of shRNAs was transduced into representative non-metastatic, epithelial (393P) and 
metastatic, mesenchymal (344P) murine lung cancer cell lines derived from a previously 
described KP genetically engineered mouse model (GEMM)93. The cell lines stably 
expressing the shRNAs from the Kinome library were either cultured in vitro or implanted 
subcutaneously in nude mice (Figure 28 A). Tumors were harvested, shRNA barcodes were 
quantified by deep sequencing and referenced with the respective in vitro cell population and 
quality control measures were completed to ensure sufficient barcode coverage across the 
library was maintained in vivo (Figure 28 B, Table 11). The phenotypic impact of gene 
knockdown was inferred by the redundant shRNA activity (RSA) algorithm, where a lower 
rank of the shRNA barcodes signified dropout from the population and greater dependency 
on the gene for tumorigenesis (Table 12). Although both cell line models have activating 
KrasG12D and p53R172H mutations, comparison of the results of the Kinome screen revealed 
that the mesenchymal cell line (344P) and the matched syngeneic tumors were more reliant 
on Cdk4 for in vitro and in vivo growth (Figure 28 C). Other top hits identified in the screen as 
more significant in mesenchymal than epithelial cells were Aurka, Atr, Pik3Ca, Plk1, and 
Adrbk2 (Figure 28 C), consistent with recent publications about the role of the spindle 
assembly checkpoint in mesenchymal cells200. We also compared these results to our 
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previously published FDAome shRNA103 screen performed in a similar manner and identified 
Cdk4 as the most consistent hit across in vitro and in vivo conditions in both screens (Figure 
28 C, Table 14 and Table 15). 
 
Figure 28. shRNA screens identify survival dependencies in lung cancer cells. 
(A) Schematic illustration of the workflow of the shRNA dropout screens. A library of lentiviral particles 
expressing 10 different barcoded shRNAs was transduced into murine KP mutant lung cancer cells. 
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The cells were cultured in vitro or implanted in nude or syngeneic 129/Sv mice and later sequenced 
for barcoded shRNAs and compared to reference cells. (B) Viral integration distribution of reference 
population, cell lines and tumors determined through barcode sequencing (counts per million). Black 
= reference, red = in vivo samples, blue = in vitro samples. (C) Results from Kinome and FDAome 
shRNA dropout screens in 393P (epithelial) and 344P (mesenchymal) cell lines and tumors compared 
based on the redundant shRNA activity (RSA). Top differential hits are labeled on the graphs, most 
important being CDK4 (red). Venn diagram shows comparisons across different conditions and top hits 
identified. (Padhye et al JCI insight, 2021, in press). 
 
CDK4 mRNA expression in a panel of 118 human NSCLC cell lines showed a positive 
correlation with our previously reported 76-gene EMT signature201 (Figure 29 A). When sub-
classified based on mutational status, 41 KRAS-mutant NSCLC cell lines also showed 
positive correlation of CDK4 mRNA with the EMT signature (Figure 29 B). A panel of epithelial 
and mesenchymal murine lung cancer cells were tested by quantitative polymerase chain 
reaction (qPCR), which demonstrated higher CDK4 mRNA levels in the mesenchymal cells 
(Figure 29 C). TCGA dataset analysis of lung adenocarcinoma patients revealed alterations 
in the CDK4-RB core pathway in about 30-40% of the cases (Figure 29 D), which represents 
over 40,000 new patients annually. These analyses demonstrate the importance of CDK4 
pathway members in patients with lung adenocarcinoma.  
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Figure 29. CDK4 levels positively correlate with EMT score in lung cancer. 
(A) Cluster plot analysis of Spearman’s rank correlation between EMT score and CDK4 mRNA 
expression of 118 human NSCLC cell lines. (B) Cluster plot analysis of Spearman’s rank correlation 
between EMT score and CDK4 mRNA expression of 41 KRAS mutant human NSCLC cell lines. (C) 
Relative mRNA expression of CDK4 in a panel of murine KP epithelial and mesenchymal cells. (D) 
CDK4 pathway components and their corresponding mutation frequencies in the provisional lung 
adenocarcinoma TCGA dataset (Firehose legacy) (n=586).  
(Padhye et al JCI insight, 2021, in press). 
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To functionally validate the shRNA screen and determine whether response to CDK4 
inhibitors is dependent on the EMT status of tumor cells, we treated a panel of human and 
murine KRAS mutant NSCLC cell lines, stratified as either epithelial or mesenchymal based 
on previous profiling93,201, with CDK4 inhibitors. Both human and murine mesenchymal 
NSCLC cells were more sensitive to the CDK4 inhibitors palbociclib, abemaciclib and 
ribociclib (Figure 30 A, B). As previously noted93, EMT status is tightly regulated by the 
ZEB1/miR-200 double negative feedback loop and manipulation of this axis can induce an 
epithelial or mesenchymal shift in tumor cells. We therefore utilized isogenic pairs of human 
(H441) and murine (393P) epithelial cell lines with ZEB1 expression to produce a 
mesenchymal phenotype39 and isogenic pairs of human (H1299) and murine (344SQ) 
mesenchymal cells with miR-200 expression to push the cells to an epithelial state115. 
Comparisons across the different cell line pairs revealed that sensitivity to all CDK4 inhibitors 
was determined by the EMT status of lung cancer cells (Table 10). 
 
Table 10. IC50 of epithelial and mesenchymal cell lines for CDK4 inhibitors. 
CDK4 inhibitor Epithelial cells IC50 Mesenchymal cells IC50 
Palbociclib  
393P 10.8 344SQ 2.2 
393P_Vector 5.2 393P_ZEB1 0.6 
344SQ_miR-200 5.2 344SQ_Vector 0.8 
344SQ_sh_ZEB1#1 1.5 344SQ_Scramble 0.6 
344SQ_sh_ZEB1#3 2   
H358 9.6 A549 1.1 
H441 10 H1299 0.5 
H441_Vector 16 H441_ZEB1 2.6 
H1299_miR-200 3 H1299_Vector 0.6 
Abemaciclib 393P 15 344SQ 2.2 
H358 1 H1299 0.2 
Ribociclib 393P 19.2 344SQ 3.8 
H358 29 H1299 3.3 
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Figure 30. Cell viability assay in a panel of epithelial and mesenchymal cells after 48 hours. 
n=8 per drug concentration. The curve was generated using a nonlinear regression fit model.  
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The downstream targets of CDK4, RB and FoxM1, are important readouts for CDK4 
kinase activity, whereas phospho-CDK4 may continue to be present for another 24 hours 
post inhibitor treatment. Suppression of the RB and FoxM1 was observed in mesenchymal 
cells upon treatment with abemaciclib and ribociclib for 24 and 48 hours (Figure 31 A). 
Epithelial tumor cells showed an initial suppression of CDK4 targets, but it was not a 
sustained response.  The mesenchymal 344SQ cells showed a more robust response to the 
inhibitor palbociclib over a range of concentrations and at shorter treatment times compared 
to epithelial cells (393P) in terms of suppression of downstream signaling and induction of 
apoptosis (Figure 31 B).   
 
Figure 31. Effect on CDK4 pathway with pharmacological inhibitors of CDK4 
(A) Western blot showing the effect on signaling in 393P and 344SQ tumor cells upon treatment with 
abemaciclib (A: 2 µM) and ribociclib (R: 2 µM) for 24 and 48 hours. (B) 344SQ and 393P cells were 
treated for 24, 48 and 72 hours with 1 and 5 µM palbociclib, and western blot analysis was utilized to 
demonstrate drug efficacy over a dose range. Cleaved caspase-3 was used as an apoptotic marker. 
(Padhye et al JCI insight, 2021, in press).  
 _____ Chapter 5: Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and 
therapeutic resistance in KRAS mutant lung cancer CDK4 
98 
 
In addition to pharmacologic inhibition, we also employed a genetic approach to 
confirm the dependency of mesenchymal tumor cells on CDK4 for survival. Mesenchymal cell 
lines with an inducible shRNA targeting CDK4 showed a greater reduction in tumor cell growth 
(Figure 32 A), with suppression of phospho-RB (Figure 32 B) compared to epithelial cells. In 
fact, epithelial 393P tumor cells appeared to have slightly greater growth rate with CDK4 
knockdown than the control cells (Figure 32 B) and continued RB phosphorylation.  
 
Figure 32. Effect on CDK4 pathway with doxycycline inducible shRNA targeting CDK4. 
(A) Top: Relative mRNA expression of CDK4 upon doxycycline mediated induction of shRNAs 
targeting CDK4 at 72 hours. Bottom: Growth rates of 393P and 344SQ cells with or without CDK4 
knockdown over 72 hours measured by MTT assay. One and two-way ANOVA test was used for 
statistical analysis, respectively.  (B) Western blot analysis of CDK4 pathway after 72 hours of CDK4 
knockdown. **** p<0.0001; ** p<0.001. 
(Padhye et al JCI insight, 2021, in press). 
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 CDK4 pathway is dynamically regulated by the EMT status of tumor cells 
Because the primary role of CDK4 is cell cycle regulation at the G1-S transition, we 
next tested if there are phenotypic differences in the manner which epithelial and 
mesenchymal NSCLC cell lines undergo cell cycle progression. Upon serum starvation for up 
to 48 hours, epithelial 393P cells almost completely (~90% of the cells) arrested in the G0-
G1 phase of the cell cycle with a complete suppression of the CDK4 pathway (Figure 33 A). 
In contrast, the mesenchymal cells resisted cell cycle arrest in serum free conditions, with 
~80% of the cells in G0-G1 state but 20% of cells continuing to cycle through S or G2/M 
(Figure 33 A). This observation corresponded to higher levels of CDK4, Cyclin D1 and 
phospho-RB in the cells when assayed by subcellular fractionation (Figure 33 B), suggesting 
that CDK4 activity in mesenchymal tumor cells could be uncoupled from extrinsic mitogenic 
signals. After release of cells from the arrested state by addition of serum containing media, 
the mesenchymal cells transitioned into S phase more readily (within 20 hours) than the 
epithelial cells, which remained arrested in G1 phase up to 36 hours before returning to the 
baseline cycling state (Figure 33 A). Although cell cycle arrest in G1 phase with palbociclib 
was similar between 393P and 344SQ cells, a significant increase in the percentage of 344SQ 
cells in G0 state (apoptotic cells) was detected (Figure 33 C, D), corresponding to increased 
cleaved caspase-3  as observed in Figure 31 B. 
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Figure 33. Cell cycle analysis in epithelial and mesenchymal cells.  
(A) Cell cycle analysis 393P and 344SQ cells using propidium iodide (PI). Baseline cell cycle was 
determined by staining cells in culture with PI. Cell cycle arrest was induced by serum starvation of 
cells for 24 hours followed by release into cell cycle by addition of FBS containing media and analyzed 
after 10, 20 and 36 hours. (B) Subcellular fractionation followed by western blot analysis of indicated 
cell cycle markers. (C) Cell cycle analysis 393P and 344SQ cells treated with palbociclib (5µM) for 12 
and 24 hours using (PI). (D) Quantification of subpopulations in different cell cycle phase. Data are 
presented as mean and statistical analysis was done using one-way ANOVA test.* p< 0.05, **p< 0.01. 
(Padhye et al JCI insight, 2021, in press). 
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Using reverse phase protein arrays (RPPA) to analyze changes in cell signaling 
proteins in a high-throughput manner, we screened a panel of previously characterized 
isogenic murine epithelial and mesenchymal lung cancer cell lines and observed an increase 
in CDK4 axis related molecules, phospho-RB and Cyclin D1 (as downstream markers for 
CDK4 signaling pathway activation), in cells with a mesenchymal phenotype (Figure 34 a). A 
subcellular fractionation assay also showed higher levels of phospho-RB, Cyclin D1 and 
CDK4 in mesenchymal cells (Figure 34 B). Immunofluroscent staining of tumor cells also 
demonstrated an activated CDK4/RB axis with a higher percentage of 344SQ tumor cells with 
positive nuclear staining for phospho-CDK4 and phospho-RB and a stronger staining for total 
CDK4 (Figure 34 C,D). 
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Figure 34. CDK4 pathway is upregulated in mesenchymal cells. 
(A) Dot plots of Cyclin D1 and RB phosphorylation (S807/811) from RPPA dataset in a panel of 
epithelial and mesenchymal murine lung cancer cell lines. (B) Subcellular fractionation of 393P, 307P 
(epithelial) and 344SQ, 344P (mesenchymal) cells for indicated markers. (C) Representative images 
of immunofluorescence on 393P and 344SQ wild type cells for indicated markers. Scale bar: 50 µM. 
(D) 4-6 biological replicates were analyzed for quantification of the fluorescent signal. One-way ANOVA 
was used for statistical analysis.  
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We next tested the effects of altering the EMT status of tumor cells on the CDK4 
signaling pathway using the previously described isogenic cell line pairs. ZEB1 
overexpression in murine (393P) and human (H441) epithelial cells produced higher levels of 
CDK4 and phospho-RB (Figure 35 A). Conversely, miR-200 expression in murine (344SQ) 
and human (H1299) cells caused a suppression of the CDK4 axis (Figure 35 B).  
 
 
Figure 35. CDK4 pathway is dynamically regulated by the EMT status of tumor cells. 
Western blot analysis of murine and human cells with ZEB1 and miR-200 expression. Cells were 
induced with 2 µg/ml of doxycycline for times indicated. 
(Padhye et al JCI insight, 2021, in press). 
 
  
 _____ Chapter 5: Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and 
therapeutic resistance in KRAS mutant lung cancer CDK4 
104 
 
Immunohistochemistry on mesenchymal 344SQ syngeneic tumors revealed higher 
phospho-CDK4 and phospho-RB staining with absent phospho-Erk, and the reverse was 
observed in the epithelial 393P syngeneic tumors (Figure 36 A). The dynamic nature of tumor 
evolution and adaptation contributes to intratumoral cellular heterogeneity and allows for 
escape from therapeutic targeting. We have previously observed that epithelial 393P tumors 
initially respond to MEK inhibitors (e.g. AZD6244), however, long-term exposure leads to 
acquired resistance with the acquisition of a mesenchymal phenotype (393P-AZDR)103. We 
investigated whether tumors that have acquired resistance to MEK inhibitors have an 
activated CDK4 pathway. 393P-AZDR tumors showed higher phospho-CDK4 and phospho-
RB staining, with suppressed phospho-Erk, an observation similar to the de novo 344SQ 
mesenchymal tumors (Figure 36 A). Cell lines derived from 393P-AZDR tumors showed 
higher phospho-CDK4 and ZEB1 expression, with generally lower levels of phospho-Erk 
(Figure 36 B). Resistant cells were no longer sensitive to AZD6244, and instead became 
sensitive to palbociclib with an IC50 similar to 344SQ cells (Figure 36 C), and greater 
suppression of phospho-RB and phospho-CDK4 in 393P-AZDR than in 393P-vehicle cell 
lines. In contrast there was an accumulation of phospho-CDK4 in 393P-vehicle cells (Figure 
36 D). We conclude from the above findings that tumor cells that demonstrate a 
mesenchymal-like phenotype, either due to intrinsic factors or arising from epithelial cells 
undergoing EMT as an adaptive resistance mechanism, have rewired survival pathways to 
activate CDK4 signaling.   
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Figure 36. CDK4 pathway is upregulated in 393P-AZDR tumors and cells. 
(A) Immunohistochemistry on tumors derived from 393P, 344SQ and 393P-AZDR tumors for indicated 
markers. Scale bar: 50 µM. (B) Western blot analysis on cell lines derived from 393P tumors treated 
with vehicle or AZD6244 for indicated markers. (C) In vitro cell viability assay on 393P, 344SQ, 393P-
vehicle and 393P-AZDR after 48 hours of AZD6244 and palbociclib treatment. n=8 per drug 
concentration. The curve was generated using a nonlinear regression fit model. **** p<0.0001; *** 
p<0.005; ** p<0.001. (D) Western blot analysis of 393P-vehicle and 393P-AZDR cells after treatment 
with palbociclib (5µM) for 48 hours for indicated markers.  
(Padhye et al JCI insight, 2021, in press). 
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 ZEB1 regulates p21 expression and causes differential CDK4 pathway activity  
To identify the mechanistic basis of the differential dependency on the CDK4 pathway 
between the phenotypic epithelial and mesenchymal cancer cells we investigated the 
canonical upstream survival pathways but did not observe their differential regulation 
between epithelial and mesenchymal cells. We then focused on the intrinsic regulators of 
CDK4 activity, p21 (WAF1/CIP1) and p27 (KIP1), and used si-RNAs for transient knockdown 
of each in epithelial and mesenchymal cells to determine the downstream effects on the 
CDK4 pathway (Figure 37 A). Knockdown of p21 had a more significant impact on the 
phosphorylation of CDK4 and RB compared to p27 (Figure 37 B), which indicated that p21 
was more important in the differential regulation of the CDK4 pathway between epithelial and 
mesenchymal tumor cells. The much higher phosphorylation of RB in 393P cells with p21 
knockdown indicated that p21 maintains a check on the CDK4-RB pathway in the epithelial 
cells and when disrupted increases activation of the pathway. Loss of p21 in mesenchymal 
cells only modestly increased phosphorylation of RB compared to the control cells, 
suggesting that an intrinsic deficiency of p21 protein in the mesenchymal cells could lead to 
a dysregulated CDK4 pathway.  
 
Figure 37. Transient knockdown of p21 and p27.  
(A) Relative mRNA expression after 48 hours of knockdown of p21 and p27 in 393P and 344SQ cells. 
(B) Western blot analysis of CDK4 pathway with p21 and p27 knockdown. 
(Padhye et al JCI insight, 2021, in press). 
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Since alterations in the tumor suppressor TP53 is one of the most commonly occurring 
co-mutation events in KRAS driven lung cancer and because p21 is a direct target of p53, we 
wanted to determine the effect of p53 and whether any differences might account for CDK4 
pathway regulation in the epithelial and mesenchymal tumor cells. With transient knockdown 
of p53, we did not observe any significant difference in downstream pathway signaling (Figure 
38 A, B). Additionally, we also utilized previously published KrasG12D mutant (K1) and 
KrasG12D/p21-/- (KC3 and KC4) murine tumor cells202 to determine if p21 could regulate the 
sensitivity of tumor cells to CDK4 inhibitors. Absence of p21 in tumor cells sensitized KC cell 
lines to palbociclib with an increase in CDK4 signaling (Figure 38 C, D). This further 
emphasized that p21-mediated CDK4 dysregulation was independent of p53 control.  
 
Figure 38. Effect of p53 on p21-CDK4 pathway. 
(A) Relative mRNA expression of Tp53 (left) and Cdkn1a (right) with transient knockdown of Tp53. (B) 
Western blot analysis of indicated markers upon transient knockdown of Tp53 for 48 hours. (C)  In vitro 
cell viability after 48 hour palbociclib treatment of K1, KC3 and KC4 cells. (D) Western blot analysis of 
indicated markers in K1, KC3 and KC4 cells.  
(Padhye et al JCI insight, 2021, in press).  
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We next sought to ascertain whether EMT status of tumor cells could directly regulate 
the expression of p21. Our previously published93 microarray datasets that interrogate 
differential gene expressions in epithelial and mesenchymal tumor cells demonstrated that 
epithelial cells have a higher expression of Cdkn1a (gene encoding for p21), including 
comparisons of 344SQ vs 393P cells (fold change 0.57, p=0.003) and 393P-ZEB1 vs 393P-
vector (fold change 0.27, p<0.0001).  We confirmed and extended this observation with a 
panel of murine cell lines by qPCR and found that p21 levels inversely correlated with ZEB1 
levels across the panel (Figure 39 A, B). Analysis of CDKN1A mRNA expression in 29 KRAS 
mutant human lung adenocarcinoma cell lines revealed an inverse correlation with a 
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Figure 39. EMT status of cancer cells determines p21 levels. 
(A) Relative expression of Cdkn1a mRNA in a panel of epithelial and mesenchymal murine lung cancer 
cells (left) and 393P vehicle and AZDR cell lines (right). (B) Relative expression of Zeb1 mRNA in a 
panel of epithelial and mesenchymal murine lung cancer cells (left) and 393P vehicle and AZDR cell 
lines (right). (C) Cluster plot analysis of Pearson’s correlation between CDKN1A mRNA and EMT score 
in 29 KRAS mutant human lung adenocarcinoma cell lines.  
(Padhye et al JCI insight, 2021, in press). 
 
 
Immunofluorescence assay on 393P, 393P-AZDR and 344SQ cells revealed that a 
higher percentage of epithelial cells had nuclear p21 than mesenchymal cells, along with 
higher co-localization of CDK4 and p21 in epithelial tumor cells (Figure 25 B). 
Immunohistochemistry analysis of epithelial (393P) and mesenchymal (344SQ) and 393P-
AZDR tumors also showed an inverse correlation between p21 and ZEB1 levels (Figure 25E). 
Pathologic analysis of human NSCLC samples for ZEB1 and p21 by IHC staining revealed 
an inverse correlation between nuclear ZEB1 and p21 H-scores (Figure 25F). We also 
grouped the samples based on low ZEB1 (<4 H-Score) or high ZEB1 (>4 H-score) staining 
and found a significant difference in p21 H-score (Figure 25G). Combined together the data 
support the regulation of p21 by EMT status and more specifically by ZEB1. 
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Figure 40. ZEB1 levels inversely correlate with p21 levels. 
(A) (Left) Immunofluroscent staining of 393P, 393P_AZDR and 344SQ cells. Scale bar top: 100 µM, 
bottom: 10 µM. (Right) Quantification of cells co-staining positive for CDK4 and p21 in each cell lines. 
4-6 biological replicates were analyzed for quantification of the fluorescent signal. (B) 
immunohistochemistry on tumors derived from 393P, 344SQ and 393P-AZDR cells Scale bar: 50 µM. 
(C) Cluster plot analysis of Pearson’s correlation between ZEB1 and p21 H scores in NSCLC 
specimens. 
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We further tested this observation by inducing EMT or MET by overexpression of 
ZEB1 or miR-200 in human and murine isogenic cell line pairs. We observed p21 
transcriptional and translational repression with ZEB1 expression. Conversely, with miR-200 
expression, there was an upregulation of p21 (Figure 41 A, B).  
 
 
Figure 41. ZEB1 mediated EMT regulates p21 expression.  
(A) ZEB1 induction for 48 hours with 2 µg/ml of doxycycline in murine and human epithelial lung cancer 
cell lines. (B) miR-200 induction for 48 hours with 2 µg/ml of doxycycline in murine and human 
mesenchymal lung cancer cell lines. (Padhye et al JCI insight, 2021, in press).  
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Transient and stable knockdown of ZEB1 in human and murine cells, respectively, 
caused p21 expression (Figure 42 A-C). Cells treated with the HDAC inhibitor mocetinostat 
undergo an MET by upregulation of the miR-200 family and ZEB1 suppression103,182. 
Treatment also produced increased expression of p21 (Figure 42 D-F). Induction of miR-200 
in tumor cells by different means pushes the cells to a more epithelial state, which is generally 
considered a less aggressive phenotype for tumor cells and more akin to a “normal” cell state. 
Expression of p21 in an epithelial like state restores the cell cycle checkpoint that is lost or 
blunted in mesenchymal tumor cells with high ZEB1 activity and a more aggressive 
phenotype. 
 
Figure 42. Genetic and pharmacological suppression of ZEB1 alters p21 expression.  
(A) Relative mRNA expression in 344SQ cells with stable ZEB1 knockdown. (B) Western blot analysis 
of indicated markers in 344SQ cells with stable ZEB1 knockdown. (C) Relative mRNA expression of 
indicated markers in H1299 cells with transient ZEB1 knockdown. (D) Relative mRNA expression of 
indicated markers in 344SQ cells upon treatment with mocetinostat (1µM) for 48 hours. (E) Western 
blot analysis of 344SQ cells upon treatment with mocetinostat (1µM) for 48 hours. (F) Relative mRNA 
expression in H1299 cells upon treatment with mocetinostat (1µM) for 48 hours. Statistical analysis for 
A, E and G:  Unpaired t-test and for F, H, J, K and M: One-way ANOVA test. **** p<0.0001; *** p<0.005; 
** p<0.001; * p< 0.05.   
(Padhye et al JCI insight, 2021, in press). 
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Luciferase reporter assays were utilized to investigate ZEB1 mediated transcriptional 
regulation of p21. The promoter region of p21 was cloned upstream of a luciferase reporter 
and transfected into human lung cancer cells with either ZEB1 or miR-200 expression. H358 
and H441 cells expressing ZEB1 led to a decrease in relative luciferin signal confirming 
transcriptional repression of the p21 promoter in the presence of high ZEB1. Conversely, an 
increase in luciferin signal was detected in H1299 cells with miR-200 induction, which 
suppresses the endogenous cellular ZEB1 expression and relieves transcriptional repression 
of the p21 promoter (Figure 43 A). Binding of ZEB1 to the endogenous p21 promoter was  
confirmed by ChIP qPCR assays in cells with inducible ZEB1 or miR-200 expression, using 
previously published primer pairs 203 (Figure 43 B). Using GAPDH as the negative control and 
miR-200c as a positive control, we confirmed direct binding of ZEB1 to the p21 promoter. 
 
Figure 43. Transcriptional repression of p21 occurs by direct binding of ZEB1 to promoter.  
(A) Relative luciferase activity of CDKN1A promoter reporter construct transfected into epithelial H358 
and H441 cells with induced ZEB1 expression or mesenchymal H1299 with induced miR-200 
expression. Relative luciferin signal was normalized to promoter-less vector control signal. (B) Fold 
enrichment by qPCR analysis of CDKN1A promoter containing ZEB1 binding site after endogenous 
ZEB1 ChIP in H441 cells with inducible ZEB1 expression or H1299 cells with inducible miR-200 
expression, using ZEB1 antibody or immunoglobulin G (IgG) control antibody.  
(Padhye et al JCI insight, 2021, in press). 
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 Suppression of p21 in mesenchymal cells regulates CDK4 pathway 
We next explored the effect of p21 on CDK4 activity in epithelial and mesenchymal 
lung cancer cells. With transient knockdown of CDK4, phosphorylation of RB was 
continuously suppressed in mesenchymal cells for 48 hours (Figure 44 A,B). On the contrary, 
CDK4 knockdown in epithelial tumor cells appeared to have only slightly muted downstream 
signaling (phosphorylation of RB), which coincided with a rather surprising accumulation of 
phosphorylated CDK4, even with very low levels of total CDK4 protein. The CDK4 
accumulation corresponded to a continued presence of p21 protein in the epithelial cells 
(Figure 44 B). The intriguing findings observed here recapitulated the data in a previous report 
by Bisteau et al.204, which showed that a sustained presence of p21 protein in cells was able 
to maintain the phosphorylation status of CDK4 (hence the stability of the complex), but still 
inhibit kinase activity. A similar observation was made in our epithelial, but not mesenchymal, 
model where the presence of p21 maintains the CDK4 in the phosphorylated state. A similar 
outcome was observed with pharmacological inhibition of CDK4, including a partial 
suppression of phospho-RB, an accumulation of phospho-CDK4 with the presence of p21 in 
epithelial cells, versus a lack of p21 with a near complete suppression of phospho-RB in the 
mesenchymal cells by 48 hours (Figure 44 C).    
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Figure 44. p21 maintains CDK4 phosphorylation despite CDK4 loss.  
(A) Relative CDK4 mRNA expression after transient knockdown using 20 nM si-RNA. (B) Western blot 
analysis after transient knockdown of CDK4 for 12, 24 and 48 hours in epithelial and mesenchymal 
cancer cells. (C) Western blot of CDK4 signaling pathway after treatment with 2 μM of abemaciclib at 
indicated times.  
(Padhye et al JCI insight, 2021, in press). 
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To further demonstrate this point, we co-immunoprecipitated CDK4 and p21 in 
mesenchymal and epithelial cancer cells (Figure 45 A). In mesenchymal 344SQ and 
344SQ_vector cells, lower amounts of CDK4-p21 complex co-immunoprecipitated together 
compared to epithelial 393P and 344SQ_miR-200 cells where an increased binding of CDK4 
and p21 was detected. We also observed the seemingly contradictory presence of phospho-
RB in epithelial cells alongside p21 expression. An explanation for this observation is the 
sequestration of p21 into the CDK4 complex, alleviating the repression from the CDK2-Cyclin 
E complex, which can then phosphorylate RB to maintain cell cycle progression. In fact, we 
observed that epithelial cells are more sensitive to the CDK2 inhibitor (miciclib) than 
mesenchymal cells (Figure 45 B), indicating that CDK2 may be the primary regulator of cell 
cycle in epithelial cells. Lower binding of p21 to CDK4 in mesenchymal cancer cells is only 
sufficient to maintain the activity of the CDK4 complex but not in abundant enough to exert 
an inhibitory effect on the downstream pathway. 
 
Figure 45. Co-immunoprecipitation of CDK4-p21 in epithelial and mesenchymal cells. 
(A) (Left) Graphical representation of the differences in CDK4-p21 complex formation in epithelial and 
mesenchymal cancer cells. (Right) Co-IP of endogenous CDK4 and p21 in epithelial (393P and 
344SQ_miR-200) and mesenchymal (344SQ and 344SQ_vec) cell lines and analyzed by western blot 
with anti-CDK4 and anti-p21 antibodies. (B) In vitro cell viability assay after 48 hour miciclib treatment 
in 393P and 344P cells. 
(Padhye et al JCI insight, 2021, in press). 
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Constitutive (344SQ_pCMV6) or doxycycline-inducible (344SQ_pTripZ) expression of 
p21 in the mesenchymal 344SQ cells was used to determine the direct effect of p21 on CDK4 
activity. Upon p21 expression, there was suppression of phospho-RB and phospho-CDK4, 
which correlated with detection of higher amounts of the CDK4-p21 complex (Figure 46 A, 
C). These cells also demonstrated slower in vitro growth compared to the vector only cells 
(Figure 46 B, D) and a decreased sensitivity to palbociclib (Figure 47 A, C). When the cells 
were subcutaneously implanted in syngeneic wildtype mice, the p21 overexpressing tumors 
grew significantly slower (Figure 47 B, D), with about one-third of tumors undergoing complete 
regression.  
 
Figure 46. Overexpression of p21 in mesenchymal cells regulates CDK4 pathway.  
(A) Constitutive overexpression of Cdkn1a in 344SQ cells. Relative expression of Cdkn1a (left), 
western blot of CDK4 pathway (middle) and co-IP of CDK4 and p21 in 344SQ cells (right). (B) Growth 
rates of 344SQ cells ± p21 OE over 4 days measured by WST-1 assay. (C) Inducible overexpression 
of Cdkn1a in 344SQ cells. Relative mRNA expression of Cdkn1a (left), western blot of CDK4 pathway 
(middle) and co-IP of CDK4 and p21 in 344SQ cells (right). (D) Growth rates of 344SQ cells ± p21 OE 
(dox induced) over 4 days measured by WST-1 assay.  
(Padhye et al JCI insight, 2021, in press). 
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Figure 47. Overexpression of p21 in mesenchymal cells regulates tumor growth.  
(A) In vitro cell viability assay after 48 hours of palbociclib treatment in 344SQ cells + p21. (B) Tumor 
volume measurements at indicated time points of 344SQ tumors + p21 (n= 5 per group). (C) In vitro 
cell viability assay after 48 hour palbociclib treatment in 344SQ cells + p21 with doxycycline induction. 
(D) Tumor volume measurements of 344SQ tumors + p21 expression with dox feed (n=9-10/group). 
Dox feed was started after tumors reached a size of 100-150 mm3 (indicated by arrow). Doxycycline 
feed was started after tumors reached a size of 100-150 mm3 (indicated by arrow).  Data are presented 
as mean ± SEM. 
(Padhye et al JCI insight, 2021, in press). 
 
 
We also generated 393P cells with stable or doxycycline-inducible knockdown of p21 
(Figure 48 A-D). A modest increase in phospho-RB was detected with p21 knockdown (Figure 
48 A,C), alongwith slightly higher growth rates and enhanced sensitivity of the epithelial 393P 
cells to palbociclib (Figure 48 B, C).   
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Figure 48. Suppression of p21 in mesenchymal cells regulates CDK4 pathway.  
(A) (Left) Relative mRNA expression of Cdkn1a in 393P cells with stable knockdown using shRNA for 
Cdkn1a. (Right) Western blot for CDK4 pathway in response to Cdkn1a knockdown. (B) (Left) Growth 
rates of 393P cells ± p21 knockdown over 4 days measured by WST-1 assay. (Right) In vitro viability 
assay after 48 hours of palbociclib treatment in 393P cells with Cdkn1a knockdown. (C) (Left) Relative 
mRNA expression of Cdkn1a in 393P cells with knockdown using doxycycline inducible shRNA for 
Cdkn1a for 48 hours. (Right) Western blot for CDK4 pathway in 393P in response to Cdkn1a 
knockdown using doxycycline inducible shRNA for Cdkn1a for 2 and 7 days. (D) (Left) Growth rates of 
393P cells ± p21 knockdown with doxycycline induction of shRNA over 4 days measured by WST-1 
assay. (Right) In vitro viability assay after 48 hours of palbociclib treatment in 393P cells with Cdkn1a 
knockdown with doxycycline induced shRNA. Statistical analysis for A, H and L: One-way ANOVA, E 
and G: Unpaired t-test and J and N: Two-way ANOVA. **** p<0.0001; *** p<0.005; ** p<0.001; * p< 
0.05; ns: not significant. (Padhye et al JCI insight, 2021, in press). 
 
We next tested the long-term effect of inhibiting CDK4 on the EMT status of tumor 
cells. With doxycycline-mediated induction of CDK4 shRNA for 7 days, we observed a shift 
towards an epithelial phenotype indicated by decreased ZEB1 and vimentin levels and an 
accumulation of phospho-Erk (Figure 49 A). We also generated palbociclib-resistant cells with 
treatment of 344SQ cells for ~4 weeks (Figure 49 B). An epithelial phenotype was observed 
with an increase in E-cadherin and decrease in ZEB1 and vimentin levels (Figure 49 C, D). 
Therefore, targeting CDK4 allows the tumor population to shift to a more epithelial state, 
which would prime the tumor cells for MEK inhibitor treatment.  
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Figure 49. CDK4 inhibition induces MET in lung cancer cells.  
(A) Western blot analysis of 393P and 344SQ cells with CDK4 knockdown for 7 days. (B) Cell viability 
after 48 hours of palbociclib treatment in 344SQ control and palbociclib resistant cells. Cell viability 
curves were generated using a nonlinear regression fit model. Data are presented as mean ± SD.  n=8 
per each drug concentration. (C) Immunofluroscent staining in 344SQ control and palbociclib resistant 
cells for indicated markers. Blue: DAPI. Scale bar: 50 µm (D) Western blot analysis of indicated 
markers in 344SQ control and palbociclib resistant cells.  
(Padhye et al JCI insight, 2021, in press). 
 
When tumor cells were treated with single-agent MEK or CDK4 inhibitor, there was a 
reciprocal activation of the CDK4 or MEK signaling pathways, respectively (Figure 50 A), 
showing a dynamic switching of signaling pathway activation and survival dependencies in 
the face of pharmacological treatments. Transient knocked down of CDK4 in mesenchymal 
cells followed by treatment with AZD6244 sensitized the previously unresponsive 
mesenchymal-like 344SQ and 344P cells to MEK inhibition (Figure 50 B). We then tested the 
effect of combination palbociclib and AZD6244 treatment using a series of fixed 
concentrations at 1:1 ratio and calculated the fraction affected (Fa) values after exposure to 
the drugs. The Chou-Talalay method 108 was used to determine the combination index (CI) 
 _____ Chapter 5: Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and 
therapeutic resistance in KRAS mutant lung cancer CDK4 
122 
 
and drug reduction index (DRI). The favorable DRI, shown in yellow (Figure 50), was used to 
confirm the CI data. The drug combinations showed favorable DRI (DRI>1) and evidence of 
synergism (CI<1) at Fa>0.5 for palbociclib and AZD6244 (Figure 50 C). These data provided 
basis for further exploring the combination of CDK4 and MEK inhibitors. 
 
Figure 50. CDK4 and MEK inhibition is synergistic. 
(A) Western blot on cells treated with AZD6244 (5µM) and palbociclib (5µM) for 48 hours. (B) In vitro 
cell viability assay on 344SQ (top) and 344P (bottom) lung cancer cell lines with or without transient 
knockdown of CDK4 and treatment with AZD6244 for 48 hours. (C) Drug Reduction Index (DRI) and 
Combination Index (CI) using Chou-Talalay method on 344SQ cells. Statistical analysis for C, E, F and 
H:  Unpaired t-test and for D and G: Two-way ANOVA test. **** p<0.0001; *** p<0.005; ** p<0.001; * 
p< 0.05. (Padhye et al JCI insight, 2021, in press). 
 
 Co-targeting CDK4 and MAPK pathways targets different tumor cell subsets 
We have previously described that MEK inhibitors preferentially target epithelial K-ras 
mutant tumor cells103,194 and with the evidence presented here that CDK4 inhibitors have a 
greater impact on mesenchymal tumor cells, we set out to test the effects of combination 
treatment on the tumor cell subpopulations. We treated human (H1299 and H358) and murine 
(393P and 344SQ) tumor cells with AZD6244 and palbociclib and stained the cells with 
annexin V and propidium iodide. Both human (H1299) and murine (344SQ) mesenchymal 
tumor cells underwent greater apoptosis in response to CDK4 inhibitors and epithelial tumor 
cells (H358 and 393P) were highly sensitive to MEK inhibition (Figure 51).  
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Figure 51. CDK4 and MEK inhibitors induce differential apoptosis in tumor subpopulations.  
(A-B) Apoptosis was determined by annexin V and propidium iodide staining after treatment with 
AZD6244 (5 µM) or palbociclib (5 µM) for 48 hours. Data are presented as the mean ± SD.  
(Padhye et al JCI insight, 2021, in press).  
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Given that tumors are heterogeneous and consist of cell subsets with distinct 
phenotypes, we utilized the previously described sensor model, which can detect the 
epithelial or mesenchymal state of individual tumor cells in real time106,194. As seen in Figure 
52 A, the majority of the cells in 2D culture were mesenchymal and GFP+. With treatment of 
mocetinostat, there was an enrichment of RFP+ epithelial cells. We utilized this system to test 
if CDK4 and MEK inhibitors differentially target epithelial and mesenchymal subpopulations. 
We observed a reduction of epithelial RFP cells with MEK inhibitor (AZD6244) treatment and 
mesenchymal GFP cells with CDK4 inhibitor (palbociclib) treatment (Figure 52 A, B). With 
dose escalation of single agent treatment, reciprocal pathway activation occurred, while 
combination treatment with both drugs suppressed MAPK and CDK4 pathways (Figure 52 C) 
and enhanced tumor cell killing. 
 
Figure 52. Distinct subpopulations within Z-cad sensor cells have differential sensitivities.  
(A) 344SQ_Z-cad cells were treated with mocetinostat (1 μM), AZD6244 (5 μM), or palbociclib (5 µM) 
for 48 hours followed by fluorescent imaging. Scale bar: 50 µM. (B) Images from (A) were quantified 
for the percentage of RFP or GFP color pixels calculated per field of view (FOV). n=4-6 FOVs. (C) 
Western blot analysis of 344SQ_Z-cad cells treated with increasing concentrations of palbociclib, 
AZD6244 or both. Padhye et al JCI insight, 2021, in press).  
 _____ Chapter 5: Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and 
therapeutic resistance in KRAS mutant lung cancer CDK4 
125 
 
Since western blots are bulk assays, we wanted to assess which specific populations 
undergo apoptosis within this heterogeneous dynamic system. We utilized a DNA binding dye 
that is cleaved by caspases present in the cells undergoing apoptosis to produce blue 
fluorescence, which can be detected by microscopy and flow cytometry. Co-localization of 
blue/green fluorescence with palbociclib treatment and blue/red fluorescence with AZD6244 
treatment demonstrated the specificity of each individual drug to target specific cell types, 
whereas the combination of both drugs targeted both subpopulations (Figure 53). 
 
Figure 53. Co-targeting CDK4 and MAPK pathways targets different tumor cell subsets.  
(A) 344SQ_Z-cad cells were treated with DMSO, AZD6244 (5 μM), palbociclib (5 μM) or the 
combination. NucView® 405 Caspase 3 substrate was used as a readout for apoptosis. Representative 
fluorescent images were acquired 48 hours after addition of drugs (left). Scale bar = 25 μM. Arrows 
indicate apoptotic cells. Images were quantified for total caspase-3+ cells as a percentage of total cells 
in 4-6 FOVs (right). (B) 344SQ_Z-cad cells treated with indicated drugs were stained with NucView® 
405 Caspase 3 substrate and analyzed by flow cytometry. Representative plots are shown. (Padhye 
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In vitro three dimensional assays very closely recapitulate the tumor growth in vivo. 
An established ex vivo tumor (EVT) model to culture lung tumors that retains tumor cell 
heterogeneity205 was utilized to test the therapeutic sensitivity of distinct tumor cell 
subpopulations. Similar to the observations in 2D cultures, we found different subpopulations 
being targeted by individual drugs when EVTs were cultured in laminin-rich Matrigel (MG). 
Since MG is known to promote an epithelial phenotype93,133,205, MEK inhibition effectively 
eliminated this cell subtype and resulted in an enrichment of the GFP+ cells. CDK4 inhibitor, 
conversely, caused a depletion of mesenchymal tumor cells within the heterogeneous EVTs 
and enrichment of the RFP+ cells (Figure 54 A-C). We also noted a change in phenotype of 
EVTs treated with palbociclib, producing more structures with a central lumen as compared 
to other groups (Figure 54 d). Lumen formation and organization in a 3D matrix is 
characteristic of epithelial cells. Clearly, treatment with CDK4 inhibitor not only targets 
mesenchymal cells but also promotes an epithelial phenotype, which makes it ideal to be 
combined with MEK inhibition. In combination treatment, both populations were targeted, 
which produced a net decrease in size and viability of EVTs (Figure 54 B, D).    
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Figure 54. Co-targeting CDK4 and MAPK pathways in Z-cad EVTs in Matrigel.  
(A) EVTs were plated in a Matrigel. After 24 hours, EVTs were treated with AZD6244 (5 μM), palbociclib 
(5 μM) or the combination for 9 days with representative images from last day of the culture shown 
(scale bar: 200 μM). (B) % of RFP and GFP color pixels in 4-6 FOVs (left  panel). Cell Titer-Glo reagent 
was added and relative luciferin signal was measured (right panel). Treatment groups were compared 
to DMSO using one-way ANOVA in all the panels. **** p<0.0001; *** p<0.005; ** p<0.001; * p< 0.05; 
ns: not significant. (C) EVTs cultured in MG and treated with drugs indicated were scored for 
percentage of structures with central lumens. n=5 FOVs. Treatment groups were compared to DMSO 
using one-way ANOVA. (D) Quantification of size of EVTs from (A) at indicated times after plating in 
MG and treatment with indicated drugs. One-way ANOVA was used for statistical significance. **** 
p<0.0001; * p< 0.05. (Padhye et al JCI insight, 2021, in press). 
EVTs were also cultured in a matrix containing MG and collagen I, and as previously 
noted collagen promotes a mesenchymal phenotype in tumor cells115,205, which made it ideal 
to test the efficacy of CDK4 inhibitor on this specific subpopulation. MEK inhibitor remained 
ineffective on the GFP+ mesenchymal tumor cells, however, there was a significant reduction 
in the viability of EVTs with CDK4 treatment (Figure 55). Combination treatment proved to be 
significantly better over the individual treatments in both Matrigel and collagen matrices in 
terms of suppression of viability of tumor cells. In summary, these results demonstrate the 
efficacy of CDK4 and MEK inhibitors in combination for effective therapeutic targeting of the 
lung cancer subpopulations.   
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Figure 55. Co-targeting CDK4 and MAPK pathways in Z-cad EVTs in Matrigel/Collagen I. 
(A) EVTs were plated in a Collagen/Matrigel (Coll/MG) matrix. After 24 hours, EVTs were treated with 
AZD6244 (5 μM), palbociclib (5 μM) or the combination for 5 days. Representative images at the end 
of experiment shown (scale bar: 100 μM), (B) Quantification of percentage RFP and GFP color pixels 
in 4-6 FOVs (left panel) and relative luciferin signal using Cell Titer-Glo reagent (right panel). Treatment 
groups were compared to DMSO using one-way ANOVA in all the panels. **** p<0.0001; *** p<0.005; 
** p<0.001; * p< 0.05; ns: not significant. (Padhye et al JCI insight, 2021, in press). 
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 CDK4i and MEKi control tumor growth and prevent emergence of resistance 
We next evaluated in vivo tumor response to the combination of CDK4 and MEK 
inhibitors. Mesenchymal (344SQ) or epithelial (393P) tumor cells were subcutaneously 
implanted in syngeneic wildtype mice. Tumor growth in response to either single agent 
(palbociclib or AZD6244) or both was monitored over a period of 6-14 weeks. Mice bearing 
344SQ tumors remained unresponsive to AZD6244, but responded to palbociclib alone or in 
combination with AZD6244 (Figure 56 A). This treatment continued for ~6 weeks (short-term) 
and scored as additive using Bliss effect analysis104 (Table 11). This promising tumor 
response in the short term led us to repeat the experiment to determine if there was a durable 
and sustained response to the combination treatment. Treatment of the cohorts for up to 10 
weeks produced the emergence of resistance to palbociclib treatment alone (Figure 56 B). 
The tumors acquired resistance to single agent palbociclib over an extended period of time, 
which was prevented with combination treatment, and the group initially treated with only 
palbociclib was resensitized upon addition of AZD6244 at week 10, either as measured by 
tumor growth or fold change of tumor volume (Figure 56 B,D). We also observed an increase 
in E-cadherin and a decrease in nuclear ZEB1 with single-agent palbociclib treatment (Figure 
56 C), demonstrating the selection for an epithelial phenotype. The combination treatment for 
a period of 14 weeks scored as an additive response (Table 11). The number of lung 
metastatic nodules were also significantly lower with palbociclib or combination (Figure 56 E).  
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Figure 56. Combination of MEK and CDK4 inhibitors controls 344SQ tumor growth. 
(A) Tumor measurements at the indicated time points in syngeneic WT mice (n=5 per group) after daily 
treatment with solvent, AZD6244 (25 mg/kg), palbociclib (50 mg/kg) or combination. Arrow indicates 
start of the treatment. (B) Mice were treated with solvent (n=5), AZD6244 (25 mg/kg) (n=10), palbociclib 
(50 mg/kg) (n=10) or combination (n=5) for 7 weeks at which point resistance to palbociclib emerged. 
5 mice from palbociclib treatment alone arm were converted to combination arm and treatment was 
continued for another 3 weeks (marked by purple X). (C) Immunohistochemical analysis on tumors 
treated with solvent or palbociclib for 7 weeks. Scale bar: 50 μM. (D) Fold change in tumors in the 
palbociclib and combo arms over 13 weeks. (E) Mouse lungs were analyzed for macroscopic 
metastatic lung nodules in each treatment group. Black solid circles: short-term solvent, black open 
circles: long term solvent. Green solid circles: short term AZD6244, green open circles: long term 
palbociclib, purple crosses: palbo then combo. Blue solid circles: short-term combo, blue open circles: 
long term combo.(Padhye et al JCI insight, 2021, in press).  
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We further tested the response of this therapeutic regimen in 393P tumors. Epithelial 
tumors that initially respond to AZD644 will develop resistance to treatment by undergoing 
EMT. When treated with single agents, 393P tumors were resistant to palbociclib alone and 
responded to AZD6244 for about 7 weeks (Figure 57 A). However, the combination of both 
the drugs suppressed tumor growth with a durable response for ~10 weeks. In the 393P tumor 
model, combination of CDK4 and MEK inhibitor scored as synergistic using the Bliss effect 
analysis (Table 11). Since 393P is a non-metastatic model, there were no significant 
differences in lung metastases (Figure 57 B).  
 
Figure 57. Combination of MEK and CDK4 inhibitors delays resistance in 393P tumors.   
(A) Tumor measurements at the indicated time points in syngeneic WT mice (n=5 per group) after daily 
treatment with solvent, AZD6244 (25 mg/kg), palbociclib (50 mg/kg) or combination. Arrow indicates 
start of the treatment. (B) Metastatic lung nodules in mice with 393P tumors. 
(Padhye et al JCI insight, 2021, in press). 
 
Previously described 393P-vehicle and 393P-AZDR cells were also implanted 
subcutaneously in syngeneic wildtype mice to assess the sensitivity to CDK4 and MEK 
inhibitors. 393P-vehicle tumors retained their sensitivity to AZD6244 and resistance to 
palbociclib (Figure 58), whereas the tumors derived from 393P-AZDR cells were unresponsive 
to AZD6244, and responsive to palbociclib, with one mouse showing complete tumor 
regression (Figure 58).  
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Figure 58. Palbociclib treatment controls tumor growth in 393P_AZDR tumors. 
(A) Tumor measurements of 393P-vehicle subcutaneous tumors in syngeneic WT mice (n=5 per group) 
after daily treatment with AZD6244 (25 mg/kg) or palbociclib (50 mg/kg). Arrow indicates start of 
treatment at day 20. Individual growth curves of 393P-vehicle tumors (bottom). (B) Tumor 
measurements of 393P-AZDR subcutaneous tumors in syngeneic WT mice (n=5 per group) after daily 
treatment with AZD6244 (25 mg/kg) or palbociclib (50 mg/kg). Arrow indicates start of treatment at day 
14. Individual growth curves of 393P-AZDR tumors (bottom).  
(Padhye et al JCI insight, 2021, in press). 
 
Table 11. Summary of Bliss effect analysis of the in vivo studies 
 
Model Combo EAR Combo actual Bliss effect 
344SQ_short term 383.4 350.9 Additive 
344SQ_long term 342.8 237.4 Additive 
393P 378.0 178.4 Synergistic 
The mean of expected additive tumor volumes with combination (combo EAR) treatment were 
calculated by Bliss independent method. The actual tumor volumes with combination (combo 
actual) treatment lower than the expected additive tumor volumes are considered as 
synergistic. 
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Primary tumor tissues were collected at the end of the mouse experiments and stained 
for the CDK4 and MAPK signaling pathway markers. Untreated 344SQ tumors showed higher 
phospho-CDK4 and phospho-RB compared to untreated 393P tumors, which had higher 
phospho-Erk (Figure 59, Figure 60). In 344SQ tumors, treatment with palbociclib led to 
suppression of phospho-CDK4 and phospho-RB staining, with an increased phospho-Erk; 
AZD6244 treatment lead to an increase in phospho-CDK4, and the combination drug 
treatment suppressed both CDK4 and MAPK signaling. 393P tumors, on the other hand, 
showed suppression of phospho-Erk when treated with AZD6244, accompanied with an 
increased expression of phospho-Cdk4. Palbociclib caused an increase in phospho-Erk in 
393P tumors as well. Combination drug treatment in both models suppressed both pathways 
significantly compared to either single agent (Figure 59, Figure 60).  
 
Figure 59. IHC analysis on 344SQ tumors. 
Tumors harvested from Figure 56 were stained with indicated markers. Scale bar: 50 μM. (Padhye et 
al JCI insight, 2021, in press). 
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Figure 60. IHC analysis on 393P tumors. 
Tumors harvested from Figure 57 were stained with indicated markers. Scale bar: 50 μM. (Padhye et 




To determine the effect of single and combination agent treatments on cell 
proliferation and cell death, we performed Ki67 staining and TUNEL assay on the tumor 
tissues. 344SQ tumors treated with palbociclib for 6 weeks had fewer proliferating and more 
apoptotic cells (Figure 61).  
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Figure 61. Ki67 and TUNEL staining in 344SQ tumors-short term treatment.  
344SQ tumors were stained with Ki67 and TUNEL assay to measure cell proliferation and cell death 
respectively. Representative IHC images are shown. Scale bar: 50 μM. Images were quantified for 
Ki67 and TUNEL staining in each treatment group. n=2-3 per group with 3-6 FOV per mouse. Statistical 
significance was determined by one-way ANOVA. **** p<0.0001; *** p<0.005; ** p<0.001; * p< 0.05; 
ns: not significant. (Padhye et al JCI insight, 2021, in press). 
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393P tumors treated with AZD6244 had fewer proliferating cells and higher apoptotic 
cells (Figure 62). However, combination inhibitor treatment in both models significantly 
suppressed cell proliferation and produced apoptosis in >60% of the tumor cells.  
 
Figure 62. Ki67 and TUNEL staining in 393P tumors.  
393P tumors were stained with Ki67 and TUNEL assay to measure cell proliferation and cell death 
respectively. Representative IHC images are shown. Scale bar: 50 μM. Images were quantified for 
Ki67 and TUNEL staining in each treatment group. n=2-3 per group with 3-6 FOV per mouse. Statistical 
significance was determined by one-way ANOVA. **** p<0.0001; *** p<0.005; ** p<0.001; * p< 0.05; 
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We also compared the cell proliferation and death in the 344SQ tumors treated long 
term (10 weeks) with the single agents and combination. 344SQ tumors acquired resistance 
to palbociclib alone after 10 weeks. This was reflected in the Ki67 and TUNEL staining, which 
were similar to 344SQ tumors treated with AZD6244, which were unresponsive (Figure 63). 
With co-administration of AZD6244 after 10 weeks of single agent palbociclib, tumors 
underwent apoptosis with limited cell proliferation, similar to the tumors treated with 
combination from the start of the experiment (Figure 63). Tumor growth and histological 
staining collectively demonstrate the efficacy of utilizing a combinatorial approach for 
treatment of heterogeneous tumors with different tumor subpopulations. 
 
Figure 63. Ki67 and TUNEL staining in 344SQ tumors-long term.  
344SQ tumors were stained with Ki67 and TUNEL assay to measure cell proliferation and cell death 
respectively. Representative IHC images are shown. Scale bar: 50 μM. Images were quantified for 
Ki67 and TUNEL staining in each treatment group. n=2-3 per group with 3-6 FOV per mouse. Statistical 
significance was determined by one-way ANOVA. **** p<0.0001; *** p<0.005; ** p<0.001; * p< 0.05; 
ns: not significant. (Padhye et al JCI insight, 2021, in press). 
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 Concomitant CDK4 and MAPK targeting augments response in lung tumors 
Autochthonous lung tumor models represent powerful and accurate preclinical models 
for recapitulating human cancer and exploration of treatment efficacy. Alterations in the tumor 
suppressor p53 is one of the most commonly occurring comutation in Kras driven lung cancer 
and cell cycle progression is controlled by p53 through direct transcriptional regulation of p21. 
Given that tumor cells with identical mutational profile can differ in phenotype and response 
to therapeutic agents, we investigated the effect on CDK4 and MEK inhibitors in different 
GEM models harboring either Kras point mutation G12D (KrasLSL/+ (Kras)) alone or coupled 
with various p53 alterations such as: homozygous deletion (KrasLSL/+;p53flox/flox 
(KPflox/flox))102,103, homozygous point mutant  (KrasLSL/+;p53m/m(KPm/m))206,207 or both 
(KrasLSL/+;p53 m/flox(KPm/flox)) which mimics loss of heterozygosity frequently observed in 
patient tumors208. We also utilized a mouse models where Kras point mutation G12D 
(KrasLSL/+ (Kras)) was coupled with homozygous deletion of miR-141/200c (KrasLSL/+; M-/- 
(KM))102,103. Schematic representations of the different alterations are presented in Figure 64. 
These conditional autochthonous lung tumors were generated through intratracheal 
administration of adenovirus expressing Cre recombinase102. 
 
Figure 64. GEMM constructs before and after cre recombination.  
(Padhye et al JCI insight, 2021, in press). 
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Previously published Kras, KPflox/flox and KM mouse models were initially utilized to 
investigate CDK4 and MAPK signaling pathways. Histological analyses on lung tumors 
displayed differences in signaling pathways across the different genetic backgrounds. 
Tumors with mutant Kras alone showed greater MAPK pathway activation compared to KP 
and KM tumors, which instead showed an activation of CDK4 pathway as demonstrated by 
phospho-CDK4 and phospho-RB staining (Figure 65).  
 
Figure 65. IHC analysis on autochthonous lung tumors for CDK4 and MAPK pathway.  
Immunohistochemistry for indicated markers on KrasLSL/+, Kras LSL/+Pflox/flox and KrasLSL/+M-/- lung 
sections 18-20 weeks post Ad-Cre infection. Scale bar: 50 μM. 
(Padhye et al JCI insight, 2021, in press). 
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We also utilized these models to interrogate if the ZEB1-p21 axis was altered within 
these tumors and could determine their sensitivity to palbociclib. Tumor regions with high 
nuclear ZEB1 corresponded to lower levels of nuclear p21 in KP and KM tumors as compared 
to Kras tumors alone (Figure 66).  
 
Figure 66. IHC analysis on autochthonous lung tumors for ZEB1 and p21. 
Immunohistochemistry for indicated markers on KrasLSL/+, Kras LSL/+Pflox/flox and KrasLSL/+M-/- lung 
sections 18-20 weeks post Ad-Cre infection. Scale bar: 50 μM. 
(Padhye et al JCI insight, 2021, in press). 
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Three months after induction, lung tumor formation was confirmed and monitored over 
6-8 weeks by micro-CT scans for changes in overall lung tumor burden in response to 
pharmacological agents. Response to AZD6244 alone across all three genotypes was similar 
to our previous103 results where K-ras tumors showed complete regression upon treatment 
and only partial response was achieved in KP and KM tumors. Palbociclib alone had more 
significant tumor growth control in KP and KM mice than AZD6244 alone with ~30% of tumors 
undergoing complete regression (Figure 67).  
 
Figure 67. Concomitant CDK4 and MAPK targeting augments response in lung tumors. 
Percentage change in overall lung tumor area of KrasLSL/+, KrasLSL/+Pflox/flox and KrasLSL/+M-/- mice after 
6-8 weeks of daily treatment with AZD6244 (25 mg/kg), palbociclib (50 mg/kg) or both as assessed by 
micro-CT imaging of mouse lungs. Significance was determined using Brown-Forsythe and Welch 
ANOVA tests. (Padhye et al JCI insight, 2021, in press). 
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Histological staining showed that treatment with each single agent led to an activation 
of reciprocal signaling pathway in KP and KM tumors (Figure 68). Palbociclib led to 
suppression of ZEB1 indicating a shift to an epithelial phenotype and AZD6244 led to an 
accumulation of ZEB1 indicating the presence of mesenchymal tumor cells (Figure 68). 
Combination of palbociclib and AZD6244 produced a more significant reduction of tumors 
over a period of 8 weeks with complete regression in ~80% mice across the three genotypes 
(Figure 67). Lack of sufficient tumor burden precluded us from staining the lung sections 
obtained from combination treatments.   
 
Figure 68. IHC analysis for indicated markers on lung sections after treatment. 
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Since p53 is more frequently mutated in human tumors than being null, we utilized a 
conditional point-mutant p53 (R172H) that allows for endogenous expression of mutant p53 
upon Cre-mediated recombination (Figure 64). This allele was coupled with KrasLSL/+ which 
generated lung tumors with KrasLSL/+; p53m/m genotype. These tumors were expected to 
behave more similar to KrasG12D/+ and p53R172HΔg from which our panel of murine NSCLC cell 
lines were derived. IHC on lung tissue revealed a higher activation of CDK4 pathway (Figure 
69). H&E stained whole sections of lung showed larger lung tumors than KrasLSL/+ or KrasLSL/+; 
p53flox/flox and average percent fold change of tumor area as measured by mirco-CT scan:  
KrasLSL/+; p53m/m (~500%) KrasLSL/+; p53flox/flox (~300%); KrasLSL/+ (~150%) (Figure 69). Three 
months after induction of lung tumors daily doses of the drugs were administered and micro-
CT image analysis of changes in overall lung tumor area was monitored. Single drug 
treatment arms either slowed tumor growth (AZD6244) or caused partial regression in some 
mice (palbociclib), however, mice treated with the combination showed complete regression 
across the cohort (Figure 69).  Patient tumors often demonstrate loss of heterozygosity (LOH) 
at one p53 allele with a missense mutation in the second allele which poses an important 
therapeutic issue. To mimic LOH, mice expressing KrasLSL/+; p53m/+ were crossed with 
KrasLSL/+; p53flox/+ to generate KrasLSL/+; p53flox/m mice. The tumors appeared to be more 
heterogeneous than the other two KP tumors with both CDK4 and MAPK pathway activated 
within a region (Figure 69). H&E stains and micro-CT scans showed that lung tumor sizes 
were comparable to KrasLSL/+; p53m/m with similar average fold change of tumor area in this 
genotype (Figure 69). Upon confirmation of lung tumors by micro-CT, we treated the mice 
daily with palbociclib, AZD6244 or both. Due to the heterogeneous nature of the tumors, either 
of the single agents could not effectively control tumor growth; however, combination yielded 
a net tumor regression across the cohort (Figure 69). We also utilized these models to 
interrogate if the Zeb1-p21 axis was altered within these tumors which could determine the 
sensitivity to palbociclib. Tumor regions with high nuclear Zeb1 corresponded to low levels or 
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lack of nuclear p21 in KrasLSL/+; p53flox/flox and KrasLSL/+; p53m/m mice (Figure 69). KrasLSL/+; 
p53flox/m demonstrated more heterogeneity and complexity in terms of Zeb1 and p21 staining.  
 
Figure 69. Response of Kras/p53 mutant and LOH tumors to CDK4 and MEK inhibitors. 
(A) Immunohistochemistry for indicated markers on Kras LSL/+m/m and Kras LSL/+m/flox lung sections 18-
20 weeks post Ad-Cre infection. Scale bar: 50 μM. (B) Percentage change in overall lung tumor area 
KrasLSL/+Pm/m and KrasLSL/+Pm/flox mice after 6-8 weeks of daily treatment with AZD6244 (25 mg/kg), 
palbociclib (50 mg/kg) or both as assessed by micro-CT imaging of mouse lungs. Significance was 
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Figure 70 shows the normal cells or epithelial cancer cells have an intact cell cycle 
regulation mediated by the intrinsic regulator p21. Increased binding of p21 to CDK4 prevents 
the kinase activity, limits RB phosphorylation and arrests cells in the G1 phase. However, this 
pathway is dysregulated in cancer cells undergoing EMT. ZEB1 is highly upregulated in 
mesenchymal cancer cells, which exerts transcriptional repression on p21. Lack of p21 leads 
to low or no binding of p21 to CDK4, allowing the kinase activity of CDK4 to occur unchecked. 
Such high dependency on CDK4 makes mesenchymal cells especially vulnerable to CDK4 
inhibitors such as palbociclib. In heterogeneous tumors, with epithelial and mesenchymal 
cancer cells, net tumor killing requires drug combinations that preferentially target the 
vulnerabilities of each subpopulation (e.g., MEKi and CDK4i). 
 
Figure 70. Proposed working model for differential therapeutic sensitivities in lung cancer. 
(Padhye et al JCI insight, 2021, in press). 
  
 _____ Chapter 5: Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and 
therapeutic resistance in KRAS mutant lung cancer CDK4 
146 
 
5.3 Discussion  
 Phenotypic switching and subsequent transcriptional rewiring in cancer cells in 
response to the tumor microenvironment or selective pressures of drug treatments allows the 
escape of cancer cells from cell death. An understanding of the mechanisms by which tumor 
cells alter their cellular state and molecular pathways can provide the basis for designing 
effective therapeutic strategies. Epithelial to mesenchymal transition is a dynamic 
phenomenon that contributes to tumor heterogeneity in cancer. We demonstrate that lung 
tumors with high ZEB1 that display mesenchymal phenotype have increased dependence on 
the CDK4 pathway for survival, which renders them especially vulnerable to CDK4-specific 
pharmacological inhibitors. Combined with the results previously published from our lab that 
showed higher sensitivity of epithelial cancer cells to MEK inhibitors103, we investigated the 
combination of CDK4 and MEK inhibitors in multiple in vitro and in vivo models that 
recapitulate EMT-mediated tumor heterogeneity and demonstrated that the combination of 
CDK4 and MEK inhibition in Kras mutant lung adenocarcinoma is an effective strategy to 
combat EMT-mediated heterogeneity and therapeutic resistance.  
CDK4 plays a key role in determining the progression of cells from G1 to S phase of 
the cell cycle. Disruption of the checkpoint leads to unregulated growth in cancer cells. 
Ordinarily, the cell cycle is regulated by extracellular mitogenic signals that are integrated by 
the MAPK pathway196,209. However, aberrant CDK4 activation in Kras mutant mesenchymal 
cancer cells can occur in a cell autonomous manner, without being coupled with extrinsic 
signals or the MAPK pathway. Thus, the independent activation of CDK4 serves as a survival 
mechanism activated in mesenchymal cancer cells allowing escape from MEK inhibitors. 
Interestingly, epithelial tumor cells are less dependent on CDK4 for survival, as shown by the 
stable knockdown of CDK4 and insensitivity to pharmacological inhibitors. Instead, CDK2-
dependent RB phosphorylation seems to be the major cell cycle pathway in epithelial cancer 
cells. A previous study identified that MAPK mediated activation of CDK2 keeps a check on 
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RB activity and prevents progression of Kras mutant lung cancers210. This is in line with our 
observations in the epithelial cancer cells that have activated MAPK pathway and a proper 
cell cycle regulation. Although the results from Walter et al210 were not studied in the context 
of EMT, our results show that the epithelial tumor cells are equally receptive to CDK2 and 
MEK inhibitors, whereas mesenchymal cancer cells are resistant. These findings reiterate the 
fact that CDK4 and MAPK pathways are closely linked in lung cancer and present an 
opportunity for therapeutic co-targeting.  
Separate studies have presented contradictory findings for the correlation of EMT with 
CDK4 pathway signaling. CDK4 inhibition in triple negative breast cancer reversed the EMT 
status of cancer cells211,212 as seen in the 344SQ mesenchymal tumors treated with 
palbociclib in the present study. Within Kras-mutant pancreatic cancer, one study showed 
that tumor cells underwent EMT with palbociclib monotherapy213 and MET in another214. 
Another study in colorectal cancer noted no difference in EMT status of tumor cells in 
response to palbociclib215. These findings highlight the fact that there are cell-type or context-
specific phenomena that warrant further investigation in different cancer types. In our studies, 
we found that modulation of the EMT status of cancer cells by perturbing the ZEB1/miR-200 
axis lead to CDK4 pathway modulation and determined the sensitivity to CDK4 inhibitors both 
in vitro and in vivo.  
Mechanistically, we identified that high ZEB1 in mesenchymal cancer cells was 
responsible for transcriptional repression of CDKN1A (gene encoding for p21) by direct 
binding to the promoter region. Conventionally, p21 is described as a suppressor of CDK4 
kinase activity and a downregulation/loss in patients predicts poor survival216,217. Studies in 
the recent years have further explored the role of p21 and revealed a dual function of p21, 
acting in some cases as an activator for CDK4 activity218. Lower levels of p21 binding are 
generally required for the assembly and stability of the CDK4-cyclin D complex. p21 binding 
to CDK4 partially accounts for maintaining phosphorylation of CDK4, primes CDK4 for 
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catalysis by releasing the activation segment without affecting kinase function (e.g. 
phosphorylation of RB)204. On the other hand, a sustained presence of p21 at higher 
stoichiometric concentrations can render CDK4 ineffective204. We found that mesenchymal 
cancer cells had lower levels of p21 in the CDK4-p21 complex, which explains increased 
CDK4 activity. Continued presence of an activated CDK4 rendered the mesenchymal cells 
highly dependent on CDK4 for survival. Increased addiction to CDK4 translated to de novo 
vulnerability to CDK4 inhibitors. With p21 overexpression in mesenchymal cancer cells, we 
detected increased CDK4-p21 complex, reduced in vitro and in vivo growth of tumors. 
Interestingly, 344SQ cells demonstrated reduced sensitivity to palbociclib with p21 
overexpression. A previous study had shown that p21 can interfere with the binding of small 
inhibitors to CDK4 complex, as we observe in wild type epithelial tumor cells and in p21 
overexpressing mesenchymal cells219. Thus, p21 serves as a regulator of CDK4 activity and 
sensitivity to inhibitors in mesenchymal lung cancer cells.  
CDK4 pathway activity can determined by other factors such cyclin activating kinase 
(CAK). This complex is responsible for the activating phosphorylation of CDK4 at T172220. 
Phosphorylation is the least studied level of CDK4 regulation. An inhibitory phosphorylation 
of CDK4 on Tyr17 has also been observed in UV irradiation-induced G1 arrest or during cell 
arrest in quiescence or in response to transforming growth factor β (TGF-β)221. The role of 
different phosphorylation sites on the activity of CDK4 and downstream signaling pathways 
has been debated over the years. A general consensus is that T172-phosphorylation of CDK4 
bound to cyclin D is the central rate-limiting event in CDK4 activation and that CDK4 activation 
is not restricted by stoichiometric inhibitory phosphorylations222. Based on the T172-
phosphorylation of CDK4 as critical to the kinase activation, an 11-gene classifier helps to 
segregate cancer subtypes and predict palbociclib sensitivity in breast cancer patients222. In 
addition to CDK4 phosphorylation, multisite RB phosphorylation also critically determines the 
effect on cell cycle progression and other biological processes. Depending on the 
phosphorylation events, RB protein can acquire unique conformations, each capable of 
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making different protein interactions and therefore exerting distinct tumor suppressor 
activities, opening avenues for independent targeting of upstream regulators223. CDK4-cyclin 
D complex is primarily responsible for S807/S811 phosphorylation, which act as priming site 
for further hyper-phosphorylation of RB by CDK2-cyclin E complex and progression through 
G1 to S phase. S807/S811 mutation results in loss of Rb phosphorylation levels beyond 
expected for mutation of only two sites, indicating an S807/S811 dependence for other 
phosphorylation events. It is still imperative to explore the role of other RB phosphorylation 
sites that are induced by different kinases. This will allow us to understand why certain cell 
types are more dependent on specific CDKs for survival which ultimately sensitized them to 
pharmacological inhibition.  
ZEB1 mediated p21 regulation was demonstrated by utilizing isogenic pairs of cell 
lines expressing ZEB1 or miR-200 as well as by treatment by mocetinostat, an HDAC 
inhibitor. Mocetinostat induces miR-200 expression, which can relieve ZEB1 repression on 
the p21 promoter. Mocetinostat can also regulate the HDACs that are present in co-repressor 
complexes with ZEB1182. Evidence from past studies suggested that class I HDACs (HDAC1, 
2 and 3) repress the p21 promoter as part of NuRD, Sin3A, NCoR-SMRT co-repressor 
complexes224. Recent work from our lab demonstrated that ZEB1 is present in such co-
repressor complexes to regulate promoter activity of important genes altered in cancer 
progression178. There is also evidence that a trimeric complex of ZEB1, HDAC1/2 and p53 in 
stromal fibroblasts promotes breast cancer progression225. Independently, p53 is a well-
established regulator of p21 expression which occurs in response to oncogenic stress to 
induce cell cycle arrest and/or apoptosis226,227. Loss of p53 in cancer can lead to the 
downregulation of p21 and unchecked cell growth227, however we did not observe a direct 
effect of p53 on p21 expression to regulate the CDK4 pathway. Evidently, a complex network 
of transcriptional regulators determine p21 levels in the cells and further investigations are 
warranted to understand these intricacies. Our findings do highlight that correlation of EMT 
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status and p21 levels can serve a biomarker for response to CDK4 inhibitors in lung cancer 
patients.  
With an understanding of how lung cancer cells adapt to therapeutic intervention, we 
interrogated the combination of CDK4 and MEK inhibitors. Normal cells possess intact cell 
cycle checkpoints and are spared by selective CDK4 inhibitors. CDK4 inhibition causes tumor 
cell senescence or apoptosis in addition to cell cycle arrest making these cancer cells 
particularly vulnerable to the inhibitors228. The remarkable success of CDK4 inhibitors in 
combination with endocrine therapy in breast cancer patients have encouraged investigations 
into the role of CDK4 inhibitors in other cancer types, including lung cancer229-232. K-RasG12V 
driven lung cancers were particularly susceptible to ablation of CDK4 with an induction of 
senescence and prevention of tumor progression199. A sustained tumor response was also 
achieved with concomitant CDK4 inactivation and RAF1 ablation in Kras/p53 driven lung 
cancers198. A phase II trial in NSCLC patients with inactivated CDKN2A treated with 
palbociclib monotherapy showed modest response with stable disease in 50% of the 
patients233. Partial response to CDK4 inhibitor in a subset of lung cancer patients warranted 
an exploration of combination with other targeted therapies to achieve durable response. 
Zhou et al234 demonstrated a synergistic growth inhibition in KRAS and CDKN2A mutant 
NSCLC xenografts with AZD6244 and palbociclib. Ongoing phase I/II clinical trials 
(NCT03170206 and NCT02022982) in advanced K-Ras driven NSCLC patients are 
investigating the combinatorial effect of MEK and CDK4 inhibitors. Additionally, the 
combination of CDK4 and MAPK pathway inhibitors have shown tumor regression in multiple 
other cancer types utilizing xenografts models, especially with KRAS, NRAS or BRAF 
mutations104. BRAF- and NRAS-mutant melanoma are particularly receptive to combinatorial 
therapy235-238 and phase I clinical studies have shown promising activity in these tumor types 
as well239. Clinical trials are currently investigating BRAF and MEK inhibitors in combination 
with ribociclib in BRAF-mutant melanoma and other solid tumors with BRAFV600 
mutations240. In K-Ras mutant colon cancer, monotherapy with either MEK or CDK4 inhibitors 
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has been disappointing241,242; however synergistic effects were observed in xenograft models 
of K-Ras mutant colorectal cancer upon treatment with a combination215,243, which led to a 
phase II clinical trial in KRAS- or NRAS-mutant colorectal cancer patients testing binimetinib 
and palbociclib in combination240. Not only are the two therapies synergistic, but studies have 
also shown that CDK4 inhibitors are able to overcome MEK inhibitor resistance244 and vice 
versa245. These findings are corroborated by our results in the present study demonstrating 
the efficacy of CDK4 and MEK inhibitors.  
Results in our immunocompetent syngeneic models will allow us to further extend our 
investigation into effects on the immune microenvironment. Evidence from past studies 
indicated that CDK4 depletion reduced infiltration of CD4+ FoxP3+ Tregs246 and CDK4 
inhibitors increased tumour immunogenicity and cytotoxic T-cell mediated clearance of tumor 
cells247. CDK4 inhibitors also enhanced effector T-cell infiltration and activation248. 
Additionally, PD-L1 degradation stability was shown to be regulated by CDK4 through cullin 
3–SPOP E3 ligase via proteasome-mediated degradation which primed the tumors for 
effective response to combination treatment with CDK4 inhibitor and PD-1-PD-L1 immune 
checkpoint blockade249. Other investigations revealed that PD-L1 expression was modulated 
RB-NF-κB axis which could be exploited to overcome cancer immune evasion triggered by 
conventional or targeted therapies250. Combination of CDK4 and MEK inhibitor induced a 
senescence-associated secretory phenotype (SASP) that provoked a natural killer cell 
surveillance program and resulted in tumor cell death251.  
The application of combinatorial treatments with MEK and CDK4 inhibitors in multiple 
pre-clinical in vitro (dual fluorescent sensor system, 3D assays) and in vivo models 
(syngeneic and autochthonous mouse models) effectively prevented outgrowth of resistant 
tumor subpopulations and was significantly better than either monotherapy. Such findings 
demonstrate that CDK4 and MAPK pathway are intertwined in lung cancer progression and 
durable response can be attained if these pathways are targeted judiciously. Fighting cancer 
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at two fronts: by interfering with two distinct regulatory networks and targeting tumor 
subpopulations should benefit patients and help to prevent resistance development. 
Additionally, timing of administration of drugs may be an important criteria to consider where 
a sequential regimen could provide improved targeting of tumor subpopulations that arise due 
to tumor plasticity.  
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Chapter 6: Conclusions and future directions 
The overarching goal of the dissertation was to contribute to the understanding of 
tumor heterogeneity in lung cancer. We established a platform to model tumor 
microenvironment and tumor cell heterogeneity, and utilized different experimental 
approaches to identify a therapeutic strategy that allowed for a durable tumor growth control 
in lung cancer. 
6.1 Tumor heterogeneity modeling 
 Major findings and significance 
There are very limited organotypic models for studying lung cancer that effectively 
capture tumor heterogeneity when compared to other cancer types like colon, breast, and 
pancreatic89,252. Our primary aim was to establish such a platform for murine lung tumors that 
would be useful for interrogating cancer cell behavior in context of tumor microenvironment 
components. First, we demonstrated that the EVTs isolated from primary syngeneic tumors 
were indeed representative of the heterogeneity within lung cancer. With flow cytometry and 
immunofluorescence staining, we were able detected immune cells, CAFs, endothelial cells, 
ECM proteins like laminin and collagen I, and phenotypically distinct cancer cells. As a proof-
of-principle, we investigated if EVTs retained biological responses to known stimuli, such as 
TGFβ treatment and alterations in the ECM composition. Characterization of EVT behavior 
was imperative before we used the platform investigated signaling pathways that can be 
targeted for therapeutic purposes. One such pathway was Src, which is known to mediate 
invasion and metastasis cancer. We found that Src pathway was activated downstream of 
collagen I-integrin β1 interaction and was necessary for initiation and maintenance of invasion 
in EVTs. Disrupting this signaling pathway, for e.g. in the absence of collagen I in the matrix, 
use of integrin β1 blocking antibody or pharmacological inhibitors of Src, led to loss of invasive 
potential in EVTs. These findings were then validated in vivo where dasatinib treatment 
prevented metastatic disease. Another significant finding was that EVTs were able to predict 
that FAK inhibitor was ineffective in lung cancer. Observations from 2D and 3D monocultures 
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would have indicated that FAK inhibitor was a potential therapeutic avenue for lung cancer, 
however, response of EVTs to FAK inhibitors was mirrored in tumor bearing mice. Therefore, 
our data suggests that EVTs can serve as a high throughput screening platform for 
pharmacological agents as well as identifying biomarker for drug sensitivity subverting the 
need to depend on time consuming animal models.   
We also focused on EMT mediated tumor cell heterogeneity because there is a large 
body of evidence in lung cancer shows that EMT is associated with most aggressive form of 
the lung cancer including chemoresistance and metastasis94,253-257. The Z-cad EVT setup 
incorporates both a real-time readout for EMT mediated tumor cell heterogeneity, as well as 
tumor microenvironment components. As a proof-of-principal, we used Z-cad EVTs to 
demonstrate that external manipulation like TGFβ treatment and ECM manipulation can 
modify cellular phenotype. One of our big questions was to understand how the genetically 
identical and phenotypically distinct tumor subpopulations respond to drug treatments in order 
to identify specific therapeutic vulnerabilities that could allow us to find synergistic 
combinations. We identified two combinatorial approaches, MEK and AXL inhibitors as well 
as MEK and CDK4 inhibitors, which targeted of epithelial and mesenchymal tumor cell 
subpopulations within heterogeneous tumors thus yielding significant tumor growth control. 
 Future Directions 
We fully characterized the EVTs derived from syngeneic primary tumors, but only 
began to scratch the surface with EVTs from autochthonous lung tumors. We have multiple 
GEMMs that are driven by Kras and p53 co-mutations and recapitulate human lung cancer 
very accurately. Upon further characterization of autochthonous EVTs, we will be able to 
utilize the platform to answer biological questions and circumvent the time constraints that 
usually accompany long term mouse experiments. In parallel to murine EVTs, the 
development of patient derived EVTs for lung cancer will be of enormous value. Patient 
derived xenografts are normally studied in either immunodeficient mouse models which lack 
accurate representation of the tumor microenvironment, or humanized mouse models which 
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can be expensive, time consuming and pose the problem of potential mouse- specific 
evolution of the human tumour118,258,259. Therefore, early attempts in different cancer types, 
including melanoma, colorectal cancer, renal carcinoma and even some instances of lung 
adenocarcinoma have been made for predicting therapeutic outcome by using a patient 
derived organoid platforms and have been successful to varying degrees142,260-263. With the 
advantages of preserving original tumor architecture, ability to cryopreserve for future use, 
expansion over long term and provide a high throughput screening of therapeutic agents, the 
murine and human EVTs will provide a powerful platform for pushing the frontiers of 
personalized medicine as well as developing a thorough understanding of the outstanding 
biological questions in lung cancer. 
Using the models, we demonstrated the significance of collagen I-integrin β1 
interaction in driving metastatic disease. The TME consists of a wide variety of ECM 
molecules in addition to collagen I that contribute to lung cancer progression. The 
unanswered questions include how ECM composition changes overtime from an early stage 
of preneoplastic disease to a more aggressive metastatic disease and what are the signaling 
cascades associated with such changes within tumor cells. The alteration is not only dynamic 
but also bi-directional with a co-operation between the aberrant tumor cells and the ECM 
proteins which allows for the emergence of the most aggressive cancer phenotype. We can 
start investigating these questions by using the autochthonous EVT model derived from lung 
tumors driven by Kras and Kras/p53 mutations and combining with synthetic-based matrices 
such as poly(ethylene glycol) (PEG) gels that are readily modifiable and tunable to the 
incorporation of desired ECM proteins and therefore can be fabricated for specific 
mechanistic interrogations 264. The extracellular matrix composition is highly conserved 
across murine and human tissues and therefore our findings from the ex vivo model would 
be readily translatable. Prior mass spectrometry data from our non-metastatic and metastatic 
tumors have identified alterations in the ECM that could be associated with aggressive 
phenotype in lung cancer265. One such hit was fibronectin that is differentially expressed in 
 __________________________________ Chapter 6: Conclusions and future directions 
156 
 
metastatic tumors. Fibronectin is also a part of the basement membrane alongwith laminin in 
lung tissue266,267, which raises the question what changes are occurring in fibronectin 
expression, deposition, cross-linking and stiffness that are associated with highly metastatic 
disease. Interestingly, fibronectin has been associated with expression of mutant p53 as well 
as increased collagen I deposition268. With EVTs driven by different genetic alterations and 
cultured in highly controllable matrices, we can begin to dissect out the specific roles of 
different ECM components and interactions with genetically and phenotypically different 
cancer cells. An understanding of such changes will allow us to block these interactions and 
prevent disease progression. 
In addition to ECM modeling, EVTs can be used to mimic other TME components 
such as immune cells and CAFs. We were already able to detect these heterotypic cells within 
the murine EVTs. Building upon what is known in the literature, we can start to layer in more 
complexities to investigate the heterotypic interactions with cancer cells. This is especially 
significant in context of phenotypically distinct tumor cells. We used the Z-cad sensor cells to 
detect changes in EMT state of cancer cells in response to therapeutic agents. There are 
many avenues that can be explored with the aid of Z-cad EVT tool. Interaction of distinct 
tumor cell subpopulations with the surrounding microenvironment (ECM, CAFs, immune cells 
etc) will aid in the understanding of how aggressive phenotypes emerge, what are the factors 
responsible for maintaining such cell types and if they contribute to therapeutic resistance. 
This will allow us to identify novel therapeutic approaches for better targeting of lung cancer 
cells.  
Another potential area of investigation is tumor cell heterogeneity itself. Epithelial-to-
mesenchymal transition is a dynamic phenomenon with cells acquiring intermediate cellular 
characteristics that lie between the two polar states, epithelial and mesenchymal. The 
markers associated with the polar states are very well-defined and for the longest time only 
these cellular states were investigated. Recent years have recognized the importance of the 
partial/hybrid EMT states where cancer cells express both epithelial and mesenchymal 
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features. Lack of defined markers associated with these subpopulations is a very open ended 
question. Z-cad sensor cells can serve as a starting point to assign a profile of markers that 
can define a particular cellular state which can then be applied to phenotypically different 
human lung cancer cells. Such an experimental approach can begin to dissect the 
partial/hybrid states of EMT.  
Phenotypic heterogeneity should also be considered in the context of the genetic 
alterations driving tumorigenesis. Lung cancer mouse models driven by different genetic 
alterations such as KrasG12D, KrasG12D/p53R172H and KrasG12D/p53-/- develop tumors that 
display distinct patterns of heterogeneity. Cancer cells derived from tumors with identical 
mutations, for e.g. 393P and 344P from primary lung tumors have KrasG12D/p53R172H mutation, 
but exhibit very different EMT characteristics. There is evidence that mutant p53 can promote 
EMT by modulating micro-RNAs such as miR-200 and miR-130b that inhibit ZEB1 post-
transcriptionally269,270. Exploring the role of selective pressures exerted by altered p53 
(deleted vs mutated) to drive a specific lineage of cancer cells alongwith imparting phenotypic 
plasticity and the extent to which there is cooperation with other transcriptional programs to 
modulate cellular phenotype is important in determining tumor evolution as it has implications 
for therapeutic sensitivities and resistance.   
 
6.2 Therapeutically targeting EMT mediated heterogeneity 
 Major findings and significance 
Kras mutant lung adenocarcinoma continues to pose a therapeutic challenge in the 
clinic. MEK inhibitors which target activated MAPK pathway have failed to provide any 
sustained benefit due to intrinsic or acquired resistance in cancer cells. In this study, we 
utilized in vivo and in vitro short hairpin RNA dropout screens in Kras/p53 (KP) mutant murine 
models of epithelial and mesenchymal lung cancer to identify survival dependencies specific 
to each epithelial and mesenchymal subpopulations and highlighted their counter-
dependencies on CDK4 and MAPK signaling. We identified CDK4 as an escape mechanism 
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for mesenchymal tumor cell subpopulations that are resistant to MEK inhibitors. Concomitant 
targeting of CDK4 and MAPK pathways with clinically approved pharmacological inhibitors 
yielded a durable tumor suppression by preventing emergence of resistance to either single 
agent. We demonstrated these findings in multiple syngeneic tumor models and 
autochthonous genetically-engineered mouse models of lung cancer. Analyses of multiple 
human cancer cell line and tumor tissue datasets confirm the signaling pathways critical to 
the findings. 
We also demonstrated that the mechanism for enhanced dependency of 
mesenchymal cells on CDK4 signaling was due to the direct ZEB1-mediated regulation of 
p21. ZEB1 upregulation is critically linked to the mesenchymal phenotype in lung cancer cells. 
We found that there was a direct transcriptional suppression by ZEB1 of p21 which is an 
intrinsic regulator of CDK4 activity. At low levels p21 does not to exert an inhibitory effect on 
CDK4 activity, causing deregulation of cell cycle and unchecked proliferation of cancer cells. 
With an increased dependency on CDK4, these cancer cells become particularly vulnerable 
to CDK4 inhibitors. Thus, these data provide evidence for the incorporation of CDK4 inhibition 
into combination strategies to target phenotypic heterogeneity and EMT plasticity within lung 
cancer, with the ultimate goal of improving the anti-tumor efficacy of targeted agents. 
 
 Future Directions 
As noted in many studies, resistance to targeted therapies eventually emerges which 
leads to recurrences and poor patient outcomes271. It is imperative stratify patients based on 
tumor characteristics to determine what subset of patients will respond to selected therapeutic 
regimen. Ongoing clinical trials assessing CDK4 and MEK inhibitor combination in lung 
cancer will provide critical information that will inform clinical decision making process based 
on the molecular profiling and histopathological analyses of tumors. ZEB1 and p21 can serve 
as biomarkers to determine sensitivity to CDK4 inhibitors. This needs to be further explored 
in lung cancer patient samples that were treated with prior chemotherapy or MEK inhibitors 
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or both. Establishing a more comprehensive biomarker profile will also be useful which can 
be done in both murine and patient tumors pre- and post-treatment.  Our study also 
establishes a direct mechanistic regulation of ZEB1-p21-CDK4 axis. There are many other 
cyclin dependent kinases that regulate cell cycle and are altered during cancer progression. 
For e.g. CDK2 which is also regulated by p21. Our data indicates that CDK2 is differentially 
activated in epithelial cancer cells but exact mechanistic basis is unknown. Separately, we 
also observe that epithelial lung cancer cells require p21 for survival, as knockdown of p21 
causes cell death. This indicates that mechanism of action of p21 is context dependent and 
can potentially regulate CDK2 activity by acting as an activator in this instance. Similarly, p27 
is an intrinsic regulator of cyclin dependent kinases that should be further explored in context 
of EMT in cancer cells. These molecular studies will start  to tease out additional mechanisms 
of resistance to CDK4 inhibitors. Recent findings indicate that compensatory upregulation of 
CDK6, or cyclin E and loss RB can mediate resistance to CDK4 inhibitors, especially in breast 
cancer272. Exploring these pathways in lung cancer will be important to combat resistance.   
The advent of immune checkpoint blockade (ICB) in the field of oncology has been 
immensely successful in producing tumor remissions by limiting malignant progression as 
well as promoting tumor clearance. A large number of clinical trials are evaluating the efficacy 
of ICB with targeted therapies to attain an additive or synergistic effect, including lung 
cancer273. MEK inhibitor in combination with ICB are being evaluated in the clinical trials 
(NCT03225664). There have been only modest response to the combined therapy in different 
cancer types, including our syngeneic and autochthonous mouse models274. On the other 
hand, CDK4 inhibitors with ICB in lung cancer have only recently been tested in pre-clinical 
models248. An expected outcome from clinical trials with CDK4 inhibitors in combination with 
ICB is resistance to therapy, either upfront or acquired overtime. In fact, our preliminary 
findings in the syngeneic mouse models show that CDK4 inhibitor with PD-L1 blockade 
effectively control tumor growth in one-third of the tumors, but most tumors grow eventually 
develop resistance. We speculate that this resistance occurs because tumor cells are capable 
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of adapting and escaping death by activating alternative survival pathways, in this case 
MAPK. With this in mind, we co-administered CDK4 and MEK inhibitors with PD-L1 blockade 
which led to a sustained tumor suppression for about 8 weeks, which was in line with 
investigations in other cancer types275-277. The next steps include the evaluation of the 
immune landscape as well as the cancer cells in treated tumors to determine why the triple 
combination is significantly better than single or double agent treatment and will form the 
basis for future clinical investigations. 
Lastly, there has been an increased focus on determining the best approach of 
administering drugs to patients278. A fundamental understanding of how cancer cells evolve 
in the face of treatments by either transcriptomic rewiring or interactions with the tumor 
microenvironment allows us to determine therapeutic vulnerabilities and optimal timing of 
drug administration for the enhancement of combination therapies. To achieve a greater 
benefit with CDK4i, MEKi and ICB, it will be worthwhile exploring the effects of upfront 
combination vs sequential drug treatments. It will help in the identification of drug-tolerant 
cells which usually remain dormant until drug withdrawal. These subpopulations can then be 
targeted with a different drug that has previously demonstrated benefit. This has specific 
clinical relevance due to the toxicities associated with the administration of multiple therapies 
at once. Using ex vivo as well as in vivo tumor models can help in establishing the optimal 
dosing schedule.  
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Table 12. Quality control metrics for the Kinome shRNA screens 
 393P 344P 
 in-vivo in-vitro in-vivo in-vitro 
reagent 1 2 3 1 2 1 2 3 1 2 
LUC_10041 1.38 0.39 -0.02 3.72 2.88 0.31 1.16 4.12 0.24 0.74 
LUC_10042 -0.28 2.36 3.94 -1.22 2.9 -0.61 -6.96 0.67 0.88 0.41 
LUC_10043 -0.02 0.09 -0.99 1.86 3.15 0.71 1.05 0.8 0.41 0.17 
LUC_10044 2.85 0.71 1.06 1.09 4.05 -0.32 -0.01 1.59 0.84 1.51 
LUC_10045 0.42 0.07 0.49 1.03 1.27 1.4 4.17 0 0.55 0.49 
LUC_10046 -0.57 -1.06 -0.2 -1.01 -4.08 0.16 3.94 5.75 -0.38 1.14 
LUC_10047 -0.34 0.06 0.21 -1.19 -2.85 0.45 1.81 2.79 3.95 3.98 
LUC_10048 2.32 2.82 0.34 3.24 2.22 -0.12 3.86 1.17 1.13 0.68 
LUC_10049 0.58 0.97 1.98 0.9 2.21 1.72 1.99 0.18 0.67 0.49 
LUC_10050 -1.72 -0.38 -1.06 -1.63 1.06 -11.82 -0.14 -5.76 0.4 0.08 
LUC_10051 0.73 4.01 1.21 3.5 2.2 -0.06 0.55 -0.66 -0.11 0.5 
LUC_10052 3.63 -1.99 0.52 3.37 1.95 -0.58 1.84 -1.68 0.97 0.87 
LUC_10053 0.36 0.7 2.6 3.35 3.99 0.59 -0.62 -9.14 0.95 0.16 
LUC_10054 -1.47 0.69 -0.44 -1.81 3.4 -1.25 0.53 -12.03 0.11 0.23 
LUC_10055 -1.3 -0.68 -0.49 -0.44 -0.99 0.16 0.59 0.24 1.81 1.67 
LUC_10056 -2.53 -3.06 -0.09 -0.69 -1.69 -11.55 -11.55 -11.55 -1.36 -2.68 
LUC_10057 1.28 0.7 -1.12 0.07 0.75 0.36 0.42 -0.87 0.34 0.39 
LUC_10058 -0.74 -10.09 -2.44 -4.1 -0.78 0.43 0.29 -10.58 -6.65 -10.58 
LUC_10059 -0.02 -1.96 -1.36 -4.1 -4.93 0.72 -12.24 -0.3 -3.95 -4.25 
LUC_10060 -1.89 -5.64 -2.07 -4.09 -4.19 -10.99 -10.99 -10.99 -10.99 -10.99 
Rpl30_10001 -0.99 1.45 -2.72 -4.68 -4.75 1.67 -1.7 -0.04 -1.73 -0.26 
Rpl30_10002 -2.81 -6.85 -2.84 -4.59 -5.92 -0.94 -11.57 -8.5 -1.04 -11.57 
Rpl30_10003 2.72 -0.86 -2.75 -1.42 0.24 -1.28 0.33 -2.12 -4.64 -2.6 
Rpl30_10004 -3.98 -1 -1.36 -0.69 -0.05 -8.09 -12.99 -12.99 -4.6 -5.72 
Rpl30_10005 -4.59 -4.45 -4.55 -3.42 -4.88 -1.08 -13.05 -13.05 -13.05 -13.05 
Rpl30_10006 0.14 -1.62 -2.69 -3.05 -1.94 -12.41 1.24 -12.41 -1.98 -5.41 
Rpl30_10007 -1.39 -1.88 -3.38 -2.45 -1.91 -1.46 -1.44 -14.32 -0.93 -3.42 
Rpl30_10008 -4.03 -4.86 -2.98 -3.95 -2.52 -1.42 -1.73 -2.76 -12.6 -5.04 
Rpl30_10009 -2.2 -2 -1.2 -2.46 2.67 -1.75 -1.17 -1.15 -2.98 -2.59 
Rpl30_10010 1.11 -3.03 -1.45 -4.62 -1.4 -11.93 -11.93 -7.51 -2.85 -7.36 
Rpl30_10011 -3.37 -0.88 -0.81 -1.58 -1.24 -3.91 -0.71 -2.21 -2.07 -3.95 
Rpl30_10012 -0.79 -10.23 -6.2 -4.48 -5.47 -0.37 -10.03 0.74 -10.03 -10.03 
Rpl30_10013 -2.1 -2.79 -7.91 -4.82 -4.16 -11.51 -11.51 -11.51 -2.57 1.55 
Rpl30_10014 -6.31 -1.31 -1.56 -6.23 -6.16 -1.26 -11.57 0.13 -4.59 -2.36 
Rpl30_10015 -4.73 -2.52 -5.41 -3.72 -4.28 -11.85 -11.85 -11.85 -0.82 -2.19 
Rpl30_10016 -2.42 -6.94 0.17 -4.55 -5.7 -12.57 -8.97 -0.58 -4.23 -5.01 
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Rpl30_10017 -2.78 -2.13 -3.33 1.11 -0.56 -1.21 -8.07 0.48 -2.9 -5.83
Rpl30_10018 -2.01 1.65 -6.21 -0.57 -0.82 -4.46 0.22 -10.87 -0.7 -7.47
Rpl30_10019 -3.65 -6.19 -4.08 -4.56 -3.87 -1.21 -8.41 0.06 -2.81 -2.21
Rpl30_10020 -4.31 -7.71 -2.93 0.3 -4.64 -10.75 -3.9 -10.75 -0.25 -10.75
Psma1_10021 0.48 1.8 0.46 -3.37 -2.48 0.97 2.85 3.32 0.9 1.26 
Psma1_10022 0.05 0.54 0.16 -0.9 -3.02 1.72 5.68 1.73 1.07 0.74 
Psma1_10023 0.67 1.09 0.55 -1.03 0.68 -1.27 0.63 0.97 1.45 1.84 
Psma1_10024 -0.14 0.52 0.63 -1.45 -0.04 3.48 1.4 2.77 0.76 0.9 
Psma1_10025 0.32 1.67 0.62 -0.46 -0.08 0.89 0.06 3.09 0.83 0.35 
Psma1_10026 -2.71 0.77 -2.09 -5.09 -5.23 -2.62 -11.47 -11.47 -6.42 -6.66
Psma1_10027 -1.38 -1.87 -3.7 -4.41 -3.91 -0.26 1.44 -0.82 -2.51 -3.41
Psma1_10028 -1.6 -2.28 -3.82 -4.57 -2.51 -0.53 -1.47 -11.63 -11.63 -11.63
Psma1_10029 -2.94 -2.64 -1.95 -4.7 -1.94 -0.96 -0.17 -0.02 -4.07 -2.93
Psma1_10030 -5.53 -2.56 -5.78 -4.23 -4.39 -10.91 -10.91 -10.91 -10.91 -10.91
Psma1_10031 -4.04 2.34 -3.58 -2.61 -4.77 -1.23 -1.5 -13.16 -3.76 -3.89
Psma1_10032 -5.03 -3.91 -2.96 -4.66 -4.11 -1.4 -3.85 -1.65 -2.82 -2.18
Psma1_10033 -3.83 -3.54 -2.49 -2.58 -0.56 -3.57 6.82 -1.08 -3.53 -6.22
Psma1_10034 -1.81 -1.99 -7.37 -4.93 -4.59 -7.15 -11.13 0.94 -11.13 -11.13
Psma1_10035 -0.32 5.82 -0.4 0.36 -0.75 -2.96 -0.14 -1.94 -3.48 -4.76
Psma1_10036 -10.25 -10.25 -1.74 -3.73 -4.29 -11.08 -11.08 -11.08 -11.08 -11.08
Psma1_10037 -8.81 -8.81 -8.81 -4.43 -5.23 -11.15 -11.15 -11.15 -1.96 -11.15
Psma1_10038 -6.37 -6.37 -6.37 -3.65 -6.37 -10.44 -10.44 -10.44 -10.44 -10.44
Psma1_10039 -6.23 -5.79 -6.48 -4.16 -3.97 0.23 -10.7 -10.7 -10.7 -10.7
Psma1_10040 -1.85 -5.17 -3.4 -4.68 -4.3 -10.76 -10.76 -10.76 -10.76 -10.76
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Table 13. Gene level dropout scores for each of the Kinome screens 
model 393P 344P 
condition nude in-vitro.2 nude in-vitro.2 
metric logP rank logP rank logP rank logP rank 
Adrbk2 -5.86 4 -5.11 5 -5.29 1 -5.06 6 
Cdk4 -4.98 7 -0.33 432 -5.04 2 -7.40 2 
Csnk2a2 -1.71 101 -1.90 78 -4.36 3 -2.36 56 
Dapk3 -3.43 21 -0.12 490 -4.29 4 -1.84 108 
Wnk1 -2.80 40 -1.16 189 -4.23 5 -1.16 207 
Rps6kc1 -1.57 117 -1.47 129 -4.07 6 -4.67 9 
Btk -0.54 368 -2.91 23 -3.90 7 -1.64 134 
Rps6ka5 -1.64 106 -2.21 54 -3.90 8 -1.22 194 
Kalrn -2.86 37 -0.89 250 -3.87 9 -2.48 48 
Aurka -2.41 46 -2.72 33 -3.78 10 -5.49 4 
Plk1 -5.44 6 -5.98 2 -3.68 11 -4.72 8 
Hipk4 -0.18 474 -0.46 392 -3.64 12 -0.43 396 
Bmpr1b -0.70 322 -2.59 37 -3.57 13 -0.85 266 
Akt1 -2.74 43 -1.44 134 -3.47 14 -1.49 156 
Smg1 -2.09 70 -1.32 151 -3.46 15 -3.86 11 
Stk16 -0.72 309 -0.43 403 -3.44 16 -3.28 19 
Wnk2 -1.20 178 -1.04 216 -3.43 17 -3.16 21 
Erbb3 -5.92 2 -4.34 6 -3.41 18 -2.64 40 
Map2k5 -3.58 18 -2.47 43 -3.28 19 -5.97 3 
Raf1 -5.50 5 -4.30 7 -3.28 20 -1.66 132 
Flt4 -1.27 163 -2.10 62 -3.22 21 -3.69 14 
Fes -4.09 12 -2.86 27 -3.13 22 -1.64 136 
Nek7 -4.06 13 -3.21 18 -3.07 23 -1.64 135 
Akt3 -2.30 53 -1.67 110 -3.01 24 -0.79 286 
Wnk3 -0.32 438 -0.61 335 -2.99 25 -0.97 242 
Rps6ka6 -2.41 45 -3.46 14 -2.95 26 -2.17 70 
Pomk -0.48 383 -1.30 155 -2.87 27 -1.25 183 
Mtor -3.79 16 -5.49 4 -2.87 28 -2.52 45 
Bub1b -2.90 35 -3.56 12 -2.84 29 -3.62 15 
Pik3cg -0.16 482 -0.05 505 -2.74 30 -0.90 255 
Stk35 -0.79 275 -1.38 143 -2.68 31 -0.77 291 
Mark3 -2.31 52 -0.66 315 -2.68 32 -1.71 122 
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Csnk1e -2.38 48 -2.11 59 -2.63 33 -1.61 139 
Jak1 -1.65 105 -2.42 45 -2.59 34 -0.84 268 
Nrbp1 -3.29 25 -1.79 92 -2.58 35 -1.67 130 
Ttk -1.32 153 -3.17 19 -2.54 36 -2.73 36 
Tnik -1.55 124 -1.85 82 -2.54 37 -0.49 378 
Prkdc -0.91 242 -0.86 257 -2.53 38 -2.02 86 
Map3k7 -0.39 414 -0.04 509 -2.47 39 -0.10 488 
Akt2 -1.57 121 -6.37 1 -2.46 40 -2.13 75 
Cdkl4 -0.66 336 -0.59 342 -2.46 41 -0.38 417 
Pik3ca -3.82 15 -1.06 211 -2.45 42 -4.31 10 
Pkn2 -1.87 85 -1.93 75 -2.43 43 -2.88 30 
Bckdk -0.97 230 -1.70 105 -2.35 44 -2.31 57 
Adck4 -1.08 202 -1.78 94 -2.30 45 -2.30 58 
Eif2ak3 -1.28 162 -1.29 159 -2.30 46 -3.17 20 
Pi4ka -0.77 289 -0.44 400 -2.29 47 -2.05 83 
Atr -5.98 1 -3.94 9 -2.27 48 -7.69 1 
Stk38 -2.06 74 -1.01 223 -2.25 49 -0.92 249 
Snrk -2.09 69 -1.88 79 -2.24 50 -1.96 93 
Pask -1.58 115 -2.56 40 -2.23 51 -0.52 365 
Sik3 -2.14 64 -1.42 140 -2.23 52 -1.55 145 
Cask -2.00 78 -1.99 69 -2.22 53 -1.54 148 
Mapk12 -0.46 390 -0.41 414 -2.19 54 -1.73 120 
Lats1 -0.70 321 -0.70 304 -2.19 55 -1.06 228 
Gsg2 -1.58 114 -1.98 72 -2.17 56 -1.14 211 
Mark1 -1.29 159 -2.03 67 -2.17 57 -2.44 51 
Pak2 -1.19 181 -3.85 10 -2.16 58 -1.89 101 
Mapk7 -0.59 360 -0.90 246 -2.16 59 -1.48 158 
Prkg1 -2.86 38 -0.70 302 -2.14 60 -1.00 236 
Ryk -3.74 17 -1.05 214 -2.14 61 -3.84 12 
Map3k6 -2.27 56 -0.35 427 -2.13 62 -2.44 52 
Mastl -1.19 183 -0.96 234 -2.13 63 -1.55 146 
Stk3 -1.79 93 -1.25 170 -2.13 64 -1.98 90 
Rps6kl1 -1.46 137 -0.32 434 -2.12 65 -2.10 80 
Prkcg -1.90 82 -1.30 156 -2.11 66 -0.54 360 
Cdk10 -1.30 157 -0.58 349 -2.10 67 -1.80 111 
Ntrk1 -0.04 513 -0.48 382 -2.10 68 -0.02 515 
Ripk4 -0.63 346 -0.82 269 -2.10 69 -1.99 88 
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Mapk6 -0.85 256 -1.43 136 -2.10 70 -1.52 150 
Pxk -1.74 99 -2.07 64 -2.09 71 -1.75 118 
Camk1d -0.80 271 -0.48 384 -2.09 72 -0.86 263 
Yes1 -3.37 23 -0.90 245 -2.05 73 -1.78 113 
Prkab2 -1.08 198 -0.63 326 -2.04 74 -3.82 13 
Nek3 -2.74 42 -0.96 233 -2.04 75 -2.52 44 
Musk -0.73 304 -0.43 402 -2.03 76 -3.10 23 
Riok2 -0.80 272 -0.64 322 -2.03 77 -1.63 137 
Vrk1 -1.21 170 -0.48 383 -2.02 78 -0.05 506 
Pink1 -0.78 283 -3.26 16 -2.02 79 -3.07 24 
Cdk6 -1.49 134 -0.87 255 -2.01 80 -2.18 67 
LUC -0.78 278 -1.24 173 -2.00 81 -1.61 140 
Mapkapk5 -0.30 443 -1.70 106 -1.98 82 -1.92 95 
Mapk9 -2.07 71 -1.98 73 -1.96 83 -1.92 97 
Bmp2k -1.46 138 -0.89 251 -1.96 84 -2.52 47 
Epha5 -2.24 58 -1.83 86 -1.95 85 -1.77 114 
Prkd3 -1.87 84 -0.22 466 -1.94 86 -0.63 332 
Ern1 -1.19 180 -3.62 11 -1.93 87 -0.51 372 
Sik1 -0.30 445 -0.42 404 -1.93 88 -0.65 326 
Prkcd -4.60 9 -2.87 26 -1.89 89 -2.54 43 
Nek1 -1.75 96 -4.30 8 -1.88 90 -1.97 92 
Trrap -3.31 24 -3.26 17 -1.88 91 -2.03 84 
Cnksr1 -0.25 456 -0.60 341 -1.88 92 -1.53 149 
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Acvr2b -1.09 194 -0.97 232 -0.43 403 -0.49 379 
Insrr -2.20 62 -0.72 298 -0.43 404 -0.92 250 
Map3k4 -0.82 270 -0.56 353 -0.43 405 -0.19 463 
Hck -0.82 269 -1.26 168 -0.43 406 -0.15 476 
Cdkl3 -0.91 243 -0.22 467 -0.42 407 -0.11 483 
Prkcb -0.73 305 -0.06 503 -0.41 408 -0.70 312 
Dclk1 -0.29 446 -0.46 393 -0.41 409 -0.39 411 
Lyn -1.32 154 -1.12 195 -0.41 410 -0.50 377 
Adrbk1 -0.04 512 -0.20 476 -0.40 411 0.00 516 
Irak1 -0.92 240 -0.69 306 -0.40 412 -0.58 346 
2610018G0
3Rik -1.95 79 -1.80 91 -0.40 413 -0.79 282 
Ttn -1.71 103 -1.66 112 -0.40 414 -0.66 324 
Prkaa2 -0.40 411 -0.49 377 -0.39 415 -0.42 404 
Tyro3 -0.24 458 -0.46 391 -0.39 416 -0.42 401 
Ephb6 -0.14 489 -0.11 494 -0.39 417 -1.30 174 
Pnck -0.04 511 -0.25 458 -0.39 418 -1.69 124 
Pdk2 -0.07 506 -0.39 419 -0.38 419 -0.43 398 
Pak3 -1.52 127 -1.61 116 -0.37 420 -1.71 123 
Tlk1 -0.64 344 0.00 517 -0.37 421 -0.35 423 
Taok3 -0.43 398 -0.34 430 -0.37 422 -0.52 368 
Epha8 -0.78 280 -0.88 253 -0.37 423 -0.57 349 
Cdk2 -0.07 507 -0.14 485 -0.37 424 -1.85 106 
Brsk1 -0.17 477 -0.26 453 -0.37 425 -0.57 348 
Tssk1 -1.08 200 -0.80 275 -0.37 426 -0.09 495 
Tyk2 -0.33 430 -1.19 179 -0.36 427 -1.36 169 
Pi4kb -1.02 216 -0.03 513 -0.36 428 -0.77 292 
Camk1 -1.50 131 -1.11 197 -0.36 429 -0.48 384 
Sgk1 -0.44 395 -0.51 370 -0.36 430 -1.49 155 
Mapkapk3 -0.41 408 -0.37 422 -0.36 431 -0.33 429 
Map4k4 -0.13 492 -0.55 355 -0.36 432 -0.68 319 
Adck3 -0.14 490 -0.53 364 -0.36 433 -0.39 414 
Cdk15 -0.21 464 -0.83 264 -0.35 434 -1.87 104 
Rps6ka3 -0.52 375 -0.66 318 -0.35 435 -0.32 432 
Src -0.89 249 -1.18 186 -0.35 436 -0.60 341 
Pik3c2b -0.18 472 -0.73 296 -0.34 437 -0.25 451 
Tnk1 -1.17 185 -0.56 354 -0.34 438 -0.66 325 
Gsk3a -0.94 236 -0.13 487 -0.34 439 -0.60 342 
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Epha2 -0.69 326 -0.17 482 -0.33 440 -0.28 442 
Pim2 -0.83 266 -1.77 96 -0.33 441 -0.32 434 
Csnk1g2 -0.84 259 -1.18 187 -0.32 442 -0.50 374 
Prkd1 -1.79 92 -1.22 177 -0.32 443 -1.17 204 
Ros1 -0.14 487 -0.61 338 -0.32 444 -1.11 220 
Acvr1b -0.67 334 -1.70 103 -0.32 445 -1.09 224 
Gsk3b -1.06 207 -0.41 412 -0.31 446 -0.53 364 
Taok1 -0.08 505 -0.30 440 -0.31 447 -0.09 490 
Prkaca -1.30 158 -0.20 474 -0.30 448 -1.27 176 
Stk32a -0.73 306 -1.19 182 -0.30 449 -2.77 35 
Gak -0.83 261 -1.22 175 -0.29 450 -0.32 435 
Pdk3 -0.79 276 -1.68 107 -0.29 451 -1.25 185 
Map3k12 -0.36 425 -0.05 508 -0.29 452 -0.24 453 
Pik3r5 -1.17 186 -0.76 288 -0.29 453 -0.77 293 
Map2k1 -0.39 416 -1.40 142 -0.28 454 -0.52 367 
Mylk3 -0.22 463 -1.68 108 -0.27 455 -0.83 272 
Chuk -0.64 343 -0.54 360 -0.27 456 -0.29 440 
Peak1 -0.31 441 -0.33 433 -0.27 457 -0.02 514 
Mapk10 -0.46 389 -1.81 90 -0.27 458 -1.23 192 
Plk2 -0.47 387 -0.63 325 -0.27 459 -0.64 329 
Mast2 -0.28 450 -0.42 407 -0.26 460 -0.15 477 
Syk -0.15 486 -1.54 123 -0.26 461 -1.01 234 
Stk25 -0.24 459 -0.62 333 -0.25 462 -0.79 283 
Ephb4 -0.76 294 -0.64 320 -0.24 463 -0.78 287 
Clk2 -0.63 349 -0.21 473 -0.24 464 -0.48 383 
Prkce -2.12 67 -1.98 71 -0.24 465 -3.45 17 
Prkg2 -0.76 293 -0.74 295 -0.24 466 -0.85 267 
Clk4 -0.67 335 -0.03 512 -0.23 467 -0.06 501 
Nek6 -0.99 223 -0.35 426 -0.23 468 -0.66 323 
Clk1 -0.67 333 -0.59 345 -0.23 469 -1.32 172 
Tssk2 -0.98 226 -1.09 202 -0.23 470 -0.92 248 
Acvr1 -0.58 364 -0.63 327 -0.22 471 -0.99 240 
Hspb8 -1.00 219 -2.23 53 -0.22 472 -1.84 107 
Ror1 -0.41 405 -0.47 386 -0.21 473 -0.09 492 
Abl1 -0.77 287 -1.09 200 -0.21 474 -1.44 162 
Stk39 -0.47 385 -1.16 192 -0.21 475 -0.61 337 
Mapk3 -0.17 479 0.00 516 -0.21 476 -0.32 433 
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Cdk5 0.00 517 -0.40 415 -0.20 477 -0.34 425 
Camkv -0.40 413 -0.76 289 -0.20 478 -0.05 504 
Csnk1a1 -2.30 54 -1.43 135 -0.20 479 -0.11 485 
Prkcq -0.10 499 -1.24 171 -0.20 480 -0.05 503 
Dyrk1a -0.06 509 -3.43 15 -0.20 481 0.00 517 
Pik3r4 -0.64 345 -2.38 46 -0.20 482 -0.69 317 
Gucy2c -0.95 234 -0.98 230 -0.20 483 -0.14 478 
Clk3 -0.09 502 -0.93 237 -0.20 484 -0.90 254 
Tgfbr1 -0.51 376 -0.93 238 -0.19 485 -0.11 484 
Nek4 -0.80 273 -0.32 435 -0.19 486 -1.58 142 
Camk2d -0.42 400 -0.42 408 -0.19 487 -0.60 340 
Pak4 -0.77 285 -0.67 309 -0.18 488 -1.92 96 
Magi1 -1.05 210 -2.47 42 -0.18 489 -0.13 480 
Twf2 -0.49 380 -1.00 226 -0.18 490 -0.21 459 
Flt3 -0.17 478 -0.25 457 -0.17 491 -0.02 513 
Map3k3 -1.05 211 -1.56 121 -0.17 492 -0.51 371 
Map2k4 -0.09 501 -0.05 506 -0.17 493 -0.45 391 
Map4k5 -0.08 503 -0.85 259 -0.16 494 -0.39 410 
Alpk2 -0.62 352 -0.25 456 -0.15 495 -0.24 452 
Tssk3 -0.22 462 -0.60 340 -0.15 496 -0.25 450 
Tnk2 -0.64 341 -2.03 66 -0.14 497 -0.59 345 
Mapkapk2 -0.53 371 -0.27 447 -0.14 498 -0.97 243 
Prkx -1.14 188 -0.85 261 -0.14 499 -0.99 241 
Stk4 -2.04 76 -1.63 114 -0.14 500 -1.09 222 
Slk -0.15 484 -1.19 181 -0.13 501 -0.84 269 
Nek5 -0.02 514 -0.05 507 -0.13 502 -0.03 510 
Pkmyt1 -0.25 457 -0.61 336 -0.13 503 -0.11 486 
Atm -0.42 399 -0.42 405 -0.12 504 -1.13 212 
Rps6ka2 -0.16 481 -0.55 356 -0.12 505 -1.48 159 
Ltk -0.10 498 -0.70 303 -0.11 506 -0.94 245 
Oxsr1 -0.43 397 -0.28 444 -0.11 507 -0.45 392 
Mlkl -0.83 268 -1.33 150 -0.10 508 -0.04 508 
Rock1 -0.49 382 -0.11 495 -0.10 509 -0.42 402 
Npr1 -0.33 429 -0.04 510 -0.08 510 -1.23 188 
Grk4 -0.45 392 -0.78 280 -0.07 511 -0.26 446 
Dyrk1b -0.07 508 -0.20 475 -0.06 512 -0.04 507 
Prkcz -1.14 187 -0.67 312 -0.05 513 -0.82 273 
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Gucy2e -0.19 469 -2.96 21 -0.05 514 -0.46 387 
Uhmk1 -0.12 495 -0.27 450 -0.05 515 -0.18 467 
Pik3r1 -0.60 356 -0.46 394 -0.03 516 -0.16 473 
Cdc42bpa -0.16 480 -0.16 483 -0.01 517 -0.31 437 
 
Table 14. Quality control metrics for the FDAome shRNA screens 
 393P 344P 
 in-vivo (sv129) in-vivo (sv129) 
reagent 1 2 3 1 2 3 
LUC_CONTROL_199590 -0.44 -0.99 0.24 -0.15 1.02 0.93 
LUC_CONTROL_199591 0.58 1.24 0.95 2.21 0.42 0.68 
LUC_CONTROL_199592 3.67 1.45 1.3 0.98 1.36 1.57 
LUC_CONTROL_199593 0.63 0.24 1.16 1.86 0.96 0.91 
LUC_CONTROL_199594 0.56 1.03 -0.32 0.53 1.6 0.02 
LUC_CONTROL_199595 1 0.52 -0.3 3.2 0.36 1.44 
LUC_CONTROL_199596 1.7 -0.11 1.08 1.34 2.09 1.42 
LUC_CONTROL_199597 0.42 0.38 0.29 1.5 1.36 1.5 
LUC_CONTROL_199598 0.97 1.68 0.11 1.37 -0.45 1.82 
LUC_CONTROL_199599 0.63 0.86 1.44 0.98 0.56 0.68 
LUC_CONTROL_199600 0.03 0.03 -0.39 0.43 0.16 0.3 
LUC_CONTROL_199601 0.5 0.6 0.46 0.35 -0.07 -0.07 
LUC_CONTROL_199602 -0.35 0.5 0.39 0.28 0.84 0.19 
LUC_CONTROL_199603 0.08 0.1 0.61 1.55 0.47 0.87 
LUC_CONTROL_199604 1.03 0.19 0.46 1.94 1.41 1.36 
LUC_CONTROL_199605 -0.46 -1.33 0.1 -0.56 -0.42 0.53 
LUC_CONTROL_199606 -0.9 -0.08 -0.29 -2.49 -0.73 -0.57 
LUC_CONTROL_199607 -1.48 -1.77 -0.53 -3.62 -1.35 -1.95 
LUC_CONTROL_199608 2.21 -0.97 2.33 -1.41 -2.23 -1.17 
LUC_CONTROL_199609 1.51 -1.22 -0.81 0.83 0.56 -0.12 
Rpl30_CONTROL_199550 -3.66 -2.43 -6.01 -2.15 -5.47 -3.24 
Rpl30_CONTROL_199551 -2.5 -2.2 -2.32 -2.16 -1.2 -2.24 
Rpl30_CONTROL_199552 -2.81 -1.29 -1.84 -3.33 -2.66 -2.27 
Rpl30_CONTROL_199553 -3.06 -2.16 -0.55 -1.52 -4.67 -4.42 
Rpl30_CONTROL_199554 -4.35 -1.56 -7.23 -0.75 -3.11 -2.37 
Rpl30_CONTROL_199555 -3.06 0.62 -2.12 -2.08 -1.62 3.62 
Rpl30_CONTROL_199556 0.65 -2.41 -2.32 -3.85 -4.82 -1.05 
Rpl30_CONTROL_199557 -1.19 -2.45 -1.86 -3.07 -2.75 4.05 
Rpl30_CONTROL_199558 -1.83 -3.17 -5.23 -1.66 -5.34 -5.74 
Rpl30_CONTROL_199559 -2.83 -2.35 -1.37 -2.67 -1.37 -1.43 
Rpl30_CONTROL_199560 -1.45 -2.73 -0.46 -1.24 -0.96 -2.42 
Rpl30_CONTROL_199561 -2.74 -0.93 -1.62 -1.71 -1.22 0.67 
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Rpl30_CONTROL_199562 -1.94 -2.15 -6.81 -4.87 -3.79 -5.3 
Rpl30_CONTROL_199563 0.23 -1.86 -0.83 -2.45 0.16 -4.01 
Rpl30_CONTROL_199564 -3.53 -3.75 2.1 2.08 3.35 3.3 
Rpl30_CONTROL_199565 -2.34 -1.22 -1.02 -0.08 1.23 -0.08 
Rpl30_CONTROL_199566 -1.35 -0.7 -2.25 -0.83 -2.53 0.91 
Rpl30_CONTROL_199567 -2.4 -1.98 -1.94 -4.46 -0.8 -4.82 
Rpl30_CONTROL_199568 -0.31 -0.07 -1.1 -1.2 -1.66 -0.3 
Rpl30_CONTROL_199569 -1.82 -2.41 -0.65 -1.66 -0.59 0.17 
Psma1_CONTROL_199570 -0.4 0.14 -0.21 0.07 -0.15 0.87 
Psma1_CONTROL_199571 -0.48 0.12 -0.08 0.14 -0.8 0.57 
Psma1_CONTROL_199572 -0.17 0.69 1.12 0.68 -0.82 1.08 
Psma1_CONTROL_199573 -0.4 -0.13 0.39 0.32 -0.91 0.45 
Psma1_CONTROL_199574 -0.64 1.2 -0.55 0.14 -0.77 0.69 
Psma1_CONTROL_199575 -1.87 -1.15 -2.89 -3.15 -4.68 -2.21 
Psma1_CONTROL_199576 -0.79 -2.69 -2.16 -3.74 -3.26 -2.09 
Psma1_CONTROL_199577 -2.09 -1.83 -2.47 -1.06 -4.2 -0.41 
Psma1_CONTROL_199578 -1.21 -1.04 -1.45 -3.77 -3.23 0.28 
Psma1_CONTROL_199579 -0.13 -3.03 -1.85 -3.59 -0.89 -0.42 
Psma1_CONTROL_199580 -5.79 -1.62 -2.03 -1.25 -1.41 -1.49 
Psma1_CONTROL_199581 -2.39 -0.92 -3.94 2.18 1.05 -1.39 
Psma1_CONTROL_199582 -3.55 -1.32 -1.94 -1.8 -2.79 -1.31 
Psma1_CONTROL_199583 0.38 -2.77 -2.26 -0.4 0.05 -1.54 
Psma1_CONTROL_199584 3.07 -2.07 -0.04 -0.66 -0.29 -1.57 
Psma1_CONTROL_199585 -2.24 -2.29 -2.23 0.19 -1.96 -2.18 
Psma1_CONTROL_199586 -1.99 -3.39 -5.29 -2.93 -0.8 -0.4 
Psma1_CONTROL_199587 -0.88 -3.44 -3.52 -1.28 -2.67 -0.79 
Psma1_CONTROL_199588 -3.08 -1.86 -1.86 1.67 -1.34 0.48 
Psma1_CONTROL_199589 -1.98 -2.77 -4.74 -0.5 1.74 -0.22 
 
Table 15. Gene level dropout scores for each of the FDAome screens 
 393P 393P 344P 344P 
 sv129 sv129 sv129 sv129 
gene logP rank logP rank 
Pik3ca -5.5 4 -8.4 1 
Cdk4 -3.2 16 -7.8 2 
Myc -4.1 11 -7.7 3 
Bcl2 -2.9 18 -6.3 4 
Prkcd -4.4 8 -5.8 5 
Cdk7 -0.7 110 -5.4 6 
Ctnnb1 -0.8 102 -5.1 7 
Plk1 -2.9 19 -4.7 8 
Mtor -2.9 17 -4.3 9 
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Cdk6 -2.0 32 -4.2 10 
Psmd1 -4.4 9 -4.1 11 
Top2b -0.2 164 -4.0 12 
Psmb1 -10.1 1 -3.9 13 
Rarb -0.8 96 -3.9 14 
Erbb2 -5.4 5 -3.7 15 
Mcl1 -1.4 56 -3.3 16 
Esr1 -4.5 7 -3.2 17 
Birc5 -0.9 88 -3.1 18 
Insr -1.8 39 -2.9 19 
Rac1 -6.5 3 -2.8 20 
Fgfr4 -1.3 61 -2.8 21 
Tec -1.1 69 -2.7 22 
Top1 -1.4 54 -2.5 23 
Epha2 -1.7 42 -2.5 24 
Notch1 -1.7 41 -2.5 25 
Itk -0.8 100 -2.5 26 
Rarg -1.1 73 -2.5 27 
Ptpn6 -1.1 68 -2.4 28 
Raf1 -8.7 2 -2.4 29 
Stat3 -4.8 6 -2.4 30 
Axl -0.7 114 -2.2 31 
Gsk3a -2.7 20 -2.2 32 
Akt2 -0.2 162 -2.2 33 
Pim1 -1.2 64 -2.2 34 
Wee1 -2.6 23 -2.1 35 
Top2a -4.2 10 -2.1 36 
Mapk3 -0.3 160 -2.1 37 
Parp3 -1.2 65 -2.1 38 
Prkcg -1.0 81 -2.0 39 
Chek2 -0.1 175 -2.0 40 
Trim24 -1.6 48 -2.0 41 
Whsc1 -1.2 63 -2.0 42 
Cd274 -0.4 152 -1.9 43 
Tnfsf13b -0.2 167 -1.9 44 
Prkci -0.2 166 -1.9 45 
Atr -1.8 36 -1.9 46 
Jak1 -0.7 112 -1.9 47 
Aurkb -2.2 28 -1.9 48 
Cdk9 -1.3 60 -1.8 49 
Mapk1 -3.6 13 -1.8 50 
Aurka -1.7 43 -1.8 51 
Fgr -0.1 170 -1.8 52 
Pak4 -2.0 30 -1.8 53 
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Abl2 -0.1 172 -1.8 54 
Mapk7 -1.9 35 -1.7 55 
Mapk12 -0.7 104 -1.7 56 
Flt4 -1.1 74 -1.7 57 
Pik3cg -1.2 66 -1.6 58 
Rps6kb1 -0.7 107 -1.6 59 
Hdac1 -0.6 123 -1.6 60 
Tyms -0.1 180 -1.6 61 
Jak2 -2.6 22 -1.5 62 
Met -2.3 25 -1.5 63 
Tyro3 -1.1 76 -1.5 64 
Fgfr1 -0.9 91 -1.5 65 
Ptgs2 -1.1 70 -1.5 66 
Rrm1 -2.0 31 -1.5 67 
Xpo1 -1.6 50 -1.5 68 
Ntrk1 -1.4 55 -1.5 69 
Egfr -1.5 51 -1.4 70 
Chek1 -0.2 163 -1.4 71 
Cdk2 -1.8 37 -1.4 72 
Gls -0.4 144 -1.4 73 
Parp1 -0.7 113 -1.4 74 
Esr2 -1.1 77 -1.4 75 
Mapk9 -0.5 135 -1.4 76 
Dot1l -1.1 72 -1.3 77 
Il1b -0.7 116 -1.3 78 
Ptk2 -1.7 40 -1.3 79 
Hdac3 -0.5 141 -1.3 80 
Eif4e -3.8 12 -1.3 81 
Map3k14 -0.6 130 -1.3 82 
Ehmt2 -1.9 34 -1.2 83 
P4hb -0.8 103 -1.2 84 
Mapk11 -1.7 45 -1.2 85 
Kdm1a -1.0 86 -1.2 86 
Brd4 -1.0 80 -1.2 87 
Ppm1d -0.7 111 -1.2 88 
Mapk8 -1.3 59 -1.1 89 
Abl1 0.0 187 -1.1 90 
Mapk14 -0.4 153 -1.1 91 
Nr2c2 -0.5 139 -1.0 92 
Pigf -0.4 146 -1.0 93 
Lyn -0.6 128 -1.0 94 
Rxrb -1.8 38 -1.0 95 
Flt1 -1.2 67 -1.0 96 
Ikbke -2.2 27 -0.9 97 
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Cdk1 -1.0 83 -0.9 98 
Prkdc -3.4 14 -0.9 99 
Alk -0.7 106 -0.9 100 
Irak4 -0.4 149 -0.9 101 
Hsp90aa1 -1.4 53 -0.9 102 
Smo -0.8 97 -0.8 103 
Casp3 -0.5 143 -0.8 104 
Prkca -0.9 93 -0.8 105 
Syk 0.0 188 -0.8 106 
Pdgfra -0.5 134 -0.8 107 
Src -0.8 99 -0.8 108 
Vegfa -1.0 85 -0.8 109 
Pgd -1.3 57 -0.8 110 
Bcr -0.6 126 -0.8 111 
Ezh2 -0.9 89 -0.8 112 
Map4 -2.5 24 -0.8 113 
Tubb4a -1.0 87 -0.7 114 
Parp2 -0.7 105 -0.7 115 
Pdgfrb -0.6 118 -0.7 116 
Map2k1 -1.1 71 -0.7 117 
Prkce -0.8 95 -0.7 118 
Txn1 -0.5 131 -0.7 119 
Btk -1.7 46 -0.7 120 
Il6 -0.4 155 -0.7 121 
Ccr5 -1.0 79 -0.7 122 
Frk -0.9 90 -0.7 123 
Idh2 -0.1 186 -0.7 124 
Mapk13 -0.4 148 -0.7 125 
Tnfrsf8 -0.3 159 -0.7 126 
Prkch -0.7 108 -0.7 127 
Ptch1 -0.6 127 -0.7 128 
Rock2 -1.5 52 -0.6 129 
Nfkb1 -2.7 21 -0.6 130 
Fyn -2.1 29 -0.6 131 
Pdk1 -0.2 165 -0.5 132 
Gsk3b -1.7 44 -0.5 133 
Fgfr2 -1.0 78 -0.5 134 
Map3k8 -0.3 161 -0.5 135 
Crebbp -0.1 179 -0.5 136 
Kit -0.1 176 -0.5 137 
Ar -0.4 147 -0.4 138 
Hdac6 -0.6 117 -0.4 139 
Mapt -0.7 109 -0.4 140 
Xiap -0.6 121 -0.4 141 
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Atm -1.1 75 -0.4 142 
Prkaa1 -0.4 154 -0.4 143 
Tnf -0.6 119 -0.4 144 
Ret -0.1 177 -0.4 145 
Idh1 -0.5 132 -0.4 146 
Hdac2 -0.6 129 -0.4 147 
Dhfr -3.4 15 -0.4 148 
Drd2 -1.6 49 -0.4 149 
Il6ra -0.9 94 -0.4 150 
Jak3 -0.1 173 -0.3 151 
Blk -0.8 101 -0.3 152 
Pik3cd -1.3 58 -0.3 153 
Map2 -0.2 168 -0.3 154 
Mknk1 -0.3 156 -0.3 155 
Nampt -0.6 125 -0.3 156 
Lap3 -1.0 82 -0.3 157 
Lck 0.0 191 -0.3 158 
Rxra -0.2 169 -0.3 159 
Fgfr3 -0.6 120 -0.3 160 
Akt1 -0.8 98 -0.2 161 
Aurkc -0.5 133 -0.2 162 
Prkcq -0.9 92 -0.2 163 
Mdm2 -0.5 138 -0.2 164 
Tek -0.1 174 -0.2 165 
Prkcb -0.7 115 -0.2 166 
Braf -0.6 124 -0.2 167 
Hdac8 -0.5 136 -0.2 168 
Ldha -1.6 47 -0.2 169 
Prkcsh -1.9 33 -0.2 170 
Rara -0.1 171 -0.2 171 
Pim3 -0.4 150 -0.2 172 
Prkcz -0.1 182 -0.2 173 
Akt3 -0.5 137 -0.1 174 
Tnfsf11 -1.2 62 -0.1 175 
Ms4a1 -0.4 151 -0.1 176 
Trpv1 -0.5 140 -0.1 177 
Ptpn11 -2.3 26 -0.1 178 
Nudt1 -0.1 183 -0.1 179 
Pik3cb -1.0 84 -0.1 180 
Flt3 -0.4 145 -0.1 181 
Cd52 -0.1 185 -0.1 182 
Bmx 0.0 192 -0.1 183 
Kdr -0.3 157 -0.1 184 
Tbk1 -0.1 178 -0.1 185 
 ______________________________________________________________ Appendices 
229 
Rock1 -0.1 184 -0.1 186 
Igf1r 0.0 189 0.0 187 
Map2k2 -0.6 122 0.0 188 
Pak1 -0.5 142 0.0 189 
Sgk3 -0.1 181 0.0 190 
Porcn -0.3 158 0.0 191 
Pim2 0.0 190 0.0 192 
